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Abstract 
 
The CBF-SMMHC fusion protein is expressed in acute myeloid leukemia (AML) 
samples with the chromosome inversion inv(16)(p13;q22). This fusion protein binds the 
transcription factor RUNX with higher affinity than its physiological partner CBF and 
disrupts the core binding factor (CBF) activity in hematopoietic stem and progenitor cells. 
Studies in the Castilla laboratory have shown that CBF-SMMHC expression blocks 
differentiation of hematopoietic progenitors, creating a pre-leukemic progenitor that 
progresses to AML in cooperation with other mutations. However, the combined function 
of cumulative cooperating mutations in the pre-leukemic progenitor cells that enhance 
their expansion to induce leukemia is not known.  The standard treatment for inv(16) 
AML is based on the use of non-selective cytotoxic chemotherapy, resulting in a good 
initial response, but with limited long-term survival. Therefore, there is a need for 
developing targeted therapies with improved efficacy in leukemic cells and minimal 
toxicity for normal cells.  
Here, we used conditional Nras+/LSL-G12D; Cbfb+/56M; Mx1Cre knock-in mice to show 
that allelic expression of oncogenic N-RasG12D expanded the multi-potential progenitor 
(MPP) compartment by 8 fold. Allelic expression of Cbf-SMMHC increased the MPPs 
and short-term hematopoietic stem cells (ST-HSCs) by 2 to 4 fold both alone and in 
combination with N-RasG12D expression. In addition, allelic expression of oncogenic N-
RasG12D and Cbf-SMMHC increases survival of pre-leukemic stem and progenitor cells. 
Differential analysis of bone marrow cells determined that Cbfb+/MYH11 and Nras+/G12D; 
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Cbfb+/MYH11 cells included increased number of blasts, myeloblasts and promyelocytes 
and a reduction in immature granulocytes, suggesting that expression of N-RasG12D 
cannot bypass Cbf-SMMHC driven differentiation block.  
N-RasG12D and Cbf-SMMHC synergized in leukemia, in which Nras+/G12D; 
Cbfb+/MYH11 mice have a shorter median latency than Cbfb+/MYH11 mice. In addition, the 
synergy in leukemogenesis was cell autonomous. Notably, leukemic cells expressing N-
RasG12D and Cbf-SMMHC showed higher (over 100 fold) leukemia-initiating cell 
activity in vivo than leukemic cells expressing Cbf-SMMHC (L-IC activity of 1/4,000 
and 1/528,334, respectively).  
Short term culture and biochemical assays revealed that pre-leukemic and leukemic 
cells expressing N-RasG12D and Cbf-SMMHC have reduced levels of pro-apoptotic 
protein Bim compared to control. The Nras+/G12D; CbfbMYH11 pre-leukemic and leukemic 
cells were sensitive to pharmacologic inhibition of MEK/ERK signaling pathway with 
increasing apoptosis and Bim protein levels but not sensitive to PI3K inhibitors. In 
addition, knock-down of Bcl2l11 (Bim) expression in Cbf-SMMHC pre-leukemic 
progenitors decreased their apoptosis levels. 
In collaboration with Dr. John Bushweller’s and other research laboratories, we 
recently developed a CBF-SMMHC inhibitor named AI-10-49, which specifically binds 
to CBF-SMMHC, prevents its binding to RUNX proteins and restores CBF function. 
Biochemical analysis in human leukemic cells showed that AI-10-49 has significant 
specificity in reducing the viability of leukemic cells expressing CBF-SMMHC (IC50= 
0.83µM), and negligible toxicity in normal cells. Likewise, mouse Nras+/G12D; 
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Cbfb+/MYH11 leukemic cells were sensitive to AI-10-49 (IC50= 0.93µM). By using the 
NrasLSL-G12D; Cbfb56M mouse model, we also show that AI-10-49 significantly prolongs 
the survival of mice bearing the leukemic cells. Preliminary mechanistic analysis of AI-
10-49 activity has shown that AI-10-49 increased BCL2L11 transcript levels in a dose 
and time dependent manner in murine and human leukemic cells, suggesting that the 
viability through BIM-mediated apoptosis may be targeted by both oncogenic signals.   
My thesis study demonstrates that Cbf-SMMHC and N-RasG12D promote the 
survival of pre-leukemic myeloid progenitors primed for leukemia by activation of the 
MEK/ERK/Bim axis, and define NrasLSL-G12D; Cbfb56M mice as a valuable genetic model 
for the study of inv(16) AML targeted therapies. For instance, the novel CBF-SMMHC 
inhibitor AI-10-49 shows a significant efficacy in this mouse model. This small molecule 
will serve as a promising first generation drug for targeted therapy of inv(16) leukemia 
and also a very useful tool to understand mechanisms of leukemogenesis driving by 
CBF-SMMHC. 
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Chapter I 
Introduction 
 
Acute Myeloid Leukemias (AMLs) comprise a variety of hematopoietic 
malignancies in the bone marrow, presenting impaired differentiation, deregulated 
proliferation and a survival advantage of myeloid progenitor cells. AML has an incidence 
of three to five cases per 100,000 population in the developed countries (Dores et al., 
2012; Sant et al., 2010; Smith et al., 2011) with a poor clinical outcome (Estey and 
Dohner, 2006; Lowenberg et al., 1999). In the United States, there are approximately 
19,000 new cases of AML diagnosed per year, with death rate close to 50% (American 
Cancer Society, www.cancer.org). Therefore, understanding the molecular basis of AML 
initiation and maintenance is critical for the development of improved treatment regimens 
of these aggressive hematopoietic malignancies. 
 
I.A Hematopoietic differentiation 
Hematopoiesis is the process that forms all the cellular components of the blood 
system in an organism. As one of the most highly regenerative tissues, approximately 
1012 blood cells arise each day in adult human bone marrow (Doulatov et al., 2012). Bone 
marrow cells present a variety of morphologies, reflecting different lineage and stages of 
differentiation. The mature hematopoietic cells include megakaryocytes/platelets, 
erythrocytes, myeloid cells (monocytes/macrophages, dendritic cells and granulocytes) 
and lymphocytes (T cells, B cells and natural killer cells). 
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I.A.1 Road map of hematopoietic differentiation 
The diverse composition of cell types in the blood is generated by the hematopoietic 
stem cells (HSCs), a rare cell population that resides in the bone marrow. The origin of 
HSCs has been the focus of developmental biologists. During mammalian embryo 
development, the hematopoietic system, together with vascular, cardiac, and skeletal 
muscle lineages, is derived from mesoderm (Murry and Keller, 2008). There are multiple 
waves of hematopoietic cells that emerge during embryo development. The initial wave 
in the mammalian yolk sac [embryonic day (E) 7.5-10.5] is termed “primitive” 
hematopoiesis, and produces nucleated primitive erythrocytes that facilitate tissue 
oxygenation during the rapid growth of embryo (Golub and Cumano, 2013; Orkin and 
Zon, 2008).  The yolk sac also generates myeloid cells that migrate to the central nervous 
system and the skin to form the microglia and epidermal specific macrophages (Bertrand 
et al., 2005; Ginhoux et al., 2010; Palis et al., 1999; Schulz et al., 2012). This initial wave 
is rapidly replaced by the “definitive” hematopoiesis, which originates in the aorta-
gonad-mesonephors (AGM) region and placenta (E8.5-13.5), generating HSCs from 
hemogenic endothelial cells (Gekas et al., 2005; Muller et al., 1994; Ottersbach and 
Dzierzak, 2005). Subsequent definitive hematopoiesis involves the colonization of HSCs 
to the fetal liver (E10.5 to after birth), thymus, spleen, and ultimately the bone marrow 
(Orkin and Zon, 2008). 
The identification of bone marrow HSCs and subsequent progenitor cells has 
advanced significantly during decades of research. Studies in 1960s, using clonal in vivo 
repopulation assays, functionally suggested the existence of multipotent HSCs (Becker et 
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al., 1963; Till and Mc, 1961). With additional use of cell surface markers, flow cytometry 
analysis and in vitro colony forming assays, led by studies in the laboratory of Irving 
Weissman in the 1990s (Morrison et al., 1997; Morrison and Weissman, 1994), a detailed 
hematopoietic progenitor cell system has been revealed as a developmental hierarchy of 
progenitor cells, with the long-term HSCs (LT-HSCs) at the apex and terminally 
differentiated cells at the bottom (Figure I.1).  
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Figure I.1 Current models of hierarchies in the adult mouse and human 
hematopoiesis. The major classes of stem and progenitor cells described in the text are 
defined by cell surface phenotypes, which are listed next to each population and in the 
bars above each schematic plot. Terminally differentiated cells are shown on the right, 
and inferred lineage relationships are depicted with arrows. (A)  Mouse; (B) Human. This 
figure was adapted from Doulatov et al., 2012. 
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In mouse studies, LT-HSCs have been historically defined as cells with two key 
functions: multilineage repopulation and self-renewal. Multilineage repopulation refers 
to the ability to produce long-term multi-lineage reconstitution in transplantation assays. 
Self-renewal is the process by which stem cells divide to make more stem cells, 
maintaining the undifferentiated state and perpetuating the stem cell pool throughout life 
(He et al., 2009).  The LT-HSC activity is contained in cells presenting surface markers 
as Lineage-(Lin-, referring to negative for a cell surface marker cocktail of differentiated 
cells, such as markers for T cells, B cells, Monocytes, Granulocytes and Erythrocytes) 
Sca1+c-Kit+ (LSK+) CD34-Flt3-(Adolfsson et al., 2001; Christensen and Weissman, 2001; 
Osawa et al., 1996). LT-HSCs have alternatively been defined by CD150+CD48-CD244− 
SLAM markers (Kiel et al., 2005). LT-HSCs can give rise to short-term HSCs (ST-HSCs) 
with cell surface markers as LSK+CD34+Flt3-(Osawa et al., 1996; Yang et al., 2005), and 
then multipotent progenitors (MPPs) with cell surface markers as 
LSK+CD34+Flt3+(Adolfsson et al., 2001). ST-HSCs and MPPs both give multi-lineage 
but transient reconstitution, and MPPs are responsible primarily for rapid lymphoid 
reconstitution (Yang et al., 2005).  
The differentiation to the myeloid-erythroid compartment has also been defined in 
the mouse, by immunophenotyping. The MPPs give rise to the lymphoid-primed 
multipotent progenitors (LMPPs, LSK+CD34+Flt3hi), with lymphoid bias and very low 
Erythro-Megakaryocytic potential (Adolfsson et al., 2005; Mansson et al., 2007). The 
LMPPs give rise to common lymphoid progenitors (CLPs, IL-7R+Lin-Sca-1loc-
KitloThy-1-) and granulocyte-macrophage progenitors (GMPs, IL-7R-Lin-Sca-1-c-
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Kit+FcRhiCD34+) (Akashi et al., 2000; Kondo et al., 1997).  A variety of early lymphoid 
progenitors showing different states of lymphoid commitment have also been identified, 
suggesting the differentiation in the lymphoid progenitors is a gradual process (Welner et 
al., 2008). The CLPs can commit to differentiate into the B cell lineage, forming the pre-
pro B, pro B, pre-B stages to give rise to mature B cells (Nutt and Kee, 2007). CLPs can 
also give rise to nature killer (NK) cells (Fathman et al., 2011; Rosmaraki et al., 2001). 
Though CLPs possess lineage B and T potential in transplantation assays (Kondo et al., 
1997), more recent studies suggest that early thymic progenitors (ETPs, c-kit+DN1, DN 
stands for “double negative”) may derive from LMPPs in the circulation, differentiate 
through DN2, DN3, DN4, double positive stages and give rise to T cells in the thymus 
[reviewed in (Ye and Graf, 2007)]. For myeloid differentiation, the “classic” model  
(Reya et al., 2001) proposes that MPPs give rise to common myeloid progenitors (CMPs, 
IL-7R-Lin-Sca-1-c-Kit+FcRloCD34+), and then CMPs give rise to GMPs and 
megakaryocyte-erythrocyte progenitors (MEPs, IL-7R-Lin-Sca-1-c-Kit+FcRloCD34-) 
(Akashi et al., 2000). The GMPs differentiate to monocytes, granulocytes, and dendritic 
cells. The MEPs differentiate into erythrocytes and megakaryocytes and platelets. 
Particularly, the differentiation steps from GMPs to granulocytes include myeloblast, 
promyelocyte, myelocyte, metamyelocyte and neutrophils (Rosenbauer and Tenen, 2007), 
which have distinct cell morphologies (Yang et al., 2013).  
Advances in the characterization of hematopoietic progenitors continue to redefine 
these models. A recent study using a single-cell transplantation system and marker mice 
have suggested a new myeloid bypass model in which the myeloid-restricted progenitors 
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with long-term repopulating activity, directly differentiated from HSCs without passing 
through an MPP stage (Yamamoto et al., 2013).  
The cell surface markers of human HSCs and their progeny do not coincide with 
those in the mouse. The first marker identified in human HSCs is CD34, expressing on 
less than 5% of all blood cells (Civin et al., 1984). Over the past decades, using in vitro 
colony forming assays and xenograft experiments on immunodeficient mice, the 
combined markers as CD34+CD38-CD90+CD45RA- for human HSCs have been 
identified (Baum et al., 1992; Bhatia et al., 1997; Conneally et al., 1997; Lansdorp et al., 
1990; Murray et al., 1995). A more recent study has shown that human HSC activity was 
restricted in CD49f (integrin subunit α6) positive cells (Notta et al., 2011). In contrast, 
CD90-CD49f- cells behave as MPPs by transplantation assay in NOD-scid-IL2Rgc−/− 
(NSG) mice. Human hematopoiesis does not follow a rigid model of myeloid-lymphoid 
segregation. A broader term, multilymphoid progenitor (MLP), has been given to 
describe any progenitor that gives rise to all lymphoid lineages, but also has myeloid 
potential (Doulatov et al., 2010). Similarly as in mice, CMPs, GMPs and MEPs have 
been isolated from human hematopoietic system (Doulatov et al., 2010; Manz et al., 
2002). The cell surface markers for each progenitor compartment are reviewed in Figure 
I.1.  
 
I.A.2 Regulation of hematopoietic differentiation 
Hematopoiesis is a tightly regulated process that balances self-renewal and 
differentiation, dormancy and proliferation of its progenitor cells. This regulation 
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involves specific molecules in the microenvironment (Kiel and Morrison, 2008; Scadden, 
2014), such as oxygen levels (Takubo et al., 2010), calcium levels (Adams et al., 2006), 
adhesion molecules (Sugiyama et al., 2006; Zou et al., 1998) and cytokines (Kondo et al., 
2000; Metcalf, 1998; Rieger et al., 2009). It also involves signaling pathways (Karanu et 
al., 2000; Schreck et al., 2014; Varnum-Finney et al., 2000), epigenetic changes 
(Borghesi, 2014) and transcriptional factors (TFs) (Orkin and Zon, 2008; Rosenbauer and 
Tenen, 2007; Zhang et al., 2004). The deregulation of hematopoietic homeostasis can 
result from genetic mutations in genes encoding signaling molecules in cytokine response 
pathways and TFs, rendering hematopoietic progenitor cells with impaired differentiation, 
survival and proliferative capacity.  
 
Role of cytokines 
Cytokines in the microenvironment serve as extrinsic signals to direct hematopoietic 
proliferation and differentiation (Metcalf, 1998). These factors act via specific cell 
membrane receptors, such as the receptor tyrosine kinase (RTK) family, the cytokine 
receptor family and the transforming growth factor- (TGF receptor family.  
Ligand binding induces intrinsic tyrosine kinase activity of RTKs and downstream 
intracellular signaling pathways leading to various biological effects (details about RTK 
signaling pathways and their deregulation in AMLs will be reviewed in Subchapter I.E). 
Stem Cell Factor (SCF) is an important cytokine for regulating HSC functions. Null-
mutations in genes that encode SCF or its receptor c-KIT (a class III RTK) result in 
severe reduction of HSC numbers and self-renewal activity (Bernstein, 1962; McCulloch 
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et al., 1965). c-KIT signaling regulates hematopoietic progenitors’ cell cycle (Leary et al., 
1992), survival (Borge et al., 1997), maintenance (Thoren et al., 2008) and adhesion to 
stromal cells in their niche (Levesque et al., 1996; Levesque et al., 1995). FMS-like 
tyrosine kinase 3 (FLT3) ligand (FL) is another important cytokine for HSC and 
lymphoid differentiation. FLT3 also belongs to the class III RTK family. Flt3-null mice 
have reduced number of B-cell progenitors and exhibit deficiency in T-cell and myeloid 
lineage reconstitution in bone marrow transplantation (Mackarehtschian et al., 1995). FL 
promotes survival of early hematopoietic progenitor cells and, in combination with other 
factors, regulates proliferation of  those cells (Rasko et al., 1995).  
The cytokine receptor family and the TGF receptor family also play important 
roles in regulating hematopoietic differentiation.  MPL is a type I cytokine receptor 
activated by the cytokine thrombopoietin. It regulates proliferation of HSCs and 
megakaryocytes (Kaushansky and Ranney, 2009). The number and function of HSCs are 
largely reduced in Mpl-null and Thpo-null mice (Alexander et al., 1996; Carver-Moore et 
al., 1996; Kimura et al., 1998). Nonsense mutations in the MPL and THPO genes cause 
congenital amegakaryocytic thrombocytopenia (Ballmaier and Germeshausen, 2009). In 
contrast, activating mutations in the MPL gene have been detected in a small fraction of 
myeloproliferative neoplasm and megakaryoblastic AML (Hussein et al., 2009; 
Pardanani et al., 2006). Interleukin-3 receptor is another important type I cytokine 
receptor in regulating hematopoiesis. Interleukin-3 is a product of CD4+ T cells that acts 
on the most immature marrow progenitors (Ihle et al., 1983; Metcalf, 1989; Pierce, 1989). 
IL-3 is capable of inducing the growth and differentiation of multi-potential 
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hematopoietic stem cells, neutrophils, eosinophils, megakaryocytes, macrophages, 
lymphoid and erythroid cells (Reddy et al., 2000). Granulocytic-monocytic colony 
stimulating factor (GM-CSF), monocytic-colony stimulating factor (M-CSF) and 
granulocyte-colony stimulating factor (G-CSF) are involved in myeloid differentiation. 
The receptors of GM-CSF and G-CSF belong to the type I cytokine receptor family while 
the M-CSF receptor belong to the class III RTK family. These cytokines stimulate 
proliferation and differentiation of hematopoietic progenitors towards GMPs, monocytes 
and granulocytes, respectively (Gasson, 1991; Lieschke et al., 1994; Stanley et al., 1983). 
TGF has been shown to inhibit the growth and differentiation of quiescent early HSCs 
and stimulate the differentiation of late progenitors (Isufi et al., 2007). Disruption of 
TGF signaling has been observed in many myeloid and lymphoid neoplasms (Isufi et al., 
2007).  
 
Role of TFs 
Triggered by multiple signals at different developmental stages, TFs activate 
lineage-specific programs in hematopoietic stem and progenitor cells dependent upon 
their expression levels and timing (Iwasaki and Akashi, 2007), and may direct cell fate 
decisions in collaboration or competition with other factors.  
The regulation of lymphoid differentiation depends on the function of specific TFs. 
For example, Ikaros and PU.1 are required primarily for the formation of early lymphoid 
progenitors (DeKoter et al., 2002; Scott et al., 1994; Wang et al., 1996a). Other factors, 
such as E2A and EBF1, have direct roles in specifying the B cell gene expression while 
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PAX5 functions to promote B cell commitment by repressing lineage-inappropriate gene 
expression and reinforcing B cell specific gene expression (Nutt and Kee, 2007). In T cell 
development, Notch-Delta signaling behaves as a multilevel regulator.  The success of T 
cell development depends on precise temporal and quantitative regulation of other factors, 
such as GATA3, TCF family factors, E2A, HEB, IKAROS, MYB, GFI1, RUNX family 
factors and PU.1, and on the modulating of Notch-Delta signals that buffer the cells 
against mechanisms promoting non-T outcomes (Rothenberg, 2007). 
The regulation of myeloid differentiation programs depend on major TFs, such as 
PU.1, CEBP proteins (in particular, C/EBP and C/EBP), GFI1 and IRF8 (Rosenbauer 
and Tenen, 2007). The TF PU.1, encoded by the SPI gene,  is critical in the formation of 
the earliest myeloid transcriptional network, generating CMPs from HSCs. Absence of 
PU.1 impairs HSC repopulation capacity and precludes differentiation into CMPs and 
CLPs (Dakic et al., 2005; Iwasaki et al., 2005; Scott et al., 1997). In addition, different 
levels of PU.1 expression are required for generation of different lineages. In the MPP 
stage, low levels of PU.1 promote B-cell development, whereas high levels favor 
macrophage development (DeKoter and Singh, 2000).  
The TF C/EBP , encoded by the CEBPA gene, plays an important role on the CMP 
to GMP transition. Genetic studies in mice have demonstrated that Cebpa-null HSCs are 
able to generate normal numbers of CMPs but they cannot produce GMPs and all 
following progenies to granulocytic lineage (Zhang et al., 1997a; Zhang et al., 2004). 
This phenotype correlates with the observation that C/EBP regulates the expression of a 
number of myeloid-specific genes, similar as PU.1 (Tenen et al., 1997). Furthermore, 
12 
 
 
 
repression of E2F (a TF functioning in cell cycle control) activity by C/EBP is critical 
for granulocytic differentiation (Porse et al., 2001).  
The TFs PU.1 and its binding partner IRF8, determine granulocytic versus 
monocytic/macrophage fates from GMPs (Rosenbauer and Tenen, 2007). In the myeloid 
lineages, high levels of PU.1 support macrophage production, whereas low levels of PU.1 
support granulocyte production (Dahl et al., 2003). Similarly, Irf8-/- mice strongly 
resembled human chronic myeloid leukemia (CML), showing a marked increase in the 
number of granulocytes and their precursors, as companied by fewer macrophages 
(Scheller et al., 1999). Accordingly, restoration of Irf8 expression in cell lines derived 
from Irf8-/- mice induced differentiation towards macrophages (Tamura et al., 2000). 
Two additional TFs, GFI1 and C/EBP are required in granulocyte specification. 
Gfi1-deficiency in mice impaired lymphoid differentiation and resulted in lack of 
neutrophilic granulocytes (Hock et al., 2003; Karsunky et al., 2002). However, the 
development of GMPs was not compromised and the block in neutrophilic differentiation 
was beyond the promyelocyte stage (Hock et al., 2003). The C/EBP-deficient mice 
closely resembled this phenotype and had additional phenotype as abnormal 
granulopoiesis beyond the promyelocyte stage (Yamanaka et al., 1997). 
These key TFs play dominant or negative roles, and in some cases antagonize each 
other to direct hematopoietic differentiation (Orkin, 2000). Disruptions of these critical 
TFs by chromosomal translocations or inversions are often seen in leukemia. Here, we 
will focus on the function of a critical TF family, core binding factors, which are 
frequently mutated in AMLs. 
13 
 
 
 
I.B Core binding factor 
The core binding factor (CBF) is a heterodimeric transcription factor that regulates 
multiple cellular processes, including cell fate, differentiation, and survival. The CBF is 
composed of two core subunits: the RUNX protein, encoded by one of three genes 
(RUNX1, RUNX2, and RUNX3), binds to DNA in cis regulatory regions, and the non-
DNA-binding partner, CBFβ, which stabilizes the complex and increases RUNX affinity 
to DNA (Blyth et al., 2005; Huang et al., 2001; Ogawa et al., 1993; Wang et al., 1993). In 
this section, I summarize the main concepts of CBF function, with focus on 
hematopoiesis. 
 
I.B.1 CBF protein structure and general functions 
The coincidental study of CBF function by scientists from fields of virology, 
leukemia and developmental biology resulted in a number of different names for the 
RUNX genes (Bae et al., 1994; Bae et al., 1995; Bae et al., 1993; Calabi et al., 1995; 
Kamachi et al., 1990; Levanon et al., 1994; Miyoshi et al., 1991; Wang and Speck, 1992; 
Zhang et al., 1997b). This confusion was resolved by the redefinition to “RUNX” names 
for the mammalian genes, and accepted by the HUGO Nomenclature Committee (van 
Wijnen et al., 2004). This nomenclature reflects an earlier discovery of Drosophila Runt 
as an essential gene in embryogenesis (Gergen and Butler, 1988), and the numbering as 
historically identified, which is summarized in Table I.1(van Wijnen et al., 2004). 
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Table I.1 Synonyms for human RUNX gene names and their chromosome location 
RUNX CBF AML PEBP2 Location 
RUNX1 CBFA2 AML1 PEBP2B 21q22 
RUNX2  CBFA1 AML3 PEBP2A 6p21 
RUNX3 CBFA3 AML2 PEBP2C 1p36 
 
Adapted from van Wijnen et al., 2004 
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The most highly conserved feature of the RUNX proteins is the N-terminal 128-
amnio-acid Runt Homology Domain (RHD), located between amino acids 50 and 177 in 
RUNX1 (Kagoshima et al., 1993; Levanon et al., 1994; Meyers et al., 1993) (Figure I.2). 
The three-dimensional structure for the RUNX1/CBF complex demonstrated the critical 
amino acids of the RHD participating in the interaction with CBF and DNA (Bravo et 
al., 2001; Huang et al., 1999; Warren et al., 2000). The CBF protein is a relatively small 
protein (21kD), with the RUNX binding domain as the only known functional domain 
(Huang et al., 1999; Wang et al., 1993). Mutation analysis has shown that the amino acids 
Gly-61 and Asn-104 of CBF are critical for binding to RUNX (Tang et al., 2000). 
Studies have also reported a number of co-factors that bind to the RHD, including the v-
Ets avian erythroblastosis virus E26 oncogene homolog 1 (ETS1) (Giese et al., 1995) and 
suppressor of variegation 3-9 homolog 1 (SUV39H1) (Chakraborty et al., 2003). The 
nuclear localization signal (NLS), following the RHD, is responsible for predominant 
nuclear localization of RUNX proteins (Kanno et al., 1998). In addition to the RHD, 
RUNX proteins have three conserved functional domains/motifs: the 
transactivation/inhibitory domains (Gu et al., 2000; Ito, 1999; Kanno et al., 1998), 
nuclear-matrix-targeting signal (NMTS) (Zeng et al., 1997) and VWRPY motif at the C-
terminus of the proteins (Aronson et al., 1997).  The VWRPY motif is required for the 
interaction with the “transducin-like enhancer of split/groucho” family of transcription 
co-repressors (Aronson et al., 1997). The RUNX genes are expressed from two alternative 
promoters (P1 or distal, and P2 or proximal) and encode several isoforms by alternative 
splicing.  For instance, RUNX1 encodes a RUNX1c isoform (the longest isoform) using 
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P1, the predominant RUNX1b using P2, and the minor isoform RUNX1a using P2 with an 
early termination in exon 7 (Blyth et al., 2005; Miyoshi et al., 1995).  RUNX1b and 
RUNX1c both possess the RHD at the N-terminal end as well as the C-terminal 
transcriptional regulatory domains, as considered to be broadly similar in function. In 
contrast, RUNX1a retains the RHD, but lacks the transcriptional regulatory domains, as 
considered a potential functional antagonist of RUNX1b and RUNX1c (Miyoshi et al., 
1995). Since the isoform RUNX1b with the N-terminal pentapeptide MRIPV is the 
predominant isoform expressed in hematopoietic cells (Bae and Lee, 2006; Miyoshi et al., 
1995), the amino acid numbering of this isoform will be utilized throughout this chapter.  
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Figure I.2 Organization of human RUNX1 protein and alternative splicing 
transcripts. (A) the human RUNX1 has the Runt Homology Domain (RHD), three 
transactivation elements (TE1, TE2 and TE3) and an inhibitory domain (ID). The 
combination of TE1 and TE2 has also been called transactivation domain (TAD). 
RUNX1 contains a nuclear localization signal (NLS), a nuclear-matrix-targeting signal 
(NMTS) and a conserved C-terminal VWRPY motif. RHD is critical for binding to CBF, 
ETS1 and SUV39H1. Posttranslational modification sites of RUNX1 by p300, PRMT1, 
ERK1/2 and HIPK2 are also shown. Ac, acetylation; Met, methylation; P, 
phosphorylation. The labeling of amino acid number is based on the RUNX1b isoform 
(accession number NP_001001890), with 453 amino acids. (B) different isoforms of 
human RUNX1 transcripts. RUNX1a and RUNX1b are transcribed from P2 promoter 
while RUNX1c is transcribed from P1 promoter. A schematic representation of the exons 
is shown at the top. Orange boxes represent the coding regions, and light green boxes 
represent the 5'- and 3'-untranslated regions. 
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CBF is predominantly present in the cytoplasm, whereas Runx has the nuclear 
localization signal (NLS) and translocates CBF into the nucleus (Adya et al., 1998). The 
RUNX proteins directly bind to the DNA consensus sequence TGYGGT (Y represents a 
pyrimidine) in promoters, enhancers and silencer regions (Kamachi et al., 1990; 
Melnikova et al., 1993; Meyers et al., 1993). CBFβ markedly increases RUNX DNA 
binding affinity (Ogawa et al., 1993; Wang et al., 1993), and protects it from proteasomal 
degradation (Huang et al., 2001).  
Despite their structural similarity, the RUNX genes have different expression 
patterns and divergent biological roles in mammalian development. These roles are 
evident from phenotypes of RUNX1-, RUNX2, and RUNX3-deficient mice, presenting 
major defects in hematopoietic, osteoblastic and neuronal development respectively 
(Inoue et al., 2002; Komori et al., 1997; Levanon et al., 2002; Okuda et al., 1996; Otto et 
al., 1997; Wang et al., 1996b). In this section, I will summarize the role of Runx1 in 
hematopoiesis. 
 
I.B.2 Runx1 function and regulation in hematopoiesis 
The Runx1-/- embryos present normal morphogenesis and yolk sac–derived 
erythropoiesis at early stages of development, but lack fetal liver hematopoiesis and die at 
E11.5-12.5 due to necrosis and hemorrhaging in the developing central nervous system 
(Okuda et al., 1996; Wang et al., 1996b), indicating that the Runx1 is required for 
definitive hematopoiesis. In developing mouse embryo, Runx1 expression is found both 
in c-Kit+CD34+ hematopoietic cells and hemogenic endothelium in sites from which 
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these hematopoietic cells are thought to emerge at E10.5 (North et al., 1999). Runx1  
marks the HSC population, and deletion of Runx1 from the vascular endothelium 
prevents HSC emergence (Chen et al., 2009; North et al., 1999; North et al., 2002; 
Yokomizo et al., 2001). Cbfb-/- embryos lack of definitive hematopoiesis and die at 
E11.5-E13.5 due to hemorrhaging in the central nervous system, presenting very similar 
phenotypes as Runx1-/- embryo, which is a genetic evidence to support the 
heterodimerization of Cbf and Runx1 in vivo (Niki et al., 1997; Sasaki et al., 1996; 
Wang et al., 1996c).  
At adult stage, RUNX1 and CBF are expressed in early human hematopoietic cells, 
with decreasing expression levels during differentiation (Bagger et al., 2012; Bagger et 
al., 2013). Accordingly, Runx1 is expressed in murine adult HSCs and differentiating 
myeloid and lymphoid cells, but has decreased expression during erythroid differentiation 
(North et al., 2004). Cbf is uniformly expressed in murine stem and progenitor cells, as 
well as mature myeloid and lymphoid cells (Kundu et al., 2002). Based on Runx1 
conditional knock-out mice, activated by Mx1-Cre system (Kuhn et al., 1995), studies 
have shown that Runx1 was not required for HSC maintenance but an expansion of HSC 
compartment (defined as LSK+CD34-) was observed (Growney et al., 2005; Ichikawa et 
al., 2004). A later study has shown that Runx1 negatively regulates quiescent HSCs in 
adult hematopoiesis, utilizing side population analysis and limiting dilution assays 
(Ichikawa et al., 2008). These data suggest that Runx1 may be a regulator of cell cycle in 
hematopoietic cells. Accordingly, exogenous RUNX1 stimulates G1 to S transition of 
murine myeloid progenitor 32D.3 cells (Strom et al., 2000). Activation of cyclin-
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dependent kinase 4 (Lou et al., 2000) and cyclin D3 (Bernardin-Fried et al., 2004) 
transcription and repression of Cdkn1a promoter (Lutterbach et al., 2000) likely 
contribute to stimulation of cell cycle progression by Runx1. Furthermore, enforced 
expression of RUNX1a, a truncated isoform of RUNX1 with DNA-binding but no 
transactivation capacity, increased the competitive engraftment potential of murine long-
term reconstituting stem cells, whereas the full-length isoform RUNX1b abrogated 
engraftment potential (Tsuzuki et al., 2007).  
Runx1-deficient adult murine bone marrow also presented inhibition of 
megakaryocytic maturation, defective T- and B-lymphocyte development and a mild 
myeloproliferative phenotype (Growney et al., 2005; Ichikawa et al., 2004). These 
phenotypes are probably due to the regulation of lineage-specific genes by Runx1. 
During megakaryocytic differentiation, Runx1 activates expression of genes encoding the 
megakaryocytic integrin proteins IIb and 2 (Elagib et al., 2003) and platelet myosin 
light chain (Jalagadugula et al., 2010). In immature myeloid cells, Runx1 activates 
expression of genes encoding myeloperoxidase (Nuchprayoon et al., 1994; Suzow and 
Friedman, 1993), neutrophil elastase (Nuchprayoon et al., 1994), the M-CSF receptor 
(Zhang et al., 1994) and C/EBP (Guo et al., 2012). In the lymphocytic lineage, Runx1 
activates T cell receptor subunits (Redondo et al., 1992) and silences the CD4 enhancer in 
T-lineage cells (Taniuchi et al., 2002). A recent study has also shown that Runx1 
promotes survival and development of progenitors specified to the B-cell lineage and 
enables the developmental transition through the preB-stage triggered by the preB-cell 
antigen receptor (preBCR) (Niebuhr et al., 2013). Last but not least, Runx1 regulates 
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PU.1, a master hematopoietic differentiation regulator, both positively and negatively in a 
lineage dependent manner (Huang et al., 2008). 
Activation or repression of the target transcription by RUNX1 is mediated by 
interaction with chromatin associated activators or repressors. These factors can also 
regulate RUNX1 activity by inducing specific post-translational modifications. For 
example, cytokines (IL-3 and thrombopoietin) can induce ERK1/2-mediated 
phosphorylation at Ser-249 and Ser-266 amino acids, in the transactivation element 3 of 
RUNX1 protein (Hamelin et al., 2006; Kanno et al., 1998; Tanaka et al., 1996). Such 
modification leads to RUNX1 dissociation from co-repressor SIN3A, activates its 
transcriptional activity and induces proteasome-mediated degradation of RUNX1 (Imai et 
al., 2004). Cyclin-dependent kinases can also phosphorylate RUNX1 and induce its 
anaphase-promoting complex mediated degradation (Biggs et al., 2006). RUNX1 can be 
methylated at amino acids Arg-206 and Arg-210 by the arginine methyltransferase 
PRMT1 (a transcriptional co-activator), which abrogates its association with SIN3A 
(Zhao et al., 2008). Another important transcriptional co-activator for RUNX1 is the 
lysine acetyltransferase p300. The interaction region of RUNX1 with p300 is between 
amino acid 178 and the C-terminus (Kitabayashi et al., 1998). The interaction of RUNX1 
with CBF leads to phosphorylation of RUNX1 at Ser-249, Thr-273 and Ser-276 sites, 
which in turn induces the phosphorylation of p300 (Wee et al., 2008). Phosphorylation of 
RUNX1 and p300 is mediated by the homeodomain interacting kinase 2 (HIPK2) 
(Aikawa et al., 2006; Wee et al., 2008). Phosphorylation of p300 stimulates its 
acetyltransferase activity and specifically acetylates RUNX1 at Lys-24 and Lys-43 sites, 
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significantly augmenting DNA binding and transcription activity of RUNX1 (Aikawa et 
al., 2006; Yamaguchi et al., 2004). The modification sites of RUNX1 mentioned above 
are summarized in FigureI.2. 
Taken together, RUNX1 and CBF are important TFs in definitive and adult 
hematopoiesis by regulating a variety of targets in a context of other cofactors. In the next 
subchapter I summarize the evidence implicating disruption of RUNX1/CBF complex 
in the promotion of hematopoietic malignancies. 
 
I.C Acute myeloid leukemia 
Leukemia is ranked as the 6th deadly cancer type in the US (Siegel et al., 2014), with 
approximately 52,000 cases diagnosed and 24,000 deaths every year (Cancer.org). From 
these, AML accounts for 19,000 diagnosed cases and 11,000 deaths. AML is 
predominantly a disease of adults, and patients over age 65 have especially poor 
outcomes (Estey and Dohner, 2006; Lowenberg et al., 1999). AML results from 
mutations that disrupt normal hematopoiesis with the clonal expansion of immature 
myeloid cells.  
 
I.C.1 Classification of AML 
Acute myeloid leukemia is characterized by an increase in the number of immature 
myeloid cells in the marrow. Patients with AML generally present with symptoms related 
to complications of pancytopenia (for example, anemia, neutropenia, and 
thrombocytopenia), including weakness and easy fatigability, infections, fever, and/or 
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hemorrhagic findings (Lowenberg et al., 1999; Meyers et al., 2005). Infiltration of 
leukemic cells into various tissues can produce a variety of other symptoms. Some 
patients also present metabolic and electrolyte abnormalities, many of which are due to a 
high turnover of the proliferating leukemic cells. 
The classification of AML is complex due to the diversity of morphology, 
immunophenotype, genetics, and clinical features. The first proposal for the morphologic 
classification of acute leukemias was developed in 1976 by the French-American-British 
(FAB) cooperation group (Bennett et al., 1976)., and subsequently  revised in the 
following years (Bennett et al., 1985a; Bennett et al., 1985b; Bennett et al., 1991b; 
Bloomfield and Brunning, 1985; Koike, 1984). This FAB classification divides AML into 
9 distinct subtypes (M0-M7 including M4Eo, Table I.2) based on morphologic 
appearance of the blasts, their reactivity with histochemical stains and immunologic 
phenotypes. This distinction reflects the particular myeloid lineage involved and the 
degree of leukemic cell differentiation. Cytogenetic analysis of leukemic blasts identified 
nonrandom clonal chromosomal aberrations in a large percentage of AML patients (Look, 
1997; Zeisig et al., 2012). Some of the lesions correlate with specific FAB subtypes, such 
as the chromosome 15/17 translocation [t(15;17)] is always presented in M3 subtype 
(Borrow et al., 1994; Tong et al., 1992), while the chromosome 16 (p13; q22) inversion 
[inv(16)] is always associated with the M4 subtype with abnormal eosinophils, named 
M4Eo subtype (Larson et al., 1986; Le Beau et al., 1983; Sole et al., 1992) (Table I.2). In 
addition, FAB subtypes are related to disease progression. For instance, the M0 subtypes 
had a significantly lower rate of complete remission (CR) and overall survival (OS) than 
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other subtypes in AML (Stasi et al., 1994). In contrast, M3 cases presented a significantly 
higher CR and OS rates (Bennett et al., 1991a). 
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Table I.2 The FAB Classification of AML and associated genetic abnormalities 
FAB 
Subtype 
Common Name 
% of 
Cases 
Associated 
Chromosomal 
Abnormalities 
% of 
Cases  
Genes 
Involved 
M0 
Acute myeloblastic leukemia with 
minimal differentiation 
3 inv(3q26) and t(3;3) 1 EVI1 
M1 
Acute myeloblastic leukemia 
without maturation 
15-20 
   
M2 
Acute myeloblastic leukemia with 
maturation 
25-30 
t(8;21) 40 AML1-ETO 
t(6;9) 1 DEK-CAN 
M3 Acute promyelocytic leukemia 5-10 
t(15;17) 98 PML-RARA 
t(11;17) 1 PLZF-RARA 
t(5;17) 1 NPM-RARA 
M4 Acute myelomonocytic leukemia 20 
11q23 20 MLL 
inv(3q26) and t(3;3) 3 EVI1 
t(6;9) 1 DEK-CAN 
M4Eo 
Acute myelomonocytic leukemia 
with abnormal eosinophils 
5-10 inv(16), t(16;16) 80 
CBFB-
MYH11 
M5 Acute monocytic leukemia 2-9 
11q23 20 MLL 
t(8;16) 2 MOZ-CBP 
M6 Erythroleukemia 3-5 
   
M7 Acute megakaryocytic leukemia 3-12 t(1;22) 5 OTT-MAL 
 
Adapted from Lowenberg et al., 1999 
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However, it became clear that in many cases FAB classification failed to distinguish 
between borderline cases, and prognostic values of AMLs classified according to other 
criteria were higher than those of the original FAB subtypes. The identification of 
recurrent genetic abnormalities and new clinical finding lead to a second classification  
by World Health Organization (WHO) proposed in 2002, which was updated in 
subsequent years  (Vardiman and Hyjek, 2011; Vardiman, 2010; Vardiman et al., 2002; 
Vardiman et al., 2009). The WHO classification includes recurrent chromosome 
inversions and translocations, as well as specific mutations as criteria to divide AMLs 
(Table I.3). It also pays attention to relationship between AMLs and precursor neoplasms. 
Although the WHO classification is very useful for clinic and research purposes, 
recent progress on molecular characterization of AMLs has unraveled heterogeneity 
within these groups, and suggests that further refinement may be required. Examples 
include the expression profiling studies identifying microRNA expression (Jongen-
Lavrencic et al., 2008; Li et al., 2008), epigenetic status (Bullinger et al., 2010; Figueroa 
et al., 2010) and gene expression profiling (Bullinger et al., 2004; Haferlach et al., 2010b; 
Valk et al., 2004b) in panels of AMLs. In addition, the next-generation sequencing 
technology also helps researchers to identify mutations in different subpopulations and 
understand the clonal evolution of leukemic cells (Ding et al., 2012; Shlush et al., 2014; 
Walter et al., 2012; Welch et al., 2012). These discoveries will, to a large extent, benefit 
the prognosis and treatment of AMLs. 
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Table I.3 The WHO Classification of AML and related precursor neoplasms 
AML with recurrent genetic abnormalities 
  AML with t(8;21)(q22;q22); RUNX1-ETO 
  AML with inv(16)(p13.1;q22) or t(16;16)(p13.1;p22); CBFB-MYH11 
  Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA 
  AML with t(9;11)(p22;q23); MLLT3-MLL 
  AML with t(6:9)(p23;q34); DEK-NUP214 
  AML with inv(3)(q21q26.2) or t(3.3)(q21;q26.2); RPN1-EVl1 
  AML (megakaryoblastic) with t(1:22)(p13;q13); RBM15-MKL1 
  AML with mutated NPM1 
  AML with mutated CEBPA 
AML with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Acute myeloid leukaemia, NOS 
  AML with minimal differentiation 
  AML without maturation 
  AML with maturation 
  Acute myelomonocytic leukaemia 
  Acute monoblastic and monocytic leukaemia 
  Acute erythroid leukaemia 
  Acute megakaryoblastic leukaemia 
  Acute basophilic leukaemia 
  Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
  Transient abnormal myelopoiesis 
  Myeloid leukaemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
 
Note: NOS, not otherwise specified 
Adapted from Vardiman et al., 2010 
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I.C.2 Treatment of AML 
The prognostic factors of AML includes age, performance status (use to quantify 
cancer patients' general well-being and activities of daily life), antecedent hematologic 
disorders, cytogenetics and mutations (Basecke et al., 2006; Breems et al., 2008; Estey, 
2001; Hamadani and Awan, 2010; Kantarjian et al., 2006; Olesen et al., 2005; Sekeres et 
al., 2004; Shah et al., 2013). The favorable factors include younger age, better 
performance status, and no antecedent hematologic disorder or prior therapy. According 
to cytogenetic abnormalities, patients have been classified into good [such as t(8;21), 
inv(16)/t(16;16), or t(15;17)], poor [such as those with -7, inv(3)/t(3;3), balanced 
translocations involving 11q23 other than t(9;11) or a complex karyotype] or 
intermediate cytogenetic risk groups (Hamadani and Awan, 2010). Favorable mutations 
include NPM1 and CEBPA mutations (Falini et al., 2005; Preudhomme et al., 2002) and 
adverse mutations include FLT3-ITD, MLL-PTD, overexpression of WT1, BAALC, ERG 
and EVI1 (Baldus et al., 2003; Bergmann et al., 1997; Dohner et al., 2002; Kottaridis et 
al., 2001; Marcucci et al., 2007).  
The standard regimen for AML induction therapy is the so-called "7+3" regimen, 
which combines a seven-day continuous intravenous infusion of cytarabine with a short 
infusion or bolus of an anthracycline given on days one through three (Burnett, 2012). 
Cytarabine, initially developed in 1960s (Evans et al., 1961; Talley and Vaitkevicius, 
1963), combines a cytosine base with an arabinose sugar. As a deoxycytidine analogue, it 
interferes with DNA synthesis during S-phase of cell cycle and blocks mitosis. 
Cytotoxicity of anthracyclines is thought to induce DNA damage and apoptosis (Laurent 
29 
 
 
 
and Jaffrezou, 2001). The commonly used anthracycline in this regimen include 
daunorubicin, doxorubicin, idarubicin or synthetic anthracycline analogues like 
mitoxantrone (Burnett, 2012; Roboz, 2012). CR may be achieved in approximately 60–80% 
of patients aged less than 60 years (Hann et al., 1997; Rees et al., 1996) and 40-60% of 
older patients (Rowe, 2009). Variations in this regimen have included the incorporation 
of high dose of cytarabine (HiDAC) (Bishop et al., 1996), double-dose induction 
(Castaigne et al., 2004), and the addition of other agents such as Cladribine, a purine 
analogue as a cytotoxic drug (Holowiecki et al., 2012; Holowiecki et al., 2004; Robak, 
2003). 
After the induction therapy, post-remission therapy aims to destroy leukemia cells 
that survived induction chemotherapy but are undetectable by conventional studies. There 
are three basic options for post-remission therapy (in order of increasing intensity): 
consolidation chemotherapy, autologous hematopoietic stem cell transplantation (HSCT), 
or allogeneic HSCT (Rowe, 2009).  Still, treatment of older adults, representing the 
majority of patients with AML, remains quite unsatisfactory. Less than 10% are long-
term survivors, and the cure rate of older patients has only minimally improved over the 
past three decades. 
The most promising treatment approaches are to develop molecularly targeted 
therapies. The feasibility and efficacy may vary between AML subtypes and specific 
mutations found in samples (Hamadani and Awan, 2010). A good example is the usage of 
all-trans retinoic acid in treating acute promyelocytic leukemia (APL). APL was 
classified as AML-M3 in the older French-American-British (FAB) classification system 
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(Table I.2) and is currently classified as acute promyelocytic leukemia with 
t(15;17)(q24.1;q21.1); PML-RARA in the WHO classification system (Table I.3). All-
trans retinoic acid promotes the terminal differentiation of malignant promyelocytes to 
mature neutrophils (Huang et al., 1988). It shows good efficacy and is now a standard 
regimen combined with chemotherapy in induction treatment (Hu et al., 2000; Jeddi et al., 
2011; Liu et al., 2011). 
  
I.C.3 CBF AML 
CBF related hematopoietic malignancies account for about 10-16% of AML (Zeisig 
et al., 2012). Specifically, 5-8% of AML cases present with the translocation 
t(8;21)(q22;q22) (Zeisig et al., 2012).  This chromosomal translocation creates the 
RUNX1-ETO fusion gene that fuses RUNX1, including the RHD, to the ETO gene 
(Rowley, 1973) (Miyoshi et al., 1991). Other chromosomal translocations associated with 
chromosome 21 implicate RUNX1 in fusion proteins as well, such as t(12;21) in acute T 
cell leukemias, creating the fusion protein TEL-RUNX1 (Look, 1997). In addition, 
RUNX1 point mutations have been identified in a variety of hematologic malignancies.  
Megakaryocytic maturation and platelet formation is regulated by RUNX1 (Bluteau et al., 
2012; Elagib et al., 2003; Jalagadugula et al., 2010; Lordier et al., 2012). Cases with 
familial platelet disorder show point mutations (nonsense, missense and intragenic 
deletion mutations) of RUNX1, and present decreased platelet counts with high incidence 
of AML (Kirito et al., 2008; Song et al., 1999). RUNX1 point mutations, including 
nonsense, missense and frameshift mutations, also occur in 5-10% de novo AML and 
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MDS (Osato et al., 1999; Preudhomme et al., 2000) and are common in therapy-related 
MDS and AML (16-40%) (Christiansen et al., 2004; Harada et al., 2003). These 
mutations frequently cluster on RHD and C-terminal of RUNX1.  
Another 5-8% of cases of AML have inv(16)(p13;q22) (Zeisig et al., 2012). This 
chromosomal inversion disrupts the CBFB gene (located on 16q22) and fuses it with the 
C-terminal half of the MYH11 gene (located on 16p13) which encodes the smooth muscle 
myosin heavy chain (SMMHC) protein (Liu et al., 1993). The fusion gene CBFB-MYH11 
encodes a fusion protein called CBFβ-SMMHC. The karyotype inv(16)(p13;q22) or the 
related t(16;16)(p13;q22) was particularly associated with the M4Eo subtype in the FAB 
classification of AML (Larson et al., 1986; Le Beau et al., 1983; Sole et al., 1992). This 
AML subtype presents eosinophils with distinctly abnormal morphology, cytochemical 
staining and ultrastructure (Le Beau et al., 1983).  
Overall, AMLs with t(8;21) and inv(16) have favorable prognosis. After induction 
therapy, frequently using anthracycline- and cytarabine, approximately 90% of the CBF 
AML patients achieve a CR (Lowenberg et al., 2011; Marcucci et al., 2005; Schlenk et al., 
2004). However, the 5 year OS rate is around 60% to 70% in younger patients (Age<60), 
and 30% in elderly patients (Age >60) (Prebet et al., 2009). In addition, the 5 year 
cumulative incidence of relapse is 57% and 48% for inv(16) and t(8;21) AMLs, 
respectively (Marcucci et al., 2005). These statistics call for a better therapy even for 
those AMLs with favorable karyotypes. HiDAC has been used in treatment of CBF 
AMLs. However, HiDAC reduced relapse rates but not necessarily increased OS in some 
studies (Marcucci et al., 2005; Miyawaki et al., 2011) and the optimal dose of cytarabine 
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and number of chemotherapy courses is not commonly defined (Paschka et al., 2013). 
The immunoconjugate gemtuzumab ozogamicin (GO) combines a DNA-damaging toxin 
with an antibody directed against the CD33 antigen, which is expressed on leukemia cells 
from more than 90 % of patients with AML (Takeshita, 2013). A significant survival 
benefit was observed in CBF AML patients who did receive GO compared with those 
who did not receive GO (OS at 5 years 79% vs 51%) (Burnett et al., 2011). However, this 
drug was withdrawn from the market in 2010 due to safety concerns. Alternative anti-
CD33 antibodies have been or are being explored in clinical trials (Paschka and Dohner, 
2013). However, there has not been any molecular therapy specifically targeting CBF-
SMMHC in clinics so far. These clinical data echo the important functions of CBF in 
hematopoiesis and raise the need for better therapies, which encourage researchers, like 
us to investigate the molecular mechanisms of CBF-SMMHC in hematopoiesis and 
leukemogenesis. 
 
I.D Molecular Function of CBF-SMMHC 
 
I.D.1 CBF-SMMHC structure 
The CBF-SMMHC is a fusion protein with N-terminal amino acid (1-165) of 
CBF and various lengths of SMMHC C-terminal end, depending on the inversion 
breakpoints in the MYH11 gene (Liu et al., 1995). All the fusion genes identified so far 
have the inversion breakpoints in the region encoding the coiled-coil domain of the 
myosin tail, which is responsible for dimerization and multimerization of the myosin 
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molecule (Shigesada et al., 2004).  The multimerization process is known to depend on 
the assembly competence domain (ACD) located within exon 40 of SMMHC (Ikebe et al., 
2001; Kummalue et al., 2002; Sohn et al., 1997). Wildtype CBF binds to RUNX1 via its 
heterodimerization interface (Warren et al., 2000), which is retained in CBF-SMMHC. 
Furthermore, the fusion between the coiled-coil domain of SMMHC and CBF creates a 
novel binding site for RUNX1, called the RUNX1 high-affinity binding domain (HABD) 
(Lukasik et al., 2002). As a result, CBF-SMMHC binds RUNX1 at two sites, which is 
associated with higher binding affinity. This high-affinity RUNX1 binding has been 
proposed to explain the dominant nature of CBF-SMMHC function over wild-type 
CBF (Lukasik et al., 2002).  A following study confirmed the higher binding affinity of 
CBF-SMMHC to RUNX1 by one order of magnitude or more, and mapped a hyper-
heterodimerization domain in residues 134-165 of CBF and exons 33-36 of SMMHC 
(Figure I.3A) (Huang et al., 2004). Also, a repression domain was mapped to exons 39-
40 in SMMHC (Huang et al., 2004; Lutterbach et al., 1999). A bipartite model for the 
structure of CBF-SMMHC complexed with RUNX1 was proposed based on those 
studies (Figure I.3B) (Shigesada et al., 2004). Basically, the fusion protein binds to 
RUNX1 by binding sites in CBF and the hyper-heterodimerization domain. In the 
meantime, the complex of CBF-SMMHC and RUNX1 form dimer and ultimately 
multimer by the coiled-coil domain.  
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Figure I.3 CBF-SMMHC structure and bipartite model of multimer assembly. (A) 
Diagram of CBF-SMMHC structure: first 5 exons of CBF (orange) fused with last 9 
exons of MYH11 (blue). Expansion of each domain was labeled as a double arrow line. 
HABD, High-Affinity Binding Domain; ACD, assembly competence domain. (B) A 
bipartite model for the structure of CBF-SMMHC complexed with RUNX1 with three 
stages. The red-colored and the gray-colored ovals represent RUNX1 and CBF, 
respectively. In the filamentous multimer, the dimeric unit is depicted in a simplified 
form. This figure was adapted from Shigesada et al., 2004. 
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I.D.2 Mechanisms of dominant inhibition 
The strong evidence supporting the dominant inhibition of CBF functions by the 
fusion protein CBF-SMMHC is the embryonic lethality due to multiple hemorrhages 
(around E12.5) and lack of definitive hematopoiesis in the Cbfb+/MYH11 embryos (Castilla 
et al., 1996), as this phenotype mimics the Cbfb-/- and Runx1-/- embryos (Niki et al., 1997; 
Okuda et al., 1996; Sasaki et al., 1996; Wang et al., 1996b; Wang et al., 1996c). 
Accordingly, definitive hematopoiesis of Cbfb-/- embryos is restored by ectopic 
expression of full-length Cbfb transgenes but not Cbfb-MYH11 transgenes (Miller et al., 
2001). 
Exogenous expression of CBF-SMMHC inhibited the G1 to S cell cycle transition 
in myeloid and lymphoid cells (Cao et al., 1997). Viral expression of CBF-SMMHC 
also slowed proliferation of murine and human primary cells (D'Costa et al., 2005). These 
observations correlate to the promotion of cell cycle by exogenous expression of RUNX1 
(Ichikawa et al., 2008; Strom et al., 2000).   
There are two classic models to explain the dominant negative role of CBF-
SMMHC on RUNX1 function:  
The sequestration model was first proposed by Paul Liu in 1995 (Liu et al., 1995). 
This model states that CBF-SMMHC forms multimeric aggregates that tether RUNX1 
from binding to CBF, and resulting in insufficient RUNX1/CBF available in 
regulatory regions of the genome. This model is supported by observations that CBF-
SMMHC can cause altered subcellular localizations of Runx1 in a state closely 
colocalized with the fusion protein. This colocalization can happen in the nucleus as 
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multimerized complexes, which sometimes form large rod-like inclusion bodies 
(Wijmenga et al., 1996). It can also happen in the cytoplasm as deposits on cytoskeletal 
filaments or aggregates (Adya et al., 1998; Lu et al., 1995). The relative distributions of 
CBF-SMMHC/RUNX1 complexes between the nucleus and the cytoplasm were shown 
to depend on the level of expression of CBF-SMMHC and also the kind of cells studied 
(Adya et al., 1998; Cao et al., 1998; Kummalue et al., 2002). Particularly in inv(16) 
leukemic cells, approximately equal distributions between nucleus and cytoplasm were 
seen (Kanto et al., 2000; Liu et al., 1996). 
The second model is the repression model, first named the “interference” model by 
Paul Liu, proposes that the RUNX1/CBF-SMMHC complex could alter the assembly of 
sequence-specific transcription factors on adjacent sites in the enhancers of certain target 
genes by either causing steric hindrance or participating in novel interactions with other 
proteins (Liu et al., 1995). A subsequent version of this model, called corepressors-
recruiting model, was proposed in 1999 by Scott Hiebert (Durst et al., 2003; Lutterbach 
et al., 1999). This model is based on the findings that CBF-SMMHC formed ternary 
complexes with RUNX1 and repressor protein mSin3A, also associated with histone 
deacetylase 8 (HDAC8) and that the C-terminal 163 amino acids (exons 38-42) of the 
myosin tail in the fusion protein acted as a transcriptional repressor. In addition, it was 
also shown that multimerization of the fusion protein by the “assembly competence 
domain” (ACD) in SMMHC region is required for transcriptional repression and 
interaction with corepressors (Durst et al., 2003). 
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In summary, multiple studies may support each of these models, leaving to 
interpretation whether CBF-SMMHC may act by sequestration or repression of target 
gene expression. There is a unifying view that sequestration and repression may both be 
contributing mechanisms to CBF-SMMHC function. The relative importance of each 
depends on the cell type and experimental or physiological conditions. Further studies 
utilizing endogenous expression of CBF-SMMHC and RUNX factors are needed to 
provide compelling evidence in support of the relevant mechanism of action. 
CBF-SMMHC can repress several RUNX related targets, such as CDKN1A (gene 
encodes p21) and RUNX3 (Cheng et al., 2008; Lutterbach et al., 1999), but there are 
several studies suggesting that CBF-SMMHC may have Cbfb/Runx1 -inhibition 
independent function. For example, the fusion protein can repress CEBPA, which is a 
critical TF for myeloid differentiation regulated by RUNX1/CBF. However, this 
repression may not result from a direct transcriptional regulation, but instead an indirect 
translational inhibition of CEBPA mRNA mediated by induction of calreticulin (Helbling 
et al., 2005). Interestingly, a recent study using Chip-sequencing technology disclosed 
that the fusion protein localized in RUNX1 occupied promoters and a set of genes was 
repressed upon CBF-SMMHC knock-down in ME-1 cells [an inv(16) patient derived 
cell line] (Mandoli et al., 2014). These data suggest that CBF-SMMHC may activate a 
distinct set of genes which may not necessarily be regulated by normal CBF. Also, during 
primitive hematopoiesis, Cbfb-MYH11 delayed differentiation characterized by sustained 
expression of Gata2, Il1rl1, and Csf2rb, a phenotype not presented in Cbfb and Runx1 
knockout embryos (Castilla et al., 1996; Hyde et al., 2010).  
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I.D.3 Leukemogenesis 
The expression of CBF-SMMHC in heterozygous Cbfb+/MYH11 knock in embryos 
induced a block in definitive hematopoiesis and mid-gestation lethality (Castilla et al., 
1996). In order to bypass this phenotype and study the role of CBF-SMMHC in 
leukemia initiation and maintenance in adult hematopoiesis, leukemia latency was 
studied in chimeric mice generated with Cbfb+/MYH11 embryonic stem (ES) cells and 
treated with the mutagen N-ethyl-N-nitrosourea (Castilla et al., 1999). This study showed 
that the fusion protein CBF-SMMHC blocked adult myeloid and lymphoid 
differentiation and these mice developed AML only after gain of cooperating mutations 
by N-ethyl-Nnitrosourea mutagenesis. A following study using retroviral insertion 
mutagenesis in the chimeras also identified genes that synergized with CBF-SMMHC in 
the pathogenesis of AML (Castilla et al., 2004), strengthening the indication that CBF-
SMMHC is necessary but not sufficient in leukemia development.  
Using a conditional allele of Cbfb56M/+ which can be restored to CbfbMYH11/+ with 
Mx1-Cre inducible system (Kuhn et al., 1995), our laboratory has previously found 
several hematopoietic abnormalities induced by the fusion protein in the adult stage (Kuo 
et al., 2008; Kuo et al., 2006). First, it expands the HSC compartments; second, it reduces 
HSC multilineage repopulation capacity under competitive conditions; third, it blocks 
megakaryocytic differentiation; forth, it induces distinct abnormal myeloid progenitors 
(AMPs) with reduced proliferation capacity able to develop AML after acquiring other 
mutations (Kuo et al., 2006). Furthermore, CBF-SMMHC impairs differentiation of 
common lymphoid progenitors, revealing an essential role for RUNX in early B-cell 
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development (Kuo et al., 2008). In addition, expression of Cbf reduces CBF-SMMHC 
induced AML as evidenced by the observation that loss of the wildtype allele of Cbfb 
accelerated the leukemogenesis in the Cbfb-/MYH11 mice (Heilman et al., 2006).  
A recent study indicated that the C-terminus of CBF-SMMHC is required to induce 
embryonic hematopoietic defects and leukemogenesis, utilizing a CBF-SMMHCC95 
knock-in allele (Kamikubo et al., 2013). In contrast, the HABD seems not to be necessary 
for leukemogenesis, even though hematopoietic defects associated with Runx1-inhibition 
were partially rescued in knock-in mice expressing CBF-SMMHC with a HABD 
deletion (Kamikubo et al., 2010), which suggest that RUNX1 dominant inhibition may 
not be a critical step for leukemogenesis by CBF-SMMHC. 
 
I.E Cooperating mutations with CBF-SMMHC 
The driver oncogenic events in AMLs have been divided into two classes according 
to the two-hit hypothesis of leukemogenesis proposed by Gary Gilliland (Dash and 
Gilliland, 2001). Briefly, the class I mutations confer a proliferation or survival 
advantage to blast cells, while class II mutations block myeloid differentiation and give 
self-renewability. According to the molecular function of CBF-SMMHC, this fusion 
protein clearly behaves as a class II mutation and it requires other cooperating mutations 
(probably the Class I mutations) to drive leukemia.  
The common secondary mutations found in inv(16) patients include activating 
mutations in c-KIT (10–45%) (Muller et al., 2008), NRAS (26–38%) (Bacher et al., 2006; 
Valk et al., 2004a), KRAS (7–17%) (Bowen et al., 2005; Valk et al., 2004a), FLT3 (<10%) 
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(Muller et al., 2008) and inactivating mutations in CBL (3-5%) (Abbas et al., 2008; 
Reindl et al., 2009). Interestingly, these mutations all result in deregulation of a very 
important pathway in hematopoiesis, the RTK signaling pathways. 
 
I.E.1 RTK signaling pathways 
 
RTKs 
Receptor tyrosine kinases (RTKs) are critical effectors of cell fate by initiating 
intracellular signaling events that elicit various cellular responses such as survival, 
proliferation, differentiation, and motility (Hubbard and Till, 2000). Fifty-eight RTKs are 
encoded within the human genome, which belong to 20 subfamilies as defined by genetic 
phylogeny (Lemmon and Schlessinger, 2010). Among that, class III RTK family, also 
named as PDGF receptor family is characterized by five extracellular immunoglobulin-
like domains, a single transmembrane segment, a juxtamembrane (JM) domain and a split 
cytoplasmic tyrosine kinase domain (TKD) (Rosnet and Birnbaum, 1993). Some 
members of class III RTK family, including c-KIT and FLT3, play major roles in 
hematopoiesis and are frequently mutated in inv(16) AMLs (Muller et al., 2008). c-KIT is 
the receptor for SCF, which is a multipotent hematopoietic growth factor for early 
progenitor cells with strong synergistic activities with other growth factors (Martin et al., 
1990; Williams et al., 1990). The FLT3 ligand (FL) is homologous to SCF and M-CSF 
(Hannum et al., 1994) and functions as a multipotent cytokine affecting a broad range of 
hematopoietic cell expansion (McKenna et al., 2000).  
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Binding of the ligand to RTKs induces dimerization of the receptors, followed by 
transphosphorylation of specific tyrosines which ultimately stabilizes the active 
conformation of the receptor (Masson and Ronnstrand, 2009). For c-KIT, 
autophosphorylation of the tyrosines in the JM domain occurs first (Mol et al., 2003). The 
JM domain is considered to sterically hold the activation loop in an inactive conformation 
in the absence of ligand binding (Mol et al., 2004). FLT3 was shown to be auto-inhibited 
by a similar mechanism (Griffith et al., 2004). Upon phosphorylation, the phosphate 
group interrupts the autoinhibited complex and the introduction of internal tandem 
duplications (ITDs) in FLT3 is thought to act in a similar manner, making a leaky 
autoinhibition (Schlessinger, 2003).  
The RTK activities are regulated by Src family kinases (SFKs) and Casitas B-cell 
lymphoma (CBL). SFKs positively regulate the receptor via phosphorylation of a Src 
Homology 2 Domain Containing Protein (SHC) and negatively regulate the receptor via 
ligand-induced internalization and activation of E3 ubiquitin ligase CBL protein (Broudy 
et al., 1999; Corey and Anderson, 1999; Masson et al., 2006). Members of the CBL 
family including CBL, CBL-b and CBL-c, play a major role in the ligand-dependent 
ubiquitination of many RTKs, such as c-KIT and FLT3 (Reindl et al., 2009; Thien and 
Langdon, 2001; Zeng et al., 2005). They all possess a highly conserved N-terminal 
domain consisting of a tyrosine kinase binding (TKB) domain and a RING finger domain, 
both necessary for ubiquitin ligase activity. The TKB domain is required for CBL 
recruitment to tyrosine-phosphorylated proteins (Lill et al., 2000). The RING finger 
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domain associates with an E2 ubiquitin-conjugating enzyme (Yokouchi et al., 1999), 
leading to the transfer of ubiquitin molecules to lysine residues on the target protein. 
The phosphotyrosine sites on the activated receptors can serve as docking sites that 
allow the binding of signaling molecules and triggers three major downstream pathways: 
MEK/ERK, PI3K and STAT pathways (Figure I.4). 
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Figure I.4 RTK signaling pathways. The red reverted triangle represents the ligand. 
The cyan columns represent the RTK dimer. All the components in the MEK/ERK, PI3K 
and STAT pathways are in purple, orange and red, respectively. Other regulatory proteins 
are in green. Arrow stands for activation and flat arrow stands for inhibition. P, 
phosphorylation. 
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MEK/ERK pathway 
The Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-
regulated kinase (ERK) signaling pathway has key roles in the transmission of 
proliferative and survival signals from membrane-bound receptors, such as c-KIT and 
FLT3 (Steelman et al., 2011).  
The RAS protein belong to a family of small GTPases including H-RAS, N-RAS, 
K-RAS4A and K-RAS4B (if not specified, K-RAS in this dissertation is used to refer to 
the ubiquitously expressed K-RAS4B) that have identical guanine nucleotide and effector 
binding domains but diverge substantially within the hypervariable region (HVR) 
(Karnoub and Weinberg, 2008; Schubbert et al., 2007). The HVR of all RAS isoforms 
terminates with a CAAX motif, where the cysteine is prenylated by farnesyltransferase 
(Ward et al., 2012). After prenylation, the AAX is removed by Ras-converting enzyme 1 
(RCE1), and the carboxyl group of isoprenylcysteine is methylated by isoprenylcysteine-
carboxyl-methyltransferase (ICMT). These lipid modifications provide weak membrane 
binding affinity that is stabilized by a second signal motif. For K-RAS4B, this is provided 
by a polybasic lysine domain, which interacts strongly with membrane. In contrast, H-
RAS, N-RAS, and K-RAS4A are palmitoylated at cysteine(s) adjacent to the CAAX 
motif. These posttranslational modifications are essential for correct trafficking and 
subcellular localization of each isoform (Mor and Philips, 2006). K-RAS4B localizes 
directly to the plasma membrane (PM) through an unknown mechanism. H-RAS, N-RAS, 
and K-RAS4A traffic from the endoplasmic reticulum (ER) though the Golgi to the PM 
in a dynamic cycle that is regulated by depalmitoylation and repalmitoylation. 
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Depalmitoylation is mediated by acyl protein thioesterase 1 (APT1) and APT2 (Mor and 
Philips, 2006). 
The RAS proteins regulate cell fate by cycling between active GTP-bound and 
inactive GDP-bound conformations (RAS-GTP and RAS-GDP). Guanine nucleotide 
exchange factors (GEFs), such as son of sevenless homolog (SOS) protein, can activate 
RAS by releasing GDP from RAS. Guanine activating proteins (GAPs), such as 
Neurofibromin 1 (NF1), act as negative regulators of RAS by favoring the 
dephosphorylation of GTP.  
After activation of RTK, the SHC adaptor protein associates with the C-terminus of 
the activated growth factor receptor after phosphorylation by SFKs (Steelman et al., 
2011). SHC recruits the growth factor receptor-bound protein 2 (GRB2) and SOS, 
resulting in the loading of membrane-bound RAS with GTP (Downward, 2003). Src 
homology-2 domain –containing phosphatase 2 (SHP2) is also recruited to the receptors 
(Heiss et al., 2006), and dephosphorylates RAS-GAP binding sites, keeping RAS in an 
active state (Dance et al., 2008). RAS-GTP then recruits RAF to the membrane where it 
becomes activated, likely via a SFK (Franklin et al., 2006; Marais et al., 1995; Marais et 
al., 1997; Mason et al., 1999). RAF is responsible for phosphorylation of MEK1/2 and 
then MEK1/2 phosphorylates ERK1/2 (Derijard et al., 1995; Xu et al., 1995). Other 
means of ERK phosphorylation have been suggested to occur via its association with the 
tyrosine phosphatase SHP2 (Ronnstrand et al., 1999). Activated ERK1/2 phosphorylates 
and activates a group of substrates, including p90 ribosomal six kinase-1 (p90Rsk-1) (Xing 
et al., 1996). p90 Rsk-1 can activate the cAMP response element-binding protein (CREB) 
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transcriptional factor, which can influence gene expression (Xing et al., 1996). Activated 
ERK can also translocate into the nucleus and phosphorylate additional TFs, such as 
ELK-1, CREB, FOS and others (Davis, 1995). These TFs bind promoters of many genes, 
including growth factor and cytokine genes that are important in promoting proliferation 
and preventing apoptosis in hematopoietic cells.  
 
PI3K pathway 
The phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that 
phosphorylate the 3′-hydroxyl group of phosphoinositides. The members of class IA 
PI3K which are activated by RTKs, exist in a heterodimeric complex composed of a 110 
kD (p110  or )-catalytic subunit and a 85 kD (p85  or p55)-regulatory subunit 
with two src homology 2 (SH2) domain which can bind to tyrosine-phosphorylated 
proteins (Klippel et al., 1994).  
Stem cell factor (SCF) induces association of the SH2 domain of the p85α subunit 
with Y721 in c-Kit (Serve et al., 1995). Besides, GAB2 is also an important mediator of 
SCF-induced PI3-kinase activation (Sun et al., 2008; Yu et al., 2006). In the case of FLT3, 
the human receptor lacks a direct binding motif for the p85α, whereas the murine form 
contains this motif and has been verified to directly associate with p85α (Rottapel et al., 
1994). Human FLT3 was found to phosphorylate docking proteins GAB1 and GAB2, 
which suggests that human FLT3 may activate the PI3K pathway indirectly through these 
intermediates (Zhang and Broxmeyer, 2000). 
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Upon activation, PI3K phosphorylate the membrane bound lipid 
phosphatidylinositol-4, 5-bisphosphate (PIP2) to phosphatidylinositol-3, -4, 5-
trisphosphate (PIP3), which can be dephosphorylated by phosphatase and tensin 
homologue (PTEN) (Engelman et al., 2006). PIP3 recruits serine/threonine kinase AKT to 
the membrane. AKT is the best known downstream target and a mediator of survival and 
proliferation (Datta et al., 1996). AKT is then phosphorylated on T308 by 3-
phosphoinositide-dependent kinase-1 (PDK1) (Scheid et al., 2002). The second 
phosphorylation at S473 by the mammalian target of rapamycin complex 2 (mTORC2) 
locks AKT in an active conformation. Phosphorylation of both residues is required to 
activate AKT, which in turn activate/inactivate a variety of substrates by phosphorylation, 
such as FOXO proteins, Bad, glycogen synthase kinase 3 (GSK3), murine double minute 
2 (MDM2) and tuberus sclerosis complex 2 (TSC2) (Engelman et al., 2006). These 
substrates further regulate other downstream targets, such as mTORC1, BCL-xL, BIM 
and MYC in protein synthesis, cell cycle, cell survival and metabolism. 
A crosstalk between PI3K and RAS has been suggested in several studies. The PI3K 
regulatory subunit p85 inhibits p110 activation by RAS and this blockage is released by 
RTK stimulation (Jimenez et al., 2002). Thus, RTKs lacking a direct p85 binding site, 
such as human FLT3, are able to activate PI3K through GAB1, GAB2 or RAS. 
Conversely, PI3K has also been shown to activate RAS and MEK (Wennstrom and 
Downward, 1999). 
 
STAT pathway 
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Normally, STATs are located in the cytoplasm. Upon phosphorylation directly by a 
RTK or SFK (Levy and Darnell, 2002), STATs dimerize and translocate into the nucleus. 
Activated STATs bind to specific DNA sequences to initiate transcription of target genes. 
For example, STAT3 activates the c-MYC gene in response to IL-6 (Coffer et al., 2000) 
and STAT5 induces expression of BCL-xL in response to erythropoietin (Socolovsky et 
al., 1999). 
The crosstalk between signaling pathways, such as STAT and MEK/ERK, play an 
important role in hematopoiesis and leukemia. Phosphorylation of a conserved C-
terminal serine residue (Ser-727) in STAT1 and STAT3 proteins by ERKs enhances the 
STAT transcriptional activity (Zhang et al., 1995), and STAT3 activity are also regulated 
by MEK 1 (Lim and Cao, 2001).  
The ability of c-KIT to activate STAT seems to be cell type, time and context 
specific, since different studies give conflict results (Gotoh et al., 1996; Joneja et al., 
1997; Linnekin et al., 1996; O'Farrell et al., 1996; Ryan et al., 1997). The findings with 
FLT3 are more consistent, as the FLT3-ITD receptor, but not the wild-type FLT3 is able 
to activate STAT5 (Grundler et al., 2005; Kiyoi et al., 2002; Rocnik et al., 2006). 
 
I.E.2 Deregulation of RTK signaling in inv(16) AML 
 
c-KIT mutations 
In CBF leukemias, c-KIT mutations accumulate within exon 8 and exon 17 (Muller 
et al., 2008). Exon 8 encodes the fifth immunoglobulin-like unit in the extracellular 
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domain of c-KIT. Exon 8 mutations can be detected in about 10-20% of inv(16) AML 
patients (Boissel et al., 2006; Cairoli et al., 2006; Care et al., 2003) and usually result in 
single amino acid substitutions at codon D419, causing hyperactivation of the receptor in 
response to SCF (Kohl et al., 2005). Exon17 contains the activating loop and the 
mutations involving exon17 seem to occur exclusively at codon D816 in inv(16) AML. 
Retroviral transduction of Cbf-SMMHC knock-in bone marrow cells with c-KIT 
D816V and D816Y mutants induced leukemia in 60% and 80% recipient mice 
respectively but not in control mice, indicating cooperation between mutated KIT and 
CBFB-MYH11 during leukemogenesis (Zhao et al., 2012). 
The prognostic impact of c-KIT mutations in inv(16) AML patients remains 
controversial. Some studies find an association between c-KIT mutations and poor 
prognosis in t(8,21) AMLs but not inv(16) AMLs (Boissel et al., 2006; Cairoli et al., 
2006). Other studies found that exon 8 mutations correlate with increased relapse rate but 
did not affect OS in inv(16) AMLs (Care et al., 2003) and exon 17 mutations of c-KIT 
increased relapse risk and adversely affect OS in inv(16) AMLs (Paschka et al., 2006).  
 
FLT3 mutations 
FMS-like tyrosine kinase 3 (FLT3) represents the single most common mutated 
gene in AML. It is affect by ITD mutations in the JM domain in 24% (Kottaridis et al., 
2001) or by activating loop mutations in 7% of cases (Thiede et al., 2002). In contrast, 
inv(16) AMLs feature FLT3 mutations at a relative lower rate (<10%) (Muller et al., 
2008).  
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The Flt3+/ITD and Flt3ITD/ITD mice develop a myeloproliferative disease with 
monocytic features (Lee et al., 2007). Analysis of this knock-in mouse model also 
revealed that Flt3-ITD conferred enhanced proliferation and survival properties to 
multipotent progenitors. Retroviral overexpression of FLT3-ITD and CBF-SMMHC in 
mice also indicated cooperation between those two oncogenes in leukemogenesis (Kim et 
al., 2008).  
 
CBL mutations 
The CBL adaptor protein is a negative regulator of RTK activity. CBL transcripts 
lacking exon 8 caused by splice donor or acceptor mutations have been identified in de 
novo inv(16) AML cases (Abbas et al., 2008; Reindl et al., 2009). The deleted transcripts 
encode protein lacking part of linker region and almost the entire RING finger domain, 
which is critical for the E3 ligase activity (Abbas et al., 2008; Swaminathan and 
Tsygankov, 2006). This CBL exon 8 mutant may transform hematopoietic cells by 
constitutively activating the FLT3 pathway (Reindl et al., 2009). . 
 
I.F RAS mutations in myeloid neoplasms 
Mutations in NRAS or KRAS occur nearly exclusively by one nucleotide 
substitutions in codons 12, 13 or 61, which abrogate intrinsic RAS GTPase activity, 
render resistance to GAPs (Schubbert et al., 2007) and thus constitutively activate RAS 
proteins and downstream effectors, such as RAF and MEK/ERK kinases (Beaupre and 
Kurzrock, 1999). Point mutations in NRAS and KRAS genes are found in approximately 
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10–15% and 5% of all AML patients, respectively. Codons most frequently mutated are 
NRAS codon 12 (43%), NRAS codon 13 (21%) and KRAS codon 12 (21%) (Bacher et al., 
2006; Bowen et al., 2005). The RAS mutations identified in the AML patients were all 
heterozygous and do not influence outcome in patients younger than 60 years. In inv(16) 
AMLs, mutations in NRAS (26–38%) (Bacher et al., 2006; Valk et al., 2004a) are more 
commen than mutations in KRAS (7–17%) (Bowen et al., 2005; Valk et al., 2004a). The 
most frequent mutations in the NRAS gene of inv(16) AML patients are NRASG12D and 
NRASQ61K (Bacher et al., 2006).  
Somatic NRAS and KRAS mutations also occur in other myeloid malignancies, 
including juvenile myelomonocytic leukemia (JMML), chronic myelomonocytic 
leukemia (CMML) and myelodysplastic syndrome (MDS) (Bos, 1989; Onida et al., 2002; 
Padua et al., 1988). Similar to inv(16) AMLs, NRAS is mutated 2 to 3 times more 
frequently than KRAS in other hematologic cancers (Bowen et al., 2005; Schubbert et al., 
2007). 
 
I.F.1 Mouse models of oncogenic Ras 
The Ras oncogenes have been studied extensively in mice, both to elucidate the 
mechanisms underlying deregulated cell growth and to develop robust in vivo platforms 
for preclinical trials. 
Allelic activation of oncogenic K-Ras in hematopoietic cells initiates a rapidly fatal 
myeloproliferative neoplasm (MPN) in KrasLSL-G12D/+/Mx1-Cre mice with a medium 
latency of 84 days after oncogenic Kras induction (Braun et al., 2004). In a mouse bone 
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marrow transplantation model using the same knock-in mice, studies have shown that K-
RasG12D induced hematopoietic malignancies in multiple lineages, including thymic T-
cell lymphoblastic lymphoma, T-cell leukemia, and phenotypes closely resembling 
human JMML (Zhang et al., 2009). K-RasG12D expression induces hyperproliferation and 
aberrant signaling in primary hematopoietic stem/progenitor cells and spontaneous 
KrasG12D/+ activation was observed even in the absence of pIpC treatment (Sabnis et al., 
2009; Van Meter et al., 2007). Similarly, KRASG12V-transduced human cord blood (CB) 
CD34+ cells displayed a strong proliferative advantage over control cells (Fatrai et al., 
2011). In addition, Allelic expression of K-RasG12D cooperates with loss of Nf1 in acute 
myeloid leukemogenesis in mice (Cutts et al., 2009). A recent study has also shown that 
mice transplanted with K-RasG12D and RUNX1-ETO co-transduced bone marrow cells 
developed accelerated AMLs (Zhao et al., 2014).  
In contrast to the aggressive MPN phenotype induced in KrasLSL-G12D/+/Mx1-Cre 
mice (Braun et al., 2004), NrasLSL-G12D/+/Mx1-Cre mice induces attenuated diseases with a 
medium latency of 363 days (Li et al., 2011). These diseases include MPN, a disorder 
mimicking human MDS, lymphoproliferation concomitant with myeloid disease, and 
histiocytic sarcoma. Recent studies have shown that NrasG12D/+ HSCs undergo moderate 
hyperproliferation with increased self-renewal associated with hyperactivation of ERK1/2 
(Wang et al., 2013). Effects of NrasG12D/+ on HSCs are bimodal, increasing the frequency 
with which some HSCs divide and reducing the frequency with which others divide (Li et 
al., 2013). Bone marrow transplantation using the NrasLSL-G12D/+ knock-in mice revealed a 
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similar prolonged latency, 96% myeloproliferative disease resembling human CMML (8% 
T-ALL) and aberrant GM-CSF signaling of the mutant cells (Wang et al., 2010a).  
Different from NrasG12D/+ mice, NrasG12D/G12D mice develop an acute MPN with a 
medium latency around 50 days, similarly to KrasG12D/+ mice (Wang et al., 2011a). 
Recipient mice transplanted with 2.5x105 NrasG12D/G12D bone marrow cells all develop T-
ALL (Wang et al., 2011a) and a higher dose (106) of NrasG12D/G12D bone marrow cell 
transplantation results in MPN, T-ALL and B-ALL (Wang et al., 2011b). Using a 
hemizygous NrasG12D/- mice, a recent study has shown that increased NrasG12D gene 
dosage, but not inactivation of WT Nras, underlined the aggressive in vivo behavior of 
NrasG12D/G12D hematopoietic cells (Xu et al., 2013). Those different diseases developed in 
different experimental settings suggest distinct requirements of hematopoietic stem cell 
activity and N-RasG12D signaling in different cell types during leukemogenesis. In the 
retroviral and transplantation system, overexpression of oncogenic human N-RASG12D 
alone rapidly (medium latency around 50 days) and efficiently induces CMML- and 
AML-like disease in mice (Parikh et al., 2006). Retroviral overexpression of murine N-
rasG12D can cooperate with RUNX1-ETO9a in AML (Zuber et al., 2009).  
 
I.F.2 Targeting oncogenic RAS 
 
Targeting posttranslational modifications 
In the 1990s, targeting posttranslational processing of RAS engendered intense 
interest. Drug discovery was first focused on farnesyltransferase inhibitors and they gave 
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disappointing results in clinical trials probably due to compensation by an alternative 
CAAX lipid modification enzyme, geranylgeranyl transferase (Downward, 2003; Karp et 
al., 2001). Unfortunately, combined inhibition of farnesyltransferase and geranylgeranyl 
proved too toxic (Downward, 2003).  
Inactivating of a prenylated Ras C-terminal processing gene, Rce1 in hematopoietic 
cells unexpectedly accelerated MPN in KrasLSL-G12D/+/Mx1-Cre mice (Wahlstrom et al., 
2007). In contrast, conditional inactivation of another C-terminal processing gene, Icmt 
attenuated MPN in these mice (Wahlstrom et al., 2008) and small molecules have been 
identified to block ICMT activity without in vivo test yet (Wang et al., 2010b).  
The palmitoylation/depalmitoylation cycle is a potential therapeutic target for 
selectively inhibiting the growth of hematologic malignancies with NRAS mutations. 
Palmostain B is a novel inhibitor for depalmitoylation mediator APT that causes entropy-
driven diffusion of H-Ras and N-Ras throughout the cell (Dekker et al., 2010). Exposing 
transduced hematopoietic cells from Nras and Kras mutant mice to palmostatin B 
specifically mislocalized N-RasG12D away from the plasma membrane and reduced CFU-
GM and AML blast colony growth without affecting kras mutant cells (Xu et al., 2012). 
More potent APT inhibitors were reported, although systemic toxicities have not been 
fully described (Hedberg et al., 2011). 
Blocking upstream growth-promoting signals that converge to activate GEFs is 
another potential therapeutic strategy. In the case of oncogenic Ras, though the 
oncoproteins are thought be constitutively active, primary hematopoietic cells from 
KrasLSL-G12D/+/Mx1-Cre mice show little basal activation of MEK/ERK or PI3K signaling 
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and respond robustly to growth factor stimulation (Braun et al., 2004; Van Meter et al., 
2007). A compound DCA1 was screened to inhibit Ras activation by interfering with 
SOS-mediated guanine nucleotide exchange, and probably also has activity against other 
exchange factors (Maurer et al., 2012). Although the long-term therapeutic potential of 
this approach is uncertain, treatment with drugs that block upstream proteins might be 
considered in hematologic cancers with RAS mutations that respond to growth factor 
stimulation. 
 
Targeting Ras effectors 
Intensive efforts have been focused on targeting RAF/MEK/ERK and 
PI3K/AKT/mTOR cascades. CI-1040 and PD0325901 are allosteric MEK inhibitors. 
Whereas CI-1040 was ineffective in Nf1flox/flox/Mx1-Cre mice with MPN (Lauchle et al., 
2009), PD0325901 induced dramatic hematologic improvement and greatly prolonged 
survival in both KrasLSL-G12D/+/Mx1-Cre and Nf1flox/flox/Mx1-Cre models of MPN (Chang 
et al., 2013; Lyubynska et al., 2011). MEK inhibitors were also tested in insertional 
mutagenesis models of AML initiated by Nf1 inactivation (Lauchle et al., 2009). In 
contrast to no beneficial therapeutic index in MPN, CI-1040 induced dramatic disease 
regression and markedly extended survival in recipients transplanted with primary Nf1-
deficient AMLs. This suggests that cooperating mutations acquired during progression to 
AML rendered these aggressive cancer cells more dependent on Raf/MEK/ERK signaling. 
However, all of these mice that initially responded to MEK inhibition ultimately relapsed 
despite continued treatment.  Due to minimal activity in RAS-mutant tumors and 
56 
 
 
 
unexpected ocular toxicity (Solit et al., 2006), clinical development of CI-1040 and 
PD0325901 was suspended. Newer MEK inhibitors, such as AZD6244 showed only 
modest and transient antitumor acitivity in advanced AMLs (Ward et al., 2012). Another 
novel potent MEK inhibitor GDC-0973 was developed with a biochemical IC50 estimate 
of 4.2 nmol/L against MEK1 and has antitumor efficacy in BRAF and KRAS mutant 
human xenograft tumor models (Hoeflich et al., 2012). 
Two well-known PI3K inhibitors, LY294002 and wortmannin, prevent ATP to bind 
to and activate PI3K. Preclinical experiments indicate that both drugs induce apoptosis in 
leukemic cells (Polak and Buitenhuis, 2012). However, it has also been demonstrated that 
both inhibitors are detrimental for normal cells (Buitenhuis et al., 2008; Gunther et al., 
1989). A novel PI3K p110 inhibitor, IC87114, has been shown to reduce proliferation 
and survival of both AML blasts and acute promyelocytic leukemia cells without 
affecting the proliferation of normal hematopoietic progenitors (Billottet et al., 2009; 
Sujobert et al., 2005). Another potent PI3K inhibitor GDC-0941 has biochemical IC50 
values of 3 to 75 nmol/L for the 4 class I isoforms of PI3K (Folkes et al., 2008). GDC-
0941 strongly inhibited growth of breast tumor cells in vitro and in vivo, especially those 
with activated PI3K pathway signaling (O'Brien et al., 2010) and presented improved 
efficacy in combination with MEK inhibitor GDC-0973 in xenograft models (Hoeflich et 
al., 2012).  
Downstream effectors such as AKT and mTOR also serve as therapeutic targets in 
the PI3K pathway. AKT phosphorylation inhibitor perifosine induces apoptosis in 
multidrug-resistant human T-ALL cells and primary AML cells, but does not affect 
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normal cells (Chiarini et al., 2008; Papa et al., 2008). The efficacy of perifosine in 
treatment of leukemia is currently examined in several Phase II clinical trials 
(NCT00391560 and NCT00873457) (Polak and Buitenhuis, 2012). As in case of mTOR 
inhibitors, although both rapamycin and its analog CCI-779 exhibit strong anti–tumor 
capacities in vitro (Meyer et al., 2011; Recher et al., 2005; Teachey et al., 2008), only a 
partial response was observed in clinical trials with rapamycin or its analog AP23573 in 
hematologic malignancies (Recher et al., 2005; Rizzieri et al., 2008). 
Due to the modest response of single-specificity inhibitors in patients, the efficacy 
of combination therapy targeting different intermediates of the PI3K signaling module is 
under investigation. Combined inhibition of mTOR and p110 with RAD001 and 
IC87114, respectively synergistically reduces proliferation of AML blasts (Tamburini et 
al., 2008). A Dual-specificity inhibitor like BEZ235 has also been identified, inhibiting 
the activity of both PI3K and mTOR (Maira et al., 2008). This compound significantly 
reduced proliferation and survival in both primary AML cells without affecting the 
clonogenic capacity of normal hematopoietic progenitors (Chapuis et al., 2010). GDC-
0980 is another dual inhibitor targeting both PI3K and mTOR. Low doses of GDC-0980 
potently inhibited tumor growth in xenograft models including those with activated PI3K 
and loss of PTEN (Wallin et al., 2011). 
 
I.G General objectives of this Thesis 
The focus of this Thesis is on how allelic expression of Cbfb-MYH11 and NrasG12D/+ 
in mouse hematopoietic cells altered the pre-leukemic compartments and progress to 
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leukemia by developing a triple mutant Cbfb56M/+/NrasLSL-G12D/+/Mx1-Cre mice. By using 
this valuable preclinical tool, we also want to identify downstream targets of those two 
oncogenes and evaluate small molecule inhibitors targeting Cbf-SMMHC and N-
RasG12D signaling effectors.  
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Preface of Chapter II 
 
The work presented in chapter II “N-RasG12D oncoprotein inhibits apoptosis of pre-
leukemic cells expressing Cbf-SMMHC via activation of MEK/ERK axis” is aimed at 
providing insights into the molecular mechanisms of inv(16) AML with the NRASG12D 
mutation, using genetic and pharmacologic approaches. Most of the data described in this 
chapter has been published in: 
Xue, L., Pulikkan, J.A., Valk, P.J., and Castilla, L.H. (2014). NrasG12D oncoprotein 
inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of 
MEK/ERK axis. Blood 124, 426-436 (Xue et al., 2014). 
All the experiments described in this chapter were performed by me. I also analyzed 
the data and wrote the manuscript. Dr. Lucio Castilla provided intellectual input and 
edited the manuscript. Dr. John Pulikkan participated in the editing of the manuscript.  
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Chapter II 
N-Ras
G12D
 oncoprotein inhibits apoptosis of pre-leukemic cells 
expressing Cbf-SMMHC via activation of MEK/ERK axis 
 
II.A Abstract 
Acute myeloid leukemia (AML) results from the activity of driver mutations that 
deregulate proliferation and survival of hematopoietic stem cells (HSCs). The fusion 
protein CBF-SMMHC impairs differentiation in hematopoietic stem and progenitor 
cells, and induces AML in cooperation with other mutations. However, the cumulative 
function of cooperating mutations in pre-leukemic expansion is not known.  Here, we 
used NrasLSL-G12D; Cbfb56M knock-in mice to show that allelic expression of oncogenic N-
RasG12D and Cbf-SMMHC increases survival of pre-leukemic short-term HSCs and 
myeloid progenitor cells and maintains the differentiation block induced by the fusion 
protein. N-RasG12D and Cbf-SMMHC synergize to induce leukemia in mice in a cell 
autonomous manner with a shorter median latency and increased leukemia-initiating cell 
activity than that of mice expressing Cbf-SMMHC. Furthermore, NrasLSL-G12D; Cbfb56M 
leukemic cells were sensitive to pharmacologic inhibition of MEK/ERK signaling 
pathway, increasing Bim protein levels and apoptosis. This study demonstrates that Cbf-
SMMHC and N-RasG12D promote the survival of pre-leukemic myeloid progenitors 
primed for leukemia by activation of the MEK/ERK/Bim axis, and define NrasLSL-G12D; 
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Cbfb56M mice as a valuable genetic model for the study of inv(16) AML targeted 
therapies. 
 
II.B Introduction 
Acute myeloid leukemia (AML) results from the accumulation of mutations that 
deregulate self-renewal, proliferation, and differentiation in hematopoietic stem and 
progenitor cells (HSPCs) (Reilly, 2005). The understanding of the mechanism dictated by 
“driver” mutations during leukemia development is essential for the identification of 
targets for therapeutic intervention, inducing cell death of AML cells with minimal 
detriment of normal cells.  
The fusion protein CBF-SMMHC is expressed in up to 5-8% of AML, and results 
from a chromosome 16 (p13; q22) inversion [inv(16)], which fuses the first five exons of 
CBFB with the last exons of MYH11 to create the fusion gene CBFB-MYH11 (Le Beau et 
al., 1983; Liu et al., 1993; Zeisig et al., 2012). The standard treatment for patients with 
inv(16) AML includes chemotherapy with cytotoxic agents, such as cytarabine and 
anthracyclines. This treatment has a favorable initial response, but the 5 year overall 
survival remains at approximately 50% to 60% (Pulsoni et al., 2008; Ravandi et al., 2007), 
and reduced to 20% in older patients (Cancer et al., 2006; Marcucci et al., 2005).  
Studies in mice and inv(16) AML patient samples have shown that CBF-SMMHC 
is a “driver” mutation in AML. Expression of the fusion protein in Cbfb+/MYH11 knock-in 
mouse embryos blocked definitive hematopoiesis (Castilla et al., 1996), and is necessary 
for leukemic development in cooperation with other mutations (Castilla et al., 1999; 
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Castilla et al., 2004). Using conditional Cbfb+/56M knock-in mice, we have shown that 
Cbf-SMMHC induces expansion of hematopoietic stem cells (HSCs), establishes a 
myeloid pre-leukemic progenitor population in the bone marrow, and predisposes to 
leukemia (Kuo et al., 2006). The leukemic cells of practically all patients diagnosed with 
subtype M4Eo AML have the inv(16), and this inversion is invariably present in relapse 
samples. Furthermore, the expression profile of inv(16) AML samples defines a unique 
signature, suggesting that CBF-SMMHC re-defines the molecular activity of targeted 
cells (Valk et al., 2004b).  
The inv(16) AML blasts have “secondary mutations” that cooperate with CBF-
SMMHC in leukemia. Frequently, these oncogenic mutations target components of 
cytokine signaling, including small GTPases (N-RAS and K-RAS), receptors (c-KIT and 
FLT3), and adaptor molecules (CBL) (Haferlach et al., 2010a; Reilly, 2005). For example, 
the predominant NRAS mutations are present in up to 45% of inv(16) AML (Muller et al., 
2008; Paschka et al., 2013), with prevalence of G12D and Q61K missense mutations 
(Bacher et al., 2006; Renneville et al., 2008). N-RASG12D can promote proliferation and 
survival in cancer via activation of MEK/ERK and PI3K/AKT pathways (Braun and 
Shannon, 2008), although its function appears to be cell type specific. Recent genetic 
studies have shown that N-RasG12D induces a spectrum of hematologic malignancies in 
mice, including myeloid- and lympho-proliferation after a long latency, but not AML (Li 
et al., 2011; Wang et al., 2013; Wang et al., 2010a; Xu et al., 2013). However, the role of 
N-RasG12D in pre-leukemic progenitor cells primed by other oncoproteins remains unclear. 
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In this chapter, we have taken a genetic approach to define the role of N-RasG12D in 
inv(16) pre-leukemic HSPCs and leukemia development. Using Cbfb56M and NrasLSL-G12D 
conditional knock-in alleles, we show that N-RasG12D cooperates with Cbf-SMMHC in 
survival of pre-leukemic myeloid progenitors and in leukemia development. We use 
transplantation assays to evaluate the median leukemia latency and leukemia-initiating 
cell (L-IC) activity of AML blasts carrying Cbfb56M or Cbfb56M and NrasLSL-G12D alleles to 
show that N-RasG12D contributes to produce aggressive leukemia. The pharmacologic 
inhibition of N-RasG12D activated pathways suggests that leukemic cell survival depends 
on MEK/ERK activity, and that PI3K/AKT signaling may not play a significant role. 
Furthermore, we show that N-RasG12D modulates Bcl-2 pro-apoptotic protein Bim 
expression in the pre-leukemic progenitor and leukemic cells, suggesting that survival 
advantage could be, at least partly, mediated by Bim inhibition.  
 
II.C Materials and Methods 
Mouse strains and treatment 
Transgenic mice carrying the Mx1-Cre, Cbfb56M, NrasLSL-G12D and Bim knock-out 
alleles have been previously described (Bouillet et al., 1999; Haigis et al., 2008; Kuhn et 
al., 1995; Kuo et al., 2006). Mx1-Cre, Nras+/LSL-G12D and Bim+/- mice were in C57BL/6 
background. Cbfb+/56M mice, originally in 129SvEv background, were backcrossed 6 
times into C57BL/6 background for this study. All mice were treated in accordance with 
federal and state government guidelines, and the University of Massachusetts Medical 
School Institutional Animal Care and Use Committee. 
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Genotyping of mice was performed as previously described (Haigis et al., 2008; Kuo 
et al., 2006). The primers for genotyping include: 
For Nras+ allele (500bp PCR product) and NrasLSL-G12D allele (345bp PCR product) 
Nras F2 (5’-AGACGCGGAGACTTGGCGAGC-3’) 
Nras SD5’ (5’-AGCTAGCCACCATGGCTTGAGTAAGTCTGCA-3’) 
Nras R1 (5’-GCTGGATCGTCAAGGCGCTTTTCC-3’)  
For Cbfb+ allele (250bp PCR product) 
WT Fwd (5’-CATCCCTGGGAATGGAGGTA-3’) 
WT Rev (5’-GAGTGGACCATTGTGGCAAG -3’) 
For Cbfb56M allele (263bp PCR product) 
Hyg Fwd (5’-GTTCAGCGAGAGCCTGACCT-3’) 
Hyg Rev (5’-CGGTGTCGTCCATCACAGTT-3’) 
For Mx1-Cre allele (450bp PCR product) 
CreA.F (5’-CCGGGCTGCCACGACCAA-3’) 
CreA.R (5’-GGCGCGGCAACACCATTTTT-3’) 
For Bim+ allele (400bp PCR product) and Bim- allele (540bp PCR product) 
223 (5'-CATTCTCGTAAGTCCGAGTCT-3’) 
224 (5'-GTGCTAACTGAAACCAGATTAG-3’) 
225 (5'-CTCAGTCCATTCATCAACAG-3’) 
Transient Cre activation was induced in mice carrying the Mx1Cre transgene with 
three intraperitoneal injections of 250g polyinosinic-polycytidylic acid [poly(I:C), 
Amersham Biosciences, Piscataway, NJ] every other day at 6 to 8 weeks of age. Mice 
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were initially monitored daily and early signs of leukemia were detected by the presence 
of c-Kit+/Lineage- cells in peripheral blood by flow cytometry. Mice with signs of 
leukemia were under observation twice daily, and moribund leukemic mice were 
euthanized when presenting limited motility, pale paws, and dehydration.  
Flow cytometry Analysis 
Pre-leukemic progenitors: bone marrow cells were harvested from femurs and tibiae 
of each mouse 20 days after Cre activation [treatment with poly(I:C) as described] and 
stained for surface markers: Lineage (Lin) cocktail [Gr1, Mac1, Ter119, B220, CD3, 
CD19 and IgM; IL-7R are also added to the cocktail to exclude common lymphoid 
progenitors (CLPs)], c-Kit, Sca1, CD34, Flt3, and FcRII/III (all from BD Biosciences, 
San Diego, CA). Immunophenotypic characterization of hematopoietic compartments 
included: stem and progenitor compartment (LSK+): Lin-Sca1+c-Kit+, LT-HSCs: 
LSK+Flt3-CD34- (Adolfsson et al., 2001), ST-HSC: LSK+Flt3-CD34+, MPPs: 
LSK+Flt3+CD34+ (Yang et al., 2005), myeloid progenitor cells (LSK-): Lin-Sca1-c-Kit+ 
(Akashi et al., 2000), CMP: LSK-CD34+FcRII/III-, GMP: LSK-CD34+FcRII/III+, and 
MEP: LSK-CD34-FcgRII/III-. 
Apoptosis analysis: bone marrow cells were harvested and stained with indicated 
cell surface markers, and stained with Annexin V and 7-AAD (BD Biosciences, San 
Diego, CA) according to manufacturer’s instructions. Early apoptotic cells were 
determined as Annexin V+/7AAD- by flow cytometry. 
Cell cycle analysis: bone marrow cells were harvested and stained with cell surface 
markers, fixed and permeabilized (BD Cytofix / Cytoperm™ Fixation / Permeabilization 
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Solution Kit; BD Biosciences, San Diego, CA). Cells were stained with Ki67 (BD 
Biosciences, San Diego, CA) and Hoechst (Immunochemistry Technologies, 
Bloomington, MN) for 1 hour on ice, and cell cycle analysis was determined by flow 
cytometry. Fluorescence-activated cell sorter (FACS) data were acquired with LSRII (BD 
Biosciences, San Diego, CA) using FACSDiva software and analyzed with FlowJo 
software (TreeStar, Ashland, OR). 
Morphology analysis of bone marrow cells 
The bone marrow cells from control, Nras, CM, and Nras/CM mice were harvested 
from femurs and tibiae, 20 days after Cre activation. Cells were suspended in PBS, 
cytospun onto glass slides (500 rpm, 1 min), and stained using Wright Giemsa (Fisher 
Scientific Company, Kalamazoo, MI). The representation of progenitor cells was 
quantified using differential counting following the cell morphology description 
previously reported (Fredrickson, 2000; Yang et al., 2013). 
Pathology 
Peripheral blood, bone marrow and spleen cells were harvested from moribund 
leukemic mice, lysed in RBC lysis buffer (5 PRIME, Gaithersburg, MD) and analyzed by 
flow cytometry, using Lineage and c-Kit cell surface markers. White blood cell counts 
were measured using a Hemavet (Drew Scientific Group, Dallas, TX). Peripheral blood 
smears were stained using Wright Giemsa (Fisher Scientific Company, Kalamazoo, MI). 
The preparation of bone marrow, spleen and liver sections and Hematoxylin and Eosin 
(H&E) staining were performed by Histoserv (Germantown, MD). The images were 
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captured using an Axioskop 40 microscope, Axio CamMRC camera (ZEISS, Oberkochen, 
Germany) and the MRGrab software (ZEISS, Oberkochen, Germany). 
Limiting dilution assay 
Spleen cells were harvested from moribund CM or Nras/CM leukemic mice and 160, 
800, 4X103, 2X104, 1X105, 5X105 or 2X106 cells as indicated in the figures were 
transplanted by intravenous injection into sub-lethally irradiated (650 rads) recipient mice 
(8 to 10 week old CD45.1+ B6.SJL-ptprc<a>model#004007 females, Taconic Farms, 
NY). Recipient mice were monitored for leukemia development up to 27 weeks or 36 
weeks as indicated. 
Colony PCR 
Bone marrow cells from 3 independent Nras/CM primary leukemic mice were 
harvested and plated onto MethoCult Medium (M3434, StemCell Technologies, BC, 
Canada) in a concentration of 5X104 cells per 35mm culture dish according to 
manufacturer’s instructions. Individual colonies (20 colonies per sample) were picked 7 
days after incubation, washed in PBS and lysed in 50l KAPA express extract buffer to 
extract genomic DNA (KAPA Biosystems, Wilmington, MA).  
Five microliter of the extracted DNA solution was load for polymerase chain 
reaction (PCR). Each reaction consists of a denaturation at 95oC for 3 minutes, followed 
by 35 cycles of amplification (95oC 15 seconds, 60oC 15seconds, 72oC 30 seconds), and a 
final extension step at 72oC 10 minutes. Primer sequences for each allele are listed below: 
For Nras+ and NrasG12D alleles 
Nras F2 (5’-AGACGCGGAGACTTGGCGAGC-3’) 
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Nras R1 (5’-GCTGGATCGTCAAGGCGCTTTTCC-3’) 
For NrasLSL-G12D allele 
Nras SD5’ (5’-AGCTAGCCACCATGGCTTGAGTAAGTCTGCA-3’) 
Nras R1 (5’-GCTGGATCGTCAAGGCGCTTTTCC-3’)  
For Cbfb+, CbfbMYH11 and Cbfb56M alleles 
mCi4.1F (5’-ATTGCATCCCTGGGAATGG-3’) 
mCi4.1R (5’-AGGCTCAACAGTATCAAGAGTCG-3’) 
hEx5/6n R (5’-TTGTCTTCTTGCCTCCATTTCC-3’) 
Sequencing for mutations in Nras and Kras 
Nine CM leukemic cells were harvest from spleens. The RNA extraction and cDNA 
synthesis (500ng of RNA was used to make cDNA using Oligo-dT primers) were 
performed as previously described (Pulikkan et al., 2012). Nras and Kras cDNA were 
amplified from the 5l total cDNA by Vent Polymerase (New England Biolabs, Ipswich, 
MA). PCR conditions are the same as above and primer sequences included: 
For Nras cDNA 
Nras Fs (5’-TCTGCGGAGTTTGAGGTTTT-3’) 
Nras Rs (5’-CTGTCCTTGTTGGCAAGTCA-3’) 
For Kras cDNA 
Kras Fs (5’-CTGAGACGGCAGGGGAAG-3’) 
Kras Rs (5’-CCAGGACCATAGGCACATCT-3’) 
The PCR products were purified using Gel Purification Kit (Qiagen, Valencia, CA) 
and sequenced by Eton Bioscience (Charlestown, MA). The sequencing primers included: 
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For mutations in Nras cDNA 
Nras seq new (5’-GACTGAGTACAAACTGGTGGTGG-3’) 
Nras seq rev (5’-CTTAATTTGCTCCCTGTAGAGGTT-3’) 
For mutations in Kras cDNA 
Kras seq (5’-AGGCCTGCTGAAAATGACTG-3’) 
Kras seq rev (5’-CCCTCCCCAGTTCTCATGTA-3’) 
The sequencing results were viewed and analyzed by Chromas software 
(Technelysium, Australia). 
Bone marrow transplantation 
Five hundred thousand or two million bone marrow cells from Nras, CM, or 
Nras/CM (all CD45.2+) mice were mixed with 2x105 CD45.1+ wild type (B6.SJL-
ptprc<a>model#004007) bone marrow cells, and transplanted by intravenous injection 
into sub-lethally irradiated recipient mice (8 to 10 week old CD45.1+ B6.SJL-
ptprc<a>model#004007 females, Taconic Farms, NY). Engraftment of donor CD45.2+ 
cells was analyzed two weeks post-transplantation in peripheral blood by flow cytometry. 
The recipient mice were then treated with 3 doses of poly(I:C), and monitored for early 
signs of leukemia up to 37 or 47 weeks as indicated. 
In vitro assays of pre-leukemic and leukemic cells 
Inhibitor response: the bone marrow cells from three Nras/CM mice 20 days after 
Cre activation were harvested, pooled, enriched for Lin- progenitors using “Negative 
Selection Mouse Hematopoietic Progenitor Enrichment Kit”, and grown in cytokine-free 
StemSpan Medium (both from StemCell Technologies, BC, Canada) in the presence of 
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DMSO, MEK (PD325901; LC Laboratories, Woburn, MA) or PI3K inhibitor (GDC-0980; 
Selleckchem, Houston, TX) for 5 hours, and Bim levels were revealed by qRT-PCR and 
immunoblot analysis. Apoptosis analysis was performed in cells with the same treatment 
for 24 hours. The leukemic cells from three Nras/CM mice were independently cultured 
in serum-free medium and treated with PI3K and MEK inhibitors as described above.  
Cell viability assay: wild type bone marrow or spleen cells from CM and Nras/CM 
leukemic mice were enriched for Lin- progenitors, and treated in cytokine-free StemSpan 
Medium with DMSO, MEK or PI3K inhibitor for 48 hours in 96 well white plates 
(Corning Incorporated, Corning, NY), in triplicates or quadruplicates for each sample. 
The cell viability was tested using CellTiter-Glo reagent (Promega, Madison, WI) 
according to manufacturer’s instructions.  
Reverse transcription and quantitative PCR (qRT-PCR) analyses 
The RNA extraction, cDNA synthesis (random primers were used), and qPCR were 
performed as previously described (Pulikkan et al., 2012). Primer sequences included: 
For Actb cDNA 
b-actin F1 (5’-CGAGGCCCAGAGCAAGAGAG-3’) 
b-actin R1 (5’-CGGTTGGCCTTAGGGTTCAG-3’) 
For Bcl2l11 cDNA 
mBim F (5’-GCTGGTGGGACCTGTTTCTA-3’) 
mBim R (5’-TTCAGTGAGCCATCTTGACG-3’) 
Immunoblot analyses 
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Cells were washed with PBS and resuspended in modified RIPA buffer (50mM Tris-
HCl pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40, 0.25% Sodium Deoxycholate) with 
protease inhibitor cocktail III (Calbiochem, Darmstadt, Germany) and phosphatase 
inhibitor cocktail II and III (Sigma-Aldrich, St. Louis, MO). Antibodies included anti-
Bim (cat#2819), anti-Bcl2 (cat#2870), anti-Bcl-xl (cat#2762), anti-Mcl-1 (cat#5453), 
anti-Phospho-Akt (Ser473) (cat#4058), anti-Akt (cat#9272), anti-Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) (cat#9101), anti-p44/42 MAPK (Erk1/2) (cat#9102), anti-
Phospho-Stat5 (Tyr694) (cat#9359), and anti-Stat5 (cat#9358, all from Cell Signaling 
Technology, Danvers, MA). 
Bim knock-down in bone marrow cells 
Retroviral production: shRNA for Scrambled (5'-TACTATCTCTAAGACTTTCT-3' 
for antisense sequence) or mouse Bcl2l11 (5’-ATATATTTAAGTACAAAGGCCT-3’ for 
antisense sequence) were cloned into retroviral vector pMSCV-LTRmiR30-PIG (LMP) 
following manufacturer directions (LMP, Thermo Scientific, Billerica, MA). Stable 
GP+E-86 viral-packaging cells (Markowitz et al., 1988) were transfected with LMP 
constructs using JetPRIME reagent (Polyplus Transfection, New York, NY), and selected 
with 4g/ml puromycin (InvivoGen San Diego, CA). Retroviral supernatants were 
concentrated and titered in 3T3 cells by GFP expression. Knock-down efficiency was 
tested in puromycin selected 3T3 cells by quantitative RT-PCR and immunoblot analyses. 
Bone marrow cell infection: bone marrow progenitor cells were harvested from CM 
mice pretreated with poly(I:C) and 5-fluorouracil, spin-infected twice with retroviral 
supernatants in 7.5mM Hepes Buffer Solution as well as 5g/ml Polybrene (American 
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Bioanalytical, Natick, MA) and cultured for 24 hours. The cells were transferred to serum 
free media for 24 hours to induce Bim expression and were analyzed for apoptosis by 
flow cytometry or sorted for GFP+7-AAD- cells using a BD FACSAria cell sorter (BD 
Biosciences, San Diego, CA) to assay knock-down efficiency. 
Statistics 
Medium latencies of Kaplan-Meier survival curves were calculated using GraphPad 
Prism 6 (GraphPad Software, Inc., La Jolla, CA). The P values of the Kaplan-Meier 
survival curves were calculated by Log-rank (Mantel-Cox) test using GraphPad Prism 6 
(GraphPad Software, Inc., La Jolla, CA). Paired P values as indicated in the experiments 
on inhibitor response of leukemic cells were calculated by two-tailed paired Student t-test 
using Excel (Microsoft Cooperation, Redmond, WA). All other P values were calculated 
by two-tailed heteroscedastic Student t-test using Excel (Microsoft Cooperation, 
Redmond, WA). The leukemia initiating cell activity (L-IC) was estimated by limiting 
dilution assay and calculated based on Poisson distribution using L-Calc software 
(StemCell Technologies, BC, Canada). The nonlinear regression curve fit for viability 
assay was generated using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA). 
 
II. D Results 
 
1. Cbf-SMMHC and N-RasG12D expand pre-leukemic stem and progenitor cells in 
mice 
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The allelic (Cbfb56M) expression of CBF-SMMHC in HSCs induces pre-leukemic 
progenitor cells with impaired differentiation capacity, and progresses to leukemia after 
the accumulation of additional mutations (Kuo et al., 2006). NrasG12D is a frequent 
mutation found in human inv(16) AML, and has been shown to promote the expansion of 
HSCs and myeloid progenitors (Li et al., 2011; Wang et al., 2013). To understand the role 
of N-RasG12D in leukemia progression, we analyzed the frequency of pre-leukemic stem 
and progenitor cells in bone marrow of Mx1Cre (Control), Nras+/LSL-G12D/Mx1Cre (Nras), 
Cbfb+/56M/Mx1Cre (CM), and Nras+/LSL-G12D/Cbfb+/56M/Mx1Cre (Nras/CM) mice, by flow 
cytometry 20 days after Cre activation. The bone marrow cellularity was increased in 
Nras mice, primarily increased in the late (Lin+) progenitor cells (Figure II.1A-C; 
p<0.05). Conversely, CM and Nras/CM mice showed a reduction in bone marrow 
cellularity, with a significant increase in the immature (Lin-) and decrease in the mature 
(Lin+) bone marrow cells (Figure II.1A-C; p<0.01), suggesting a block in myeloid 
differentiation. The number of early progenitor [Lin-Sca1+c-Kit+, (LSK+)] cells in Nras, 
CM, and Nras/CM increased to 5, 3 and 2 fold respectively (Figure II.1D, representative 
FACS plots are shown in Figure A.1 in Appendix A). Activation of N-RasG12D increased 
the multi-potential progenitors (MPPs) by 8 fold, with minimal change of the long-term 
and short term HSCs (LT-HSCs and ST-HSCs; Figure II.1E). Activation of Cbf-
SMMHC increased the MPPs and ST-HSCs by 2 to 4 fold, and reduced the LT-HSCs by 
2 to 3 fold in CM and Nras /CM mice (Figure II.1E; p<0.05). The percentage of ST-
HSCs and MPPs increased similar in CM and Nras/CM, suggesting that Cbf-SMMHC 
directed the expansion of ST-HSC and early progenitors in bone marrow (Figure II.2A-
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B). The total number of myeloid progenitor cells (LSK-) increased 2 fold in the three 
groups compared to Controls (Figure II.1F, p<0.05). The N-RasG12D expression 
expanded all myeloid compartments proportionally (Figure II.1G and Figure II.2C-D) 
as previously shown (Li et al., 2011). The expression of Cbf-SMMHC increased 
primarily the CMP compartment in the bone marrow of CM and Nras/CM mice (Figure 
II.1G and Figure II.2C-D) and hindered N-RasG12D mediated expansion of GMPs in 
Nras/CM mice.  
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Figure II.1 Cbf-SMMHC and N-RasG12D expand pre-leukemic stem and progenitor 
cells. Quantification of bone marrow cells from Mx1Cre (Control, white), Nras+/LSL-
G12D/Mx1Cre (Nras, grey), Cbfb+/56M/Mx1Cre (CM, black), and Nras+/LSL-
G12D/Cbfb+/56M/Mx1Cre (Nras/CM, diagonal) mice by flow cytometry, 20 days after Cre 
activation. (A-C) n=8-14 mice per group: (A) bone marrow cell numbers (per mouse) in 
each group; (B) lineage negative (Lin-) bone marrow cell numbers in each group; (C) 
lineage positive (Lin+) bone marrow cell numbers in each group. BM, bone marrow. *, 
P<0.05; **, P<0.01. 
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Figure II.1 (Cont.) Cbf-SMMHC and N-RasG12D expand pre-leukemic stem and 
progenitor cells. (D-E) n=4-8 mice per group: (D) LSK+ cell numbers in bone marrow; 
(E) long-term (LT-HSCs, LSK+CD34-FLT3-), short-term (ST-HSCs, LSK+CD34+FLT3-) 
hematopoietic stem, and multipotential progenitor (MPPs, LSK+CD34+FLT3+) cell 
number in each group. (F-G) n=5-12 mice per group: (F) LSK- cell numbers; (G) 
common myeloid progenitor (CMP, LSK-CD34+FcRII/III-), megakaryocyte-erythroid 
progenitor (MEP, LSK-CD34-FcRII/III-), and granulocyte-monocyte progenitor (GMP, 
LSK-CD34+FcRII/III+) cell numbers in each group. BM, bone marrow. *, P<0.05; **, 
P<0.01.  
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Figure II.2 Cbf-SMMHC and N-RasG12D expand pre-leukemic stem and progenitor 
cells in mice. (A-B) n=4-8 mice per group: (A) percentage of LSK+ cells in bone marrow; 
(B) percentage of LT-HSC, ST-HSC and MPP in bone marrow. (C-D) n=5-12 mice per 
group: (C) percentage of LSK- compartment; (D) percentage of CMP, MEP and GMP 
compartments in each group. BM, bone marrow. *, P<0.05; **, P<0.01. 
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The morphology (differential counts) analysis of bone marrow cells from each 
genetic group revealed that CM and Nras/CM samples had an increase in 
blast/myeloblasts and promyelocytes and a reduction in immature neutrophils and 
eosinphils (Figure II.3).    
These results show that N-RasG12D and Cbf-SMMHC expression increase short-
term HSCs, MMPs and common myeloid progenitor cells in the early pre-leukemia stage 
in vivo, and suggest that this expansion is mainly driven by Cbf-SMMHC activity in 
Nras/CM mice.  
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Figure II.3 Expression of Cbf-SMMHC increases blasts, myeloblasts as well as 
promyelocytes and reduces neutrophils and eosinophils. Bone marrow cells from 
Control, Nras, CM and Nras/CM mice were harvest, cytospun and stained 20 days after 
Cre activation. (A) representative pictures of different bone marrow cell morphologies.  
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Figure II.3 (Cont.) Expression of Cbf-SMMHC increases blasts, myeloblasts as 
well as promyelocytes and reduces neutrophils and eosinophils. (B) bone marrow cell 
differential counts in each group (n=3 mice per group). *, P<0.05; **, P<0.01. 
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2. Cbf-SMMHC and N-RasG12D provide survival advantage to pre-leukemic 
progenitor cells 
To better understand the role of N-RasG12D and Cbf-SMMHC on pre-leukemic 
progenitor cells, we inquired their functions on proliferation and apoptosis of bone 
marrow progenitors in vivo. Early apoptosis (AnnexinV+/7AAD-) was analyzed in bone 
marrow cells from mice by flow cytometry 20 days after Cre activation. Apoptosis was 
significantly reduced by N-RasG12D or Cbf-SMMHC in both LSK+ and LSK- 
compartments (Figure II.4; p<0.05), with an additive effect in cells expressing N-
RasG12D and Cbf-SMMHC (Figure II.4; p<0.01). A similar result was obtained based 
on a different gating strategy (Figure A.2 in Appendix A). The analysis of cell cycle 
(Hoechst and Ki67 staining) of stem and early progenitor cells (LSK+) revealed a 
reduction in the G0 fraction in CM and Nras/CM mice and an increase in the S/G2/M 
fraction increased in Nras/CM mice (Figure II.5). However, proliferation of myeloid 
progenitor cells (LSK-) was reduced (increased G0/G1 vs S/G2/M) in mice expressing 
Cbf-SMMHC (CM and Nras/CM groups; Figure II.5).  
These results suggest that N-RasG12D and Cbf-SMMHC increase the survival of 
pre-leukemic stem and progenitor cells. In addition, Cbf-SMMHC increases 
proliferation of stem and early progenitor cells but reduces proliferation of myeloid 
progenitor cells. 
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Figure II.4 Apoptosis analyses of bone marrow pre-leukemic cells expressing Cbf-
SMMHC and N-Ras
G12D
. Bone marrow cells from mice treated as in Figure II.1 were 
stained with 7-AAD and Annexin V, and analyzed by flow cytometry. (A) cells were first 
gated by FSC-A/SSC-A, then gated for single cells by FSC-A/FSC-H, and the following 
gating of each compartment is shown; (B) quantification of the ratio of apoptosis levels 
for LSK- (left) and LSK+ (right) cells of each group normalized to control group (n=5-11, 
*, P<0.05; **, P<0.01). 
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Figure II.5 Cell Cycle analyses of bone marrow pre-leukemic cells expressing Cbf-
SMMHC and N-Ras
G12D
. Bone marrow cells from mice treated as in Figure II.1 were 
stained with Ki67 and Hoechst and analyzed by flow cytometry for cell cycle phase. (A) 
cells were first gated by FSC-A/SSC-A, then gated for single cells by FSC-A/FSC-H, and 
the following gating of each compartment is shown; (B) quantification (percentage) of 
cells in G0 (white), G1 (dotted), or S/G2/M (grey) phase for LSK
+ (left) and LSK- (right) 
groups (n=4-8, *, P<0.05; **, P<0.01). 
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3. N-RasG12D cooperates with Cbf-SMMHC to induce acute myeloid leukemia 
To determine whether N-RasG12D synergizes with Cbf-SMMHC in leukemia 
initiation, leukemia latency was analyzed in CM, Nras and Nras/CM mice after Cre 
activation. Nras mice remained healthy up to 35 weeks (experimental endpoint), and CM 
mice developed leukemia with a median latency of 21.43 weeks and 89% penetrance 
(Figure II.6A, dashed and solid lines, respectively; Table II.1). Nras/CM mice 
developed leukemia with a reduced median latency (13.72 weeks, P= 8x10-4) and full 
penetrance (Figure II.6A, dotted line; Table II.1). The median leukemia latency of 
secondary transplantation assays (5x105 leukemic cells) from Nras/CM mice was 
consistently shorter than that of CM mice even with some heterogeneity in each group 
(Nras/CM: 3 weeks, 100% penetrance, CM: 19 weeks, 62.5% penetrance, P<0.0001; 
Figure II.6B-D and Table II.1). The leukemia initiating cell activity (L-IC) was 
estimated using limiting dilution assays in two representative leukemic cells from CM 
and Nras/CM mice, respectively. Concordant to the median latency data, the L-IC 
activities in CM leukemias were 1/528,334 (range: 1/1,268,433 to 1/220,064; 95% 
confidence) and 1/68,380 (range: 1/152,523 to 1/30,657; 95% confidence) for two 
independent clones (B92 and A287), while L-IC activities in Nras/CM leukemias were 
1/1,283 (range: 1/2,927 to 1/562; 95% confidence) and higher than 1/160 leukemic cells 
for two independent clones (B81 and B286) (Figure II.6E-H), which are over 400 fold 
higher than CM leukemias.  
The mice that appear health at the end of experiments (36 weeks) transplanted with 
either A287 or B81 primary leukemic clone were analyzed for appearance of c-kit+ cells 
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in peripheral blood by flow cytometry, existence of cells that harboring CbfbMYH11 alleles 
in white blood cells in peripheral blood and bone marrow by PCR of genomic DNA and 
spleen weight (Figure A.3 and Figure A.4 in Appendix A). There is no sign of leukemia 
development revealed in all the mice (around or less than 1% c-kit+ cells in peripheral 
blood, no CbfbMYH11 allele revealed by PCR in peripheral blood or bone marrow cells, 
spleen weight around 0.1g) except that one mouse transplanted with 160 Nras/CM B81 
leukemic cells. That mouse appeared normal and presented elevated percentage of c-kit+ 
cells (10.2%, Figure A.3C in Appendix A) and enlarged spleen (0.3418g, Figure A.3D 
in Appendix A) in peripheral blood with no detection of recombined Cbf-SMMHC 
allele in genomic DNA from peripheral blood, bone marrow and spleen cells (Figure 
A.4B in Appendix A). That mouse was still counted as leukemia free survival (Figure 
II.6H).  
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Figure II.6 N-Ras
G12D
 induces an accelerated leukemia with higher L-IC activity in 
cooperation with Cbf-SMMHC. (A) Kaplan-Meier curves of leukemia-free survival in 
Nras (dash), CM (solid) and Nras/CM (dotted) mice after Cre activation (time 0); (B) 
Kaplan-Meier survival curves of recipients transplanted with leukemic cells from CM 
(solid) and Nras/CM (dotted) mice; (C-D) Kaplan Meyer survival curves of recipients 
transplanted with leukemic cells from 5x105 (500K) CM (C) or Nras/CM (D) mice, 
plotted as individual clones; red blocks represent the clones used for limiting dilution 
assays. 
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Figure II.6 (Cont.) N-Ras
G12D
 induces an accelerated leukemia with higher L-IC 
activity in cooperation with Cbf-SMMHC. (E-F) Kaplan Meyer survival curves for 
limiting dilution assays, using four concentrations, of two CM leukemia samples; (G-H) 
Kaplan Meyer survival curves for limiting dilution assays, using four concentrations, of 
two Nras/CM leukemia samples. Note: For mice transplanted with 800 B81 leukemic 
cells, one mouse was found dead one day after bleeding at the end of experiment, 
presenting no sign of leukemia (Figure A.3C-D and Figure A.4B in Appendix A) and 
counted as leukemia free survival; for mice transplanted with 160 B81 leukemic cells, 
one mouse presented enlarged spleen (0.3418g) and elevated percentage of c-kit+ cells 
(10.2%) in peripheral blood with no detection of recombined Cbf-SMMHC allele in 
genomic DNA from peripheral blood, bone marrow and spleen cells at the end of 
experiment (Figure A.3C-D and Figure A.4B in Appendix A) and counted as leukemia 
free survival.  
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Table II.1 Leukemia burden in mice carrying the Cbfb
56M
; NRas
LSL-G12D
 knock-in alleles 
Groups Median latency (w) Spleen weight (g) WBC (range 103/µL) 
WT Na 0.08 ± 0.01 5.76 - 9.56 
CM 21.43 1.59 ± 1.21 17.00 - 558.00 
Nras/CM 13.72 2.94 ± 1.37 22.88 - 638.60 
CM 2ry 19 0.31 ± 0.18 6.36 - 32.60 
Nras/CM 2ry 3 0.28 ± 0.11 35.38 - 454.20 
Nras/CM Trans 28.15 0.34 ± 0.06 40.08 - 306.00 
 
Note: wild type (WT); Cbfb+/56M/Mx1Cre (CM); Nras+/LSL-G12D/Cbfb+/56M/Mx1Cre (Nras/CM); 
weeks (w); grams (g); White blood cell count (WBC); secondary transplantation (2ry); Recipient 
mice engrafted with bone marrow cells carrying Nras+/LSL-G12D/Cbfb+/56M/Mx1Cre (Nras/CM 
Trans). 
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The pathology of leukemia was similar between genetic groups (CM and Nras/CM) 
and between primary and secondary leukemias. Analysis of peripheral blood cellular 
composition from leukemic mice revealed a consistent increase in white blood cell (WBC) 
count and increased presence of leukocytes with immature morphology (Figure II.7A 
and Table II.1). Immunophenotypic analysis of peripheral blood revealed the 
predominant presence of immature (c-Kit+, Lin-) cells (Figure II.7B-C). The spleen of 
primary and secondary leukemic mice was enlarged (Table II.1), with evident disruption 
in splenic architecture (Figure II.7D). Histological staining also revealed that leukemic 
cells infiltrated into bone marrow and liver. Quantification of leukemic cell burden was 
confirmed in peripheral blood, spleen and bone marrow from Nras/CM, CM and 
Nras/CM secondary leukemic mice (Figure II.7C).  
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Figure II.7 Characterization of leukemia in mice expressing Cbf-SMMHC and N-
Ras
G12D
. (A) representative Wright Giemsa staining of peripheral blood smears from wild 
type (control), moribund Nras/CM, CM, and Nras/CM secondary leukemic mice. Scale 
bars, 5m. 
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Figure II.7 (Cont.) Characterization of leukemia in mice expressing Cbf-SMMHC 
and N-Ras
G12D
. (B) representative FACS analysis of peripheral blood cells from wild 
type Control, and moribund CM, Nras/CM or Nras/CM secondary leukemic mice, 
showing progenitor cell marker c-Kit (x-axis) and lineage markers (y-axis); (C) 
quantification of FACS analysis in Figure II.7B and similar FACS analysis of peripheral 
blood (PB, left), bone marrow (BM, center) and spleen (SP, right) cells from wild type 
control (WT), moribund CM, Nras/CM, and Nras/CM secondary leukemic mice (**, 
P<0.01). 
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Figure II.7 (Cont.) Characterization of leukemia in mice expressing Cbf-SMMHC 
and N-Ras
G12D
. (D) representative H&E histology sections of bone marrow, spleen and 
liver from wild type control, and moribund CM, Nras/CM mice, and Nras/CM secondary 
leukemic mice (LK, leukemia). Scale bar in bone marrow and spleen: 50m; in liver: 
100m. 
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Juvenile myelomonocytic leukemia can present homozygous mutant NRAS 
expression by uniparental disomy (UPD) (Dunbar et al., 2008). The phenomenon was 
replicated in the N-RasG12D chronic myelomonocytic leukemia (CMML) and AML 
mouse models (Wang et al., 2010a; Xu et al., 2013). Genomic PCR analysis of colony 
forming units (CFUs) from 3 independent Nras/CM leukemia samples confirmed the 
presence the mutant NrasG12D and wild type alleles as well as CbfbMYH11 alleles in all 
cases (Nras+/G12D/Cbfb+/MYH11 genotype; Figure II.8), suggesting that UPD is not a 
frequent event in our AML model.  In addition, we sequenced 9 CM leukemic samples 
and we did not find any spontaneous mutations in codon 12, 13 or 61 of Nras or Kras 
transcripts (Figure II.9 and Figure A.5 in Appendix A). The dilution experiment showed 
a sensitivity of detecting as low as 11% to 20% Nras heterozygous mutations by this 
sequencing method (Figure II.9).  
Together, these data suggest that allelic NrasG12D expression synergizes with Cbf-
SMMHC to induce myeloid leukemia in mice. 
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Figure II.8 Colony PCR confirms presence of both Nras
+
 and Nras
G12D
 alleles. 
Individual colonies formed from three Nras/CM leukemic samples were picked. Genomic 
DNA were extracted and amplified for specific alleles. Result from a representative 
sample is shown. Lanes 1-4 are PCR products from control genomic DNA samples: Lane 
1, Mx1-Cre; Lane 2, Nras+/LSL-G12D/Cbfb+/56M; Lane 3, bulk Nras/CM Leukemic cells; 
Lane 4, water. All of colonies present Nras+/G12D/Cbfb+/MYH11 genotype except for two. 
Those two colonies do not give conclusive PCR products probably due to limited cell 
number in the colonies.  
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Figure II.9 No mutations in codon 12, 13, 61 of Nras or Kras genes were identified in 
CM leukemic cells. Nras and Kras cDNA of 9 CM leukemic cells were sequenced for 
mutations in codon 12, 13 and 61. Nras cDNA from Nras/CM leukemic cells (clone B286) 
serves as a positive control for NrasG12D mutation sequencing with half C (blue) and half 
T (red) in the ACC codon while Nras cDNA from wildtype lineage negative bone 
marrow cells serves as a negative control. Serial dilution was performed by diluting Nras 
cDNA from Nras/CM leukemic cells with Nras cDNA from wildtype lineage negative 
bone marrow cells (1:1, 1:2, 1:4, 1:8 and 1:16 ratio corresponding to 50%, 33%, 20% 11% 
and 6% of Nras/CM cDNA). Representative sequencing results from Nras codon 12 and 
13 of CM leukemic cells (clone B90) are also shown; the complete results of CM 
leukemic cell sequencing are shown in Figure A.5 in Appendix A. 
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4. N-RasG12D and Cbf-SMMHC drive cell autonomous AML in mice  
We inquired whether expression of N-RasG12D and Cbf-SMMHC is sufficient to 
induce leukemia using a donor-cell leukemia assay (Figure II.10A). Briefly, 5x105 
untreated CD45.2+ bone marrow cells from CM, Nras or Nras/CM mice were 
transplanted with 2 x105 CD45.1+ wild type bone marrow cells into sub-lethal irradiated 
CD45.1+ recipient mice. The engraftment efficiency of CD45.2+ donor cells was 
evaluated two weeks after transplantation by flow cytometry analysis of peripheral blood 
cells [donor (CD45.2) cell range: 42-60%, 17-37%, and 38-54% for Nras, CM and 
Nras/CM respectively]. Cre-mediated activation of oncoprotein expression was induced 
by poly(I:C) treatment, and the leukemia latency was monitored thereafter. Under this 
experimental design, Nras/CM recipient mice developed leukemia with a median latency 
of 28.15 weeks and 75% penetrance (Figure II.10B, dotted line; Table II.1). Conversely, 
Nras and CM recipient mice remained healthy for 37 weeks (experimental endpoint; 
Figure II.10B, dashed and solid lines). To test whether the incomplete penetrance in the 
Nras/CM group was due to the limited number of bone marrow cells transplanted, we 
increased the number of donor cells to 2x106 and observed a median latency of 24.72 
weeks and full penetrance of disease in Nras/CM group (Figure II.10C, dotted line). In 
this context, 40% and 50% disease penetrance was observed in Nras and CM groups 47 
weeks after Cre activation, respectively (Figure II.10C, dashed and solid lines). The 
Nras/CM group presented accelerated leukemia development compared to both Nras and 
CM groups, with P value as 0.0031 and 0.0015, respectively (Figure II.10C).  
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Figure II.10 N-Ras
G12D
 and Cbf-SMMHC drive cell autonomous AML in mice. (A) 
experimental design of leukemia analysis in mice transplanted with CD45.2+ test 
[Nras+/LSL-G12D/Mx1Cre (Nras), Cbfb+/56M/Mx1Cre (CM), or Nras+/LSL-
G12D/Cbfb+/56M/Mx1Cre (Nras/CM)] bone marrow cells. The lightning bolt stands for sub-
lethal irradiation; (B) Kaplan-Meier survival curves of recipient mice transplanted with 
5x105 Nras (dash), CM (solid) or Nras/CM (dotted) bone marrow cells and Cre-activated 
after 2 weeks. Red arrow depicts the disease onset of a mouse with mix leukemic and 
myelo-proliferative cells; (C) Kaplan-Meier survival curves of recipient mice 
transplanted with 2x106 Nras (dash), CM (solid) or Nras/CM (dotted) bone marrow cells 
and Cre-activated after 2 weeks; P value (Nras vs Nras/CM) = 0.0031, P value (CM vs 
Nras/CM) = 0.0015. Note: Cells from the peripheral blood of mice that appeared health in 
the group transplanted with either 2x106 Nras or CM bone marrow cells still showed 
presence of mutated alleles during the thesis preparation (data not shown). These mice 
are monitored for the development of disease beyond 47 weeks as shown in the thesis. 
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Immunophenotypic analysis of the peripheral blood cells from mice transplanted 
with 5x105 Nras/CM bone marrow cells revealed a myeloid leukemia phenotype similar 
to that described for the Nras/CM mice (5/6 mice), including increased number of 
leukocytes with immature morphology (Figure II.11A and Table II.1), and increased 
number of Lin-kit+ cells (as illustrated in Figure II.11B, and quantified in Figure II.11C). 
These mice showed splenomegaly (Table II.1) and infiltration of leukemic cells in bone 
marrow, spleen and liver (Figure II.11C-D). One mouse (Figure II.10B, red arrow) 
presented a mixed AML and myelo-proliferative phenotype, with intermediate levels of 
Lin-kit+ cells and high levels of Gr1+Mac1+ cells in peripheral blood, bone marrow and 
spleen (Figure II.11A right, Figure II.11B bottom row and Figure II.11C open-square).  
Together, these studies show that N-RasG12D accelerates Cbf-SMMHC mediated 
leukemia in the presence of competitor wild type bone marrow cells.  
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Figure II.11 Characterization of donor-cell leukemia expressing Cbf-SMMHC and 
N-Ras
G12D
. (A) representative Wright Giemsa staining of peripheral blood smears from 
control (left) and moribund Nras/CM recipient mice with leukemia (LK, center) or with 
mixed myelo-proliferative and leukemia (MPN/LK, right); leukemic cells (red open 
arrow) and granulocytes (black arrow) are shown. Scale bars, 5m. 
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Figure II.11 (Cont.) Characterization of donor-cell leukemia expressing Cbf-
SMMHC and N-Ras
G12D
. (B) FACS analysis of peripheral blood cells from control (top), 
representative leukemic moribund Nras/CM recipient mice (5/6) showing progenitor cell 
marker c-kit (x-axis) and lineage markers (y-axis), and the Nras/CM* (bottom) mouse 
with a mix of leukemia and myelo-proliferative phenotypes; (C) quantification of 
percentage of wild type (Control) and Nras/CM leukemic cells (Nras/CM Trans) in 
peripheral blood (PB), bone marrow (BM) and spleen (SP) cells. Open-square represents 
the mouse that developed mixed AML and myelo-proliferative phenotypes. 
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Figure II.11 (Cont.) Characterization of donor-cell leukemia expressing Cbf-
SMMHC and N-Ras
G12D
. (D) representative H&E histology sections of bone marrow, 
spleen and liver from control and moribund Nras/CM recipient mice (Nras/CM 
transplantation LK). Scale bars of bone marrow and spleen sections: 50m; for liver 
sections: 100m. 
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5. Endogenous N-rasG12D and Cbf-SMMHC co-regulate Bim protein levels 
Our results showed a reduction in apoptosis on the pre-leukemic progenitor cells 
expressing N-RasG12D and Cbf-SMMHC (Figure II.4). To understand the mechanism 
underlying this survival advantage, we tested the expression of apoptosis-associated 
proteins from the Bcl-2 family, including Bim, Bcl2, Bcl-xl and Mcl-1, in pre-leukemic 
Lin- bone marrow cells (Figure II.12A-B). The expression levels of Bcl2, Bcl-xL, and 
Mcl-1 were inconsistent in Nras/CM pre-leukemic cells, and similar in leukemic cells 
(Figure II.12B and F). However, Bim-EL protein levels were reduced 50% in Nras and 
CM and 80% in Nras/CM Lin- pre-leukemic cells when compared to controls (Figure 
II.12A). Interestingly, levels of Bim transcript, Bcl2l11, were reduced 30% by the Cbf-
SMMHC and 50% by both oncoproteins in pre-leukemic Lin- bone marrow cells, but 
were unchanged in Lin- cells expressing N-RasG12D (Figure II.12C). Similarly, Nras/CM 
leukemic cells showed lower apoptosis and reduced Bim-EL levels when compared to 
CM leukemic cells (Figure II.12D-E).  
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Figure II.12 N-Ras
G12D
 and Cbf-SMMHC reduce Bim-EL levels in pre-leukemic 
and leukemic cells. (A) immunoblot analysis of Bim-EL expression in Lin- bone marrow 
cells from Control and Nras, and pre-leukemic cells from CM and Nras/CM mice (three 
independent samples per group); quantification relative to total Erk level (right panel), *, 
P<0.05. (B) immunoblot analysis of Bcl2, Bcl-xl, and Mcl-1 expression in Lin- 
progenitor cells from control, Nras, CM, and Nras/CM mice (top, three independent 
samples per group); quantification relative to total Erk level (bottom), **, P<0.01. 
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Figure II.12 (Cont.) N-Ras
G12D
 and CBF-SMMHC reduce Bim-EL levels in pre-
leukemic and leukemic cells. (C) Bcl2l11 transcript levels in pre-leukemic (Lin-) bone 
marrow cells from Control, Nras, CM, and Nras/CM mice, relative to Actb by qRT-PCR 
(n=4, *, P<0.05). (D) apoptosis analysis (Annexin V+/7-AAD-) of c-Kit+ gated CM or 
Nras/CM leukemic cells (n=4, *, P<0.05). 
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Figure II.12 (Cont.) N-Ras
G12D
 and CBF-SMMHC reduce Bim-EL levels in pre-
leukemic and leukemic cells. (E) immunoblot analysis of Bim-EL expression in CM or 
Nras/CM leukemic cells used in (D), and quantification relative to total Erk levels (right 
panel), *, P<0.05. (F) immunoblot analysis of Bcl2, Bcl-xl, and Mcl-1 expression in CM 
or Nras/CM leukemic cells used in (D; top); quantification of protein levels normalized to 
Erk levels (bottom). 
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6. N-RasG12D induces survival of Nras/CM leukemic cells through activation of 
MEK/ERK 
Previous studies have shown that Erk1/2 can induce proteasomal degradation of the 
Bim-EL isoform (Luciano et al., 2003). Since N-RasG12D reduced Bim-EL protein but not 
transcript levels, we investigated if N-RasG12D regulates Bim-EL levels post-
translationally in Nras/CM leukemic cells via the PI3K or MEK/ERK pathways. 
Biochemical analysis of Erk, Akt and Stat5 phosphorylation revealed that CM leukemic 
cells had a heterogeneous activation of these proteins. The first two clones showed 
phosphorylation of all three proteins; the third clone showed a strong phosphorylation of 
Stat5 but not the other two; the fourth clone show only phosphorylation of Erk. Nras/CM 
leukemic cells showed a consistent activation of ERK and low activation of AKT but not 
STAT5 phosphorylation (Figure II.13A). Five-hour treatment of Nras/CM leukemic 
cells from 3 mice with the MEK inhibitor PD325901, a potent inhibitor of myelo-
proliferative neoplasm in KrasG12D and Nf1-/- mice (Chang et al., 2013; Lauchle et al., 
2009; Lyubynska et al., 2011), increased Bcl2l11 transcript levels in a dose dependent 
manner, and increased Bim-EL protein levels (Figures II.13B-C). However, treatment 
with the PI3K inhibitor GDC-0980 (Wallin et al., 2011) did not significantly affect Bim 
transcript or protein levels. In addition, apoptosis of Nras/CM leukemic cells was 
significantly increased by treatment with the MEK inhibitor (paired t-test P<0.05), but 
not consistently increased by treatment with the PI3K inhibitor at 24 hours (Figure 
II.13D).  
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Figure II.13 Inhibition of MEK/ERK pathway increases Bim-EL levels and induces 
apoptosis. (A) immunoblot analysis of Stat5, Akt and Erk phosphorylation in four CM 
and Nras/CM leukemic samples. 
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Figure II.13 (Cont.) Inhibition of MEK/ERK pathway increases Bim-EL levels and 
induces apoptosis. (B) immunoblot analysis of Bim-EL, phospho-Akt, Akt, phospho-
Erk1/2 and Erk1/2 levels in Nras/CM leukemic cells treated for 5 hours with DMSO 
(Con.), MEK inhibitor PD325901 or PI3K inhibitor GDC-0980 (left); quantification of 
Bim-EL protein levels normalized to Erk1/2 is shown for 3 independent Nras/CM clones 
(right). A vertical line has been inserted to indicate a repositioned gel lane. (C) Bcl2l11 
transcript levels after the same 5 hour treatment were analyzed by qRT-PCR and values 
normalized to Actb; this experiment was performed in 3 independent Nras/CM clones, 
each by triplicates (average value of each clone relative to control was shown in the 
figure). (D) quantification of apoptosis (Annexin V+/7AAD-) levels in c-Kit+ gated 
Nras/CM leukemic cells treated for 24 hours; this experiment was performed in 3 
independent Nras/CM clones, each by triplicates (average value of each clone relative to 
control was shown in the figure). *, paired t-test P<0.05. 
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We inquired whether inhibition of MEK/ERK or PI3K is important for leukemic cell 
growth. Treatment of Nras/CM leukemic cells with 0.032µM PD325901 reduced 
significantly their viability when compared to CM leukemic and wild type Lin- bone 
marrow cells (35.43.7%, 74.911.5% and 75.16.9% viability, respectively; Figure 
II.14A). The dose response treatment of Nras/CM leukemic cells with GDC-980 was 
similar to that of CM leukemic and wild type Lin- bone marrow cells (Figure II.14B).  
The sensitivity of pre-leukemic progenitors to MEK/ERK and PI3K inhibitors was 
tested in vitro using Lin- bone marrow cells from Nras/CM mice 20 days after Cre-
activation. Five-hour treatment with MEK inhibitor increased 50% Bim-EL protein and 
30% Bcl2l11 transcript levels, and increased apoptosis 30% at 24 hours (Figure II.15). 
Similar treatment with the PI3K inhibitor significantly increased Bcl2l11 transcript levels 
to 3 fold but the protein levels were not increased accordingly, and the apoptosis was 
increased 30% (Figure II.15). 
Taken together, these results show that the viability of Nras/CM leukemic cells 
depend on MEK/ERK signaling and not on PI3K signaling in vitro, and correlate with the 
expression of the apoptotic protein Bim-EL.  
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Figure II.14 Inhibition of MEK/ERK pathway specifically reduced cell viability of 
Nras/CM leukemic cells. Dose response curve of Lin- wild type bone marrow (WT Lin-
BM, open circle), CM leukemic cells (CM LK, open square), or Nras/CM leukemic cells 
(Nras/CM LK, open triangle) to (A) MEK inhibitor (PD325901), or (B) PI3K inhibitor 
(GDC-0980), for 48 hours; cell viability were measured by CellTiter-Glo assays. 
Nonlinear regression curve fit was generated by inhibitor (log) vs. normalized response- 
variable slope analysis; the mean of 3 independent clones from each group is shown. *, 
P<0.05; **, P<0.01. 
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Figure II.15 Response of Nras/CM pre-leukemic cells to MEK/ERK or PI3K 
inhibitors. (A) immunoblot analysis of Bim-EL, phospho-Akt, Akt, phospho-Erk1/2 and 
Erk1/2 levels (left), and quantification of relative Bim-EL protein levels normalized to 
Erk1/2 from pre-leukemic Nras/CM samples treated with MEK inhibitor PD325901 and 
PI3K inhibitor GDC-0980 for 5 hours (right). A vertical line has been inserted to indicate 
a repositioned gel lane. (B) Bcl2l11 transcript levels after 5h treatment with MEK 
inhibitor PD325901 and PI3K inhibitor GDC-0980, by qRT-PCR; values were 
normalized to Actb in the same treatment and are expressed relative to untreated control; 
assays were performed by triplicate of the pooled sample. (C) apoptosis analysis 
(Annexin V+/7AAD-) in c-Kit+ gated Nras/CM Lin- bone marrow cells treated for 24 
hours; assays were performed by triplicate of the pooled sample. *, P<0.05; **, P<0.01. 
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7. Bim knock down reduces apoptosis of CM bone marrow progenitor cells 
To investigate if Bim is an important mediator of survival downstream of N-RasG12D 
in Cbf-SMMHC-associated leukemia, we tested apoptosis in pre-leukemic bone marrow 
cells expressing Cbf-SMMHC and reduced Bim levels (Figure II.16A). The Bim 
shRNA vectors reduced 70% of Bim transcript and protein levels in NIH3T3 cells 
(Figure II.16B-C), and reduced 60% of transcript levels in sorted GFP+, 7-AAD
- CM 
bone marrow cells (protein levels from cells infected with Bim shRNA was below 
detection threshold, Figure II.16B and D). Accordingly, CM bone marrow pre-leukemic 
cells transduced with Bim shRNA showed 45% reduction in apoptosis when compared to 
cells transduced with Scrambled shRNA (Figure II.16E). These data suggest that Bim is 
an important mediator of apoptosis in pre-leukemic cells expressing Cbf-SMMHC. 
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Figure II.16 Reduction of Bim-EL levels inhibits apoptosis in CM pre-leukemic cells. 
(A) Experimental design of Bim knock-down strategy. (B) relative Bcl2l11 transcript 
levels (qRT-PCR) in puromycin-selected NIH-3T3 (3T3) or sorted GFP+7-AAD- CM 
pre-leukemic cells infected with either Scrambled shRNA (shScr) or Bim shRNA 
(shBim); *, P<0.05; **, P<0.01. (C) immunoblot analysis of Bim-EL levels in puromycin 
selected NIH-3T3 cells (left panel); quantification of Bim-EL protein levels normalized 
to Erk1/2 (right panel). A vertical line has been inserted to indicate a repositioned gel 
lane. (D) immunoblot analysis of Bim-EL levels in sorted GFP+7-AAD- CM pre-
leukemic cells. (E) quantification of apoptosis (Annexin V+/7-AAD-) levels in c-Kit+ 
GFP+ CM pre-leukemic cells infected with either Scrambled (shScr) or Bim (shBim) 
shRNA; **, P<0.01.  
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8. Heterozygous knock-out of Bcl2l11 does not cooperate with Cbf-SMMHC in 
leukemogenesis 
To test whether reduced Bim levels could serve as a cooperating event in Cbf-
SMMHC mediated leukemogenesis, we monitored leukemia development in Bim+/-/Mx1-
Cre (Bim-h) and Bim+/-/Cbfb+/56M/Mx1-Cre (Bim-h/CM) mice after Cre activation and 
compared to leukemia development in Cbfb+/56M/Mx1-Cre (CM) and Nras+/LSL-
G12D/Cbfb+/56M/Mx1-Cre (Nras/CM) mice which we have shown in Figure II.6A. Bim-h 
mice did not develop leukemia up to 35 weeks (experimental endpoint, Figure II.17, 
orange dashed line). Bim-h/CM mice developed leukemia with a medium latency of 
28.14 weeks and 71% penetrance (Figure II.17, orange solid line) which was not 
significantly different from CM mice (median latency of 21.43 weeks and 89% 
penetrance, Figure II.17, black solid line). These results suggest that inactivation of one 
allele of Bcl2l11 gene does not accelerate Cbf-SMMHC mediated leukemogenesis.  
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Figure II.17 Loss of one allele of Bcl2l11 gene does not accelerate Cbf-SMMHC 
mediated leukemogenesis. Kaplan-Meier curves of leukemia-free survival in Bim+/-
/Mx1-Cre (Bim-h, orange dashed), Cbfb+/56M/Mx1-Cre (CM, black solid), Nras+/LSL-
G12D/Cbfb+/56M/Mx1-Cre (Nras/CM, black dashed) and Bim+/-/Cbfb+/56M/Mx1-Cre (Bim-
h/CM, orange solid) mice after Cre activation (time 0). NS, not significant.  
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II.E Discussion 
Acute myeloid leukemia results from the stepwise accumulation of mutations that 
drive transformation of hematopoietic stem and progenitor cells. The pre-leukemic 
compartment is thought to include a group of clonal progenitor cells with common 
founding mutation(s) and a combination of different subsequent mutations that deregulate 
their proliferation, survival, and differentiation programs (Jan et al., 2012; Walter et al., 
2012; Welch et al., 2012). Recent studies demonstrated that pre-leukemic progenitors 
found in human AML survive chemotherapy and are a reservoir for relapse AML 
(Corces-Zimmerman et al., 2014; Shlush et al., 2014). Therefore, the elucidation of the 
cumulative functional contribution of each mutation towards leukemia is essential for the 
understanding of disease progression and the design of effective therapies targeting driver 
mutations. The inv(16) chromosomal rearrangement is a founding mutation that creates a 
pre-leukemic myeloid population in the bone marrow (Kuo et al., 2006). However, inv(16) 
is necessary but not sufficient for leukemogenesis (Castilla et al., 1999; Castilla et al., 
2004; Kuo et al., 2006). In this study, we show that NrasG12D, a frequent mutation found 
in inv(16) AMLs, may regulate the survival of the pre-leukemic cells though 
Mek/Erk/Bim pathway, and synergizes with Cbf-SMMHC in leukemia development. 
Recent studies have shown that NrasG12D conditional knock-in mice develop an 
indolent myelo-proliferative phenotype, and eventually develop a diverse spectrum of 
hematologic cancers with long disease latency (Li et al., 2011). Similarly, mice 
transplanted with NrasG12D bone marrow develop CMML-like phenotype only after a 
prolonged latency (Wang et al., 2010a). Here, we show that co-expression of N-RasG12D 
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and Cbf-SMMHC modified the cellular composition of the bone marrow significantly, 
with a reduction in its cellularity due to a block in myelo-lymphoid differentiation 
(lineage positive cells). However, the pre-leukemic early progenitors (ST-HSCs and 
MPPs) and myeloid progenitors (CMPs) were increased. These results showed that 
CBF-SMMHC is dominant over N-RasG12D because N-RasG12D was unable to overcome 
the differentiation block imposed by Cbf-SMMHC to induce myelo-proliferation, and 
are consistent with data demonstrating that NRAS mutations are acquired as a secondary 
event in human inv(16) AML (Paschka et al., 2013). The Nras/CM pre-leukemic 
progenitors remained in the bone marrow and transformed to leukemia with a latency 
reduced from 21.43 weeks, as seen in the CM group, to 13.72 weeks, indicating that 
allelic expression of N-RasG12D cooperated with Cbf-SMMHC in leukemia. In addition, 
the synergy was evident when expression of these oncoproteins was activated after 
engraftment into recipient mice, demonstrating that the synergy is cell autonomous.  
We have found that N-RasG12D and Cbf-SMMHC contribute on the reduction of 
apoptosis in the pre-leukemic bone marrow progenitors. This survival signal may direct 
the expansion of pre-leukemic cells, and may participate in leukemia transformation.  N-
RASG12D was shown to provide survival advantage for human umbilical cord blood cells 
expressing AML1-ETO (Chou et al., 2011), suggesting that N-RASG12D –mediated pro-
survival activity could be a general mechanism in leukemia. In addition, considering that 
Cbf-SMMHC has been shown to impair Runx1 function (Castilla et al., 1996) and that 
Runx1-loss reduced HSC apoptosis (Cai et al., 2011), it is possible that the pro-survival 
activity of Cbf-SMMHC could be mediated by Runx1 inhibition.  
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The analysis of protein levels of the BCL-2 family members revealed that Bim-EL 
protein levels correlated with apoptosis in pre-leukemic and leukemic cells. In pre-
leukemic cells, N-RasG12D expression decreased Bim-EL protein levels but not transcript 
levels, indicating that N-RasG12D may affect Bim-EL levels by proteasome degradation 
though MEK/ERK pathway as previous reported (Hubner et al., 2008; Luciano et al., 
2003). Interestingly, N-RasG12D synergized with Cbf-SMMHC to decrease Bim-EL 
protein and transcript levels, which correlated with the increase in Bim-EL protein and 
transcript levels by the MEK inhibitor. On the other hand, PI3K inhibitor increased Bim-
EL transcript but not protein levels, probably because Mek/Erk pathway still actively 
decreased Bcl2l11 transcripts and degraded Bim-EL protein. Consistent with these results, 
knock-down of Bim-EL levels decreased apoptosis in pre-leukemic progenitor cells 
expressing Cbf-SMMHC. The pharmacologic experiments also revealed that expression 
of Bim-EL was regulated by Mek/Erk pathway in the Nras/CM leukemic cells. These 
results suggest that Bim-EL may be a critical effector of apoptosis in the transformation 
of pre-leukemic progenitor cells. However, heterozygous knock-out of Bim was not 
sufficient in accelerating leukemia mediated by Cbf-SMMHC, suggesting existence of 
other downstream targets of N-RasG12D which may participate in leukemogenesis, though 
a quantification of Bim expression levels in Bim-/+ bone marrow cells compared to 
wildtype cells is needed.  
Consistent with the regulation of Bim-EL levels, pharmacologic inhibition of N-
RasG12D activity showed that the oncogenic N-Ras activity seems to be modulated during 
leukemia progression. Our results show that leukemic cell viability depends primarily on 
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the activity of the Mek/Erk pathway, suggesting that MEK inhibitors may efficiently 
reduce leukemia in the treatment of inv(16) / NRASG12D AML. 
In conclusion, allelic co-expression of Cbf-SMMHC and N-RasG12D promote the 
survival of pre-leukemic progenitors by activation of the MEK/ERK pathway and 
inhibition of Bim-EL protein levels. The transgenic mice characterized in this study are 
an attractive genetic tool for mechanistic studies and for the development of efficacious 
AML targeted therapies. 
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Preface of Chapter III 
 
The work presented in chapter III “Pharmacologic inhibition of CBF-SMMHC 
activity abrogates inv(16) leukemia” is aimed at providing additional insights in 
molecular mechanisms of inv(16) AML using pharmaceutical approaches. The studies 
included in this chapter are unpublished. Part of these studies have been included in a 
manuscript, currently under review for publication, and describe the development of a 
CBFβ-SMMHC specific inhibitor, AI-10-49, as part of a collaborative effort by four 
laboratories.  
Chapter III only includes the experiments performed by me, with the exception of 
the in vivo treatment experiments described in Figure III.5, which were performed by me 
and Dr. John Pulikkan.  
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Chapter III 
Pharmacologic inhibition of CBF-SMMHC activity  
abrogates inv(16) leukemia 
 
III.A. Abstract 
Inv(16) generates a fusion protein called CBF-SMMHC in acute myeloid leukemia 
(AML). This oncogene disrupts transcriptional factor core binding factor (CBF) function 
and drives leukemia by cooperation with other secondary genes. Here, we report a small 
molecule called AI-10-49 which selectively binds to CBF-SMMHC and thus restores 
normal CBF function. This CBF-SMMHC inhibitor AI-10-49 specifically reduced 
viability of mouse and human leukemic cells expressing CBF-SMMHC with minimal 
toxicity to normal cells and induces expression of a pro-apoptotic gene BCL2L11. This 
process is not mediated by increasing RUNX3 expression. In addition, AI-10-49 
significantly prolongs the survival of mice bearing Cbf-SMMHC/N-RasG12D leukemic 
cells. This study is a proof-of-principle that transcriptional factors can be targeted in 
leukemia therapy. This small molecule AI-10-49 will serve as a promising drug for 
treating inv(16) leukemia and also a very useful tool to understand mechanisms of 
leukemogenesis driving by CBF-SMMHC. 
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III.B. Introduction 
AML is the most common form of adult leukemia (Kumar, 2011). Long-term 
survival for AML remains poor and varies with the mutational composition. The 
transcription factor fusion protein CBFβ-SMMHC, is expressed in AML with the 
chromosome inversion inv(16)(p13;q22) (Liu et al., 1993)). It cooperates with activating 
mutations in components of cytokine signaling pathways in leukemia transformation, 
such as c-KIT, NRAS, KRAS and FLT3 (Castilla et al., 1999; Castilla et al., 2004; Muller 
et al., 2008; Ravandi et al., 2007). 
CBFβ is a component of the heterodimeric transcription factor CBF, where it 
binds to RUNX proteins and enhances their affinity for DNA (Adya et al., 2000). The 
CBF complex plays a key role in regulating hematopoiesis (de Bruijn and Speck, 2004). 
CBFβ-SMMHC outcompetes CBFβ for binding to RUNX1 (Lukasik et al., 2002), 
deregulates RUNX1 transcription factor activity in hematopoiesis (Liu et al., 1995; 
Shigesada et al., 2004), and induces AML (Castilla et al., 1999; Kuo et al., 2006). 
Current inv(16) AML treatment using non-selective cytotoxic chemotherapy 
results in a good initial response, but limited long-term survival. Studies in mice and 
patient samples support the concept that inv(16) is a driver mutation that generates pre-
leukemic progenitor cells that, upon acquisition of additional cooperating mutations, 
progress to leukemia (Castilla et al., 1999; Castilla et al., 2004; Kottaridis et al., 2002; 
Kuo et al., 2006; Nakano et al., 1999; Shih et al., 2008). Furthermore, they suggest that 
inhibition of CBFβ-SMMHC activity is essential to eliminate leukemic cells effectively. 
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In Chapter II, we established a leukemic mouse model expressing both Cbfβ-
SMMHC and N-RasG12D mutations. We have shown that pre-leukemic cells expressing 
Cbfβ-SMMHC had reduced apoptosis and pro-apoptotic protein Bim levels than wildtype 
bone marrow progenitors. However, the mechanisms of the survival benefits provided by 
Cbfβ-SMMHC need further investigation.  
In collaboration with Dr. John Bushweller’s and other research laboratories, we 
developed a small molecule called AI-10-49 which specifically disrupts binding of 
CBFβ-SMMHC to RUNX proteins and restores normal CBF function (Illendula et al., 
manuscript submitted). In this chapter, we show that AI-10-49 specifically reduced 
viability of mouse and human leukemic cells expressing CBFβ-SMMHC. It also restores 
BCL2L11 and RUNX3 transcript levels. However, repression of RUNX3 does not affect 
the efficacy of AI-10-49. In addition, treatment of AI-10-49 significantly prolongs the 
survival of mice harboring leukemic cells expressing both Cbfβ-SMMHC and N-RasG12D. 
This small molecule will serve as a very promising first-generation drug targeting CBF-
SMMHC and a useful tool for understanding mechanisms of inv(16) leukemogenesis.  
 
III.C. Materials and Methods 
Cell viability assay 
For mouse cells: bone marrow cells from wild type mice or spleen cells from 
Nras+/LSL-G12D/Cbfb+/56M/Mx1Cre (Nras/CM) leukemic mice were enriched for Lin- 
progenitors, and treated in cytokine-free StemSpan Medium with DMSO or AI-10-49 
(Cbf-SMMHC inhibitor) for 48 hours in triplicates.  
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For the human cells: mobilized human bone marrow enriched for progenitor cells 
were treated in RPMI medium + 20%FBS with DMSO or AI-10-49 for 48 hours in 96 
well plates in quadruplicates. Similarly, ME-1 cells [a human inv(16) leukemic cell line 
(Yanagisawa et al., 1991)] were treated in RPMI medium + 20% FBS + 15mM HEPES + 
Penicillin/Streptomycin with DMSO or AI-10-49 for 24 hours in quadruplicates. 
Cells were all plated in 96 well white plates (Corning Incorporated, Corning, NY). 
The cell viability was tested using CellTiter-Glo reagent (Promega, Madison, WI) 
according to manufacturer’s instructions.  
RUNX3 knock-down 
Lentiviruses: Lentiviral supernatants (pLKO.1 vector) expressing shRNA for eGFP 
or human RUNX3 were purchased from UMASSMED stock (RNAi Core Facility, 
http://www.umassmed.edu/shrna/) of Open Biosystems (GE Healthcare, Lafayette, CO). 
The clone number and sense sequences of RUNX3 shRNA are as below: 
TRCN0000013668 (668) 5’-CCCAGCACTTTGTAGTCTCAT-3’ 
TRCN0000013670 (670) 5’-CCAAGGCACCTCGGAACTGAA-3’ 
TRCN0000013671 (671) 5’-CGACCGCTCACCTACCCGCAT-3’ 
RUNX3 knock-down in HeLa cells: HeLa cells were infected with the lentiviral 
supernatants in 4g/ml Polybrene (American Bioanalytical, Natick, MA). Three days 
after infection, HeLa cells were selected in 4g/ml puromycin for three days until all the 
uninfected cells (negative control) were dead. The puromycin resistant HeLa cells were 
lysed for RNA and protein extraction and assayed for RUNX3 knock-down by 
subsequent quantitative RT-PCR and immunoblot analysis. 
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RUNX3 knock-down in ME-1 cells: ME-1 cells were infected twice with lentiviral 
supernatants in 40g/ml Polybrene (American Bioanalytical, Natick, MA). Two days 
after infection, ME-1 cells were selected in 5g/ml puromycin for three days until all the 
uninfected cells (negative control) were dead. The puromycin resistant ME-1 cells were 
cultured in the presence of DMSO, or 1M AI-10-49 for either 6 hours to extract RNA 
and perform quantitative RT-PCR or 24 hours to perform CellTiter AQueous One 
Solution Cell Proliferation Assay (MTS, Promega, Madison, WI). For the MTS assay, 
20l reagent was added to 100l cell culture in a 96 well plate. The plate was incubated 
at 37oC for three hours and read for 490 nm absorbance.  
Reverse transcription and quantitative PCR (qRT-PCR) analyses 
The RNA extraction, cDNA synthesis (random primers were used), and qPCR were 
performed as previously described (Pulikkan et al., 2012). Primer sequences included: 
Mouse 
For Actb cDNA 
b-actin F1 (5’-CGAGGCCCAGAGCAAGAGAG-3’) 
b-actin R1 (5’-CGGTTGGCCTTAGGGTTCAG-3’) 
For Bcl2l11 cDNA 
mBim F (5’-GCTGGTGGGACCTGTTTCTA-3’) 
mBim R (5’-TTCAGTGAGCCATCTTGACG-3’) 
Human 
For ACTB cDNA 
hBactin F (5’-AGAAAATCTGGCACCACACC-3’) 
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hBactin R (5’-AGAGGCGTACAGGGATAGCA-3’) 
For BCL2L11 cDNA 
hBim F (5’-TGGTCTGCAGTTTGTTGGAG-3’) 
hBim R (5’-CAGACATTTGGGGGAACAAG-3’) 
For RUNX3 cDNA 
a. Used in HeLa cells 
hRx3 F2 (5’-CGCTGTTATGCGTATTCCC-3’) 
hRx3 R (5’-CAATGCCACCACCTTGAAG-3’) 
b. Used in ME-1 cells 
Rx3 Cheng F (5’-CAGAAGCTGGAGGACCAGAC-3’) 
Rx3 Cheng R (5’-GTCGGAGAATGGGTTCAGTT-3’) 
For this particular reaction above, samples were amplified for 40 cycles of 30 
seconds at 95oC and 30 seconds at 62oC according to a reference (Cheng et al., 2008). All 
other reactions were performed as default settings of the StepOne Plus Sequence 
Detection System (Applied Biosystems, Grand Island, NY).  
Immunoblot analyses 
Cells were washed with PBS and resuspended in modified RIPA buffer (50mM Tris-
HCl pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40, 0.25% Sodium Deoxycholate) with 
protease inhibitor cocktail III (Calbiochem, Darmstadt, Germany) and phosphatase 
inhibitor cocktail II and III (Sigma-Aldrich, St. Louis, MO). Antibodies included anti-
RUNX3 (cat#9647) and anti-p44/42 MAPK (ERK1/2) (cat#9102, all from Cell Signaling 
Technology, Danvers, MA). 
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AI-10-49 in vivo treatment 
One hundred thousand or two thousand spleen cells from Nras/CM secondary 
leukemic mice were transplanted by intravenous injection into sub-lethally irradiated 
(550 rads) recipient mice (8 to 10 week old CD45.1+ B6.SJL-ptprc<a>model#004007 
females, Taconic Farms, NY). The recipient mice were treated with either 50l DMSO or 
AI-10-49 (207.5mg/kg) by intraperitoneal injections everyday starting from Day 5 to Day 
14 after transplantations. Then mice were monitored twice everyday for early signs of 
leukemia. 
Statistics 
Medium latencies of Kaplan-Meier survival curves were calculated using GraphPad 
Prism 6 (GraphPad Software, Inc., La Jolla, CA). The P values of the Kaplan-Meier 
survival curves were calculated by Log-rank (Mantel-Cox) test using GraphPad Prism 6 
(GraphPad Software, Inc., La Jolla, CA). All other P values were calculated by two-tailed 
heteroscedastic Student t-test using Excel (Microsoft Cooperation, Redmond, WA). The 
nonlinear regression curve fit for viability assay was generated using GraphPad Prism 6 
(GraphPad Software, Inc., La Jolla, CA). 
 
III.D. Results 
1. A small molecule AI-10-49 was developed to specifically inhibit binding of 
CBF-SMMHC to RUNX 
In collaboration with Dr. John Bushweller’s and other research laboratories, we 
developed a small molecule called AI-10-49 which can specifically inhibit binding of 
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CBF-SMMHC to RUNX (Illendula et al., manuscript submitted). AI-10-49 is a bivalent 
version of a lead compound AI-10-47 (Figure III.1A). AI-10-47 binds to CBF and 
disrupts its binding to RUNX. CBF-SMMHC was proposed to assemble from dimer to 
multimer (Shigesada et al., 2004). We have shown in the submitted manuscript that the 
bivalent AI-10-49 selectively bond to CBF-SMMHC, disrupted the binding of the 
fusion protein to RUNX, and thus restored the normal binding of CBF to RUNX as well 
as transcription of downstream targets (Figure III.1B).  
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Figure III.1 A small bivalent molecule AI-10-49 can specifically inhibit CBF-
SMMHC binding to RUNX. (A) structure of monovalent AI-10-47 and bivalent AI-10-
49; (B) mechanism of AI-10-49 function based on the dimerization/multimerization of 
CBF-SMMHC.  
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2. AI-10-49 specifically affects viability of mouse and human leukemic cells 
expressing CBF-SMMHC and increases BCL2L11 transcript levels 
To assay if the CBF-SMMHC inhibitor AI-10-49 can specifically affect viability of 
inv(16) leukemic cells, Lin- wild type bone marrow or Nras+/LSL-G12D/Cbfb+/56M/Mx1Cre 
(Nras/CM) leukemic cells were treated with different concentration of AI-10-49 for 48 
hours. The IC50 for AI-10-49 was reduced 4.5 fold in Nras/CM leukemic cells compared 
to wild type bone marrow cells (0.93 M versus 4.20 M; Figure III.2A). In Chapter II, 
we have shown that Cbfβ-SMMHC pre-leukemic progenitors had reduced Bcl2l11 
transcript levels than wildtype bone marrow progenitors. To ask whether CBF-SMMHC 
regulates Bcl2l11 transcription, Lin- Nras/CM leukemic cells were treated with DMSO, 
1M or 4M AI-10-49 for 24 hours. We found that Bcl2l11 transcript levels increased 
upon CBF-SMMHC inhibition dose dependently (Figure III.2B). Accordingly, 
viability of human inv(16) patient derived ME-1 cells (Yanagisawa et al., 1991) were 
also selectively reduced by AI-10-49 with a 24-hour IC50 of 0.83M, compared to 48-
hour IC50 of 42.18M in normal human bone marrow progenitors (Figure III.3A-B). 
Similar to mouse cells, BCL2L11 transcript levels increased upon CBF-SMMHC 
inhibition in ME-1 cells treated with AI-10-49 (Figure III.3C). These results show that 
inhibition of CBF-SMMHC/RUNX binding specifically affects leukemic cell viability 
and increases pro-apoptotic gene BCL2L11 expression in murine and human cells. 
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Figure III.2 AI-10-49 specifically reduces viability of Nras/CM leukemic cells and 
increases Bcl2l11 transcript levels. (A) Lin- wild type bone marrow cells (WT Lin- BM) 
or Nras/CM leukemic (Nras/CM LK) cells were treated with different concentration of 
CBF-SMMHC (CM) inhibitor AI-10-49 for 48 hours and assayed for cell viability. The 
IC50 for WT and LK cells are 4.20M and 0.93M, respectively. (B) Lin
- Nras/CM 
leukemic cells was treated with DMSO, 1M or 4M of CM inhibitor (CM inh) AI-10-
49 for 24 hours and Bcl2l11 transcripts were measured by qRT-PCR and values were 
normalized to Actb transcripts. *, P<0.05; **, P<0.01. 
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Figure III.3 AI-10-49 specifically reduces viability of ME-1 cells and increases 
BCL2L11 transcript levels. (A) human mobilized bone marrow cells were treated with 
CM inhibitor AI-10-49 for 48 hours and assayed for cell viability, presenting an IC50 of 
42.18M. (B) ME-1 cells were treated with AI-10-49 for 24 hours and assayed for cell 
viability, presenting an IC50 of 0.83M. (C) ME-1 cells were treated with 1M AI-10-49 
for 6 or 20 hours and BCL2L11 transcripts were measured by qRT-PCR and values were 
normalized to ACTB transcripts; **, P<0.01. 
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3. The survival signals provided by CBF-SMMHC may not be solely mediated by 
RUNX3 repression 
RUNX3 has been shown to be transcriptionally repressed by CBF-SMMHC in 
AML cells (Cheng et al., 2008). Accordingly, we have shown that upon AI-10-49 
treatment, RUNX1 occupancy on RUNX3 promoter and RUNX3 transcription was 
restored in ME-1 cells (Illendula et al., manuscript submitted). Furthermore, RUNX3 
transcriptionally upregulates pro-apoptotic gene BCL2L11 to induce apoptosis in gastric 
cells (Yamamura et al., 2006; Yano et al., 2006). Since CBF-SMMHC inhibition by AI-
10-49 increased Bcl2l11 transcript levels and affected viability of leukemic cells (Figure 
III.2 and Figure III.3), we want to study whether RUNX3 plays an important role in AI-
10-49 mediated eliminating of leukemic cells. Three different shRNA lentiviruses 
targeting RUNX3 were tested in HeLa cells. All of them showed a significant knock-
down of RUNX3 transcript and protein levels compared to shRNA targeting eGFP 
(Figure III.4A-B). Two shRNA lentiviruses targeting RUNX3 were selected to infect 
ME-1 cells and significantly reduced RUNX3 transcripts to basal levels even upon AI-
10-49 treatment (Figure III.4C). However, AI-10-49 can still efficiently affect ME-1 cell 
viability with reduced RUNX3 transcript levels (Figure III.4D). These data suggested 
that RUNX3 may not be a critical mediator in reducing viability of inv(16) leukemic cells 
upon CBF-SMMHC inhibition.  
 
 
134 
 
 
 
 
 
Figure III.4 Efficacy of AI-10-49 is not affected upon RUNX3 knock-down in ME-1 
cells. (A) HeLa cells were infected with lentiviruses expressing shRNA for eGFP or 
RUNX3, selected for puromycin resistance and assayed for RUNX3 transcript levels by 
qRT-PCR with values normalized to ACTB transcripts. (B) immunoblot analysis of 
RUNX3 and ERK1/2 levels in puromycin resistant HeLa cells (left panel); quantification 
of RUNX3 protein levels normalized to ERK1/2 (right panel). (C) ME-1 cells were 
infected with lentiviruses expressing shRNA for eGFP or RUNX3, selected for 
puromycin resistance and treated with 1M CM inhibitor AI-10-49 for 6 hours. RUNX3 
transcript levels were assayed by qRT-PCR and values normalized to ACTB transcripts. 
(D) Puromycin resistant ME-1 cells were treated with AI-10-49 for 24 hours and cell 
viabilities were measured by the MTS assay. *, P<0.05; **, P<0.01; NS, not significant.  
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4. AI-10-49 significantly prolonged survival of Nras/CM leukemic mice 
To test whether inhibition of Cbf-SMMHC can benefit leukemia treatment, mice 
were transplanted with either 100,000 or 2,000 of Nras/CM leukemic cells and treated 
with 10 doses of AI-10-49 (207.5mg/kg). In both cases, AI-10-49 significantly prolonged 
survival of the mice bearing Nras/CM leukemic cells (P < 0.0001; Figure III.5). Medium 
latency was prolonged from 21 to 30 days with AI-10-49 treatment when 100,000 
leukemic cells were transplanted (Figure III.5A). Similarly, medium latency was 
prolonged from 34 to 61 days with AI-10-49 treatment when 2000 leukemic cells were 
transplanted (Figure III.5B). These results demonstrated that AI-10-49 has a significant 
survival benefit to Nras/CM leukemic mice. 
 
 
136 
 
 
 
 
 
Figure III.5 AI-10-49 prolongs survival of Nras/CM leukemic mice. Mice were 
transplanted with either 100,000 (A) or 2000 (B) Nras/CM leukemic cells, and treated 
with either DMSO (black) or 207.5mg/kg AI-10-49 (red) everyday from Day 5 to Day 14 
after transplantation. Kaplan-Meier survival curves show significant prolonged medium 
latencies due to AI-10-49 treatment in both cases.  
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III.E. Discussion 
Dysregulated gene expression is a hallmark of cancer and is particularly important 
for the maintenance of cancer stem cell properties, such as self-renewal. As such, the 
targeting of proteins that drive transcriptional dysregulation, so called “transcription 
therapy”, represents an avenue for drug development with immense potential. A number 
of fusion proteins involving transcription factors have been identified as drivers of 
disease in leukemia (Look, 1997; Zeisig et al., 2012), which provide excellent targets for 
therapeutic intervention.  
Our results provide a clear proof-of-principle for this approach, as AI-10-49 
specifically inhibits CBFβ-SMMHC/RUNX binding and shows efficacy against CBFβ-
SMMHC driven leukemia in vitro and in vivo with no apparent side-effects to normal 
cells. Specificity of action is a key component of the development of a targeted drug. 
Imatinib, for example, inhibits ABL kinase and its efficacy in CML is clearly a result of 
effective inhibition of the BCR-ABL fusion protein that drives CML. However, even this 
agent inhibits both the BCR-ABL fusion protein as well as wildtype ABL. The “holy 
grail”, as it were, of targeted therapy with fusion or mutated protein drivers of cancer is to 
achieve inhibition of the fusion or mutated protein with little to no effect on the wildtype 
protein, thereby minimizing any toxicity or cancer promotion associated with inhibition 
of the wildtype protein. This study demonstrates that AI-10-49 represents a clear example 
of such selectivity for inv(16) leukemia, inhibiting CBFβ-SMMHC activity while having 
a minimal effect on CBFβ function. In addition, AI-10-49 clearly possesses the key 
properties of a high quality chemical probe recently outlined by Frye (Frye, 2010), 
138 
 
 
 
namely a clear molecular profile of activity, mechanism of action, identity of active 
species, and proven utility. 
In the Chapter II, we established that CBF-SMMHC and N-RasG12D cooperates in 
providing survival advantage and reduced expression of a pro-apoptotic gene Bcl2l11 in 
pre-leukemic cells. Here we found that inhibition of CBF-SMMHC by AI-10-49 in 
mouse or human leukemic cells expressing CBF-SMMHC restored the Bcl2l11 
transcript levels. These suggested that CBF-SMMHC directly or indirectly reduces 
Bcl2l11 transcript levels. Studies have shown that BCL2L11 transcript levels are induced 
by RUNX3 and FOXO3 in gastric cells (Yamamura et al., 2006; Yano et al., 2006), and 
CBF-SMMHC represses RUNX3 levels in AML cells (Cheng et al., 2008). However, 
based on our results, though AI-10-49 treatment did restore RUNX3 transcript levels in 
ME-1 cells, repression of RUNX3 expression did not affect the efficacy of AI-10-49. 
Therefore, the survival signals provided by CBF-SMMHC are not only mediated by 
repression of RUNX3. It will be interesting to investigate whether BCL2L11 transcript 
levels are essential in the survival of the inv(16) leukemic cells and also search for other 
potential mediators downstream of CBF-SMMHC. 
In summary, AI-10-49 is a direct, potent, and specific first generation CBFβ-
SMMHC inhibitor that induces cell death in inv(16) leukemic cells and establishes a 
proof-of-principle that transcription factor fusion oncoproteins can be directly targeted 
for leukemia treatment. It will also serve as a very useful tool to further understand the 
functions of CBFβ-SMMHC in pre-leukemic and leukemic cells. 
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Chapter IV 
Discussion 
 
The work presented in this thesis was directed at understanding the molecular 
mechanisms of CBF-SMMHC in inv(16) AML. In Chapter II, I described the alterations 
in pre-leukemic progenitor cells expressing both CBF-SMMHC and N-RasG12D 
oncproteins, using a mouse model, and investigated into downstream targets. In Chapter 
III, I characterized a small molecule targeting CBF-SMMHC and tested its efficacy in 
the mouse model developed in Chapter II. In this chapter, I provide additional discussion, 
overall conclusions and future directions for the results presented.   
 
IV.A Pre-leukemic alteration by CBF-SMMHC and N-RASG12D 
Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy with a 
5-year overall survival (OS) between 30 and 40% (Estey and Dohner, 2006; Lowenberg 
et al., 1999). AMLs predominantly occur in adults and patients over age 65 have 
especially poor outcome (Estey and Dohner, 2006; Lowenberg et al., 1999). Even in 
patients with favorable cytogenetics as inv(16), the 5 year probabilities of OS and 
leukemia-free survival for the elderly (Age >60) patients are only 31% and 27% (Prebet 
et al., 2009). This relative low rate of OS is mainly due to the relapsed, treatment-
refractory disease. The 5 year cumulative incidence of relapse is 57% for inv(16) AMLs 
(Marcucci et al., 2005).  
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This situation raises important questions of how AMLs develop and progress as well 
as what is the cellular basis of relapse.  The existence of a pre-leukemia stage in human 
AML has been suggested in two recent studies, utilizing next generation sequencing 
technologies in AML patient genomes and xenograft in immunodeficient (NOD-scid-
IL2Rgc−/−, NSG) mice (Jan et al., 2012; Shlush et al., 2014). The first study revealed that 
a small proportion of residual hematopoietic stem cells (HSCs) in AML patient samples 
presented some of mutations also identified in the leukemic cells (Jan et al., 2012). 
Detailed single-cell analysis disclosed a clonal evolution of the pre-leukemic HSCs to 
full-blown leukemia and a potential mechanism contributing to relapse. The second study 
showed that these mutated pre-leukemic HSCs had higher multilineage repopulation 
advantage over non-mutated HSCs in xenografts. They survived in chemotherapy, 
accumulated multiple oncogenic mutations, and served as a cellular reservoir for 
developing de novo and relapse AML (Shlush et al., 2014). Therefore, investigation on 
the pre-leukemia stage altered by different driver and secondary mutations are essential 
for understanding the mechanisms of leukemogenesis and providing insights for 
treatment of de novo and relapse leukemias. 
The pre-leukemia stage for AML in humans is asymptomatic, and the patient is first 
diagnosed with de novo AML after the full-blown leukemia has occurred. In addition, 
expansion of pre-leukemic cells is limited because they are usually outcompeted by their 
malignant descendants (Greaves, 2009). Therefore, mouse models harboring recurrent 
mutations observed in human AMLs are valuable genetic tools to study the dynamics of 
the pre-leukemia stage. The chromosome 16 inversion [inv(16)(p13;q22)] is thought to be 
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a founding mutation in the HSCs, creating a pre-leukemic population of cells, which 
persist asymptomatic in the bone marrow for years. The first insight on the role of the 
fusion protein in pre-leukemic hematopoiesis was reported by our laboratory (Kuo 2006). 
Considering that inv(16) AML patients frequently present mutations in receptor tyrosine 
kinase (RTK) signaling pathways, such as NRAS, KRAS and FLT3 (Muller et al., 2008), 
we studied the role of NRASG12D mutation in the pre-leukemic progenitor cells, using a 
mouse model with allelic expression of Cbf-SMMHC and N-RasG12D. Our results 
showed that both Cbf-SMMHC and N-RasG12D expanded the stem and early progenitor 
compartments (LSK+) as well as the myeloid progenitor compartments (LSK-), consistent 
with previous and recent studies on mice harboring individual oncogenes (Kuo et al., 
2006; Li et al., 2011; Wang et al., 2013). Importantly, the co-expression of these mutated 
genes is not sufficient to induce an aggressive leukemia. The introduction of the NrasG12D 
into Cbfb+/MYH11 mice did not induce a proliferative expansion of maturing myeloid cells, 
as observed in Nras+/G12D mice, probably due to the dominant role of Cbf-SMMHC. It 
will also be interesting to analyze extramedullary hematopoiesis in Nras+/LSL-
G12D/Cbfb+/56M/Mx1Cre mice since Nras+/LSL-G12D/Mx1Cre present an increased stem and 
progenitor cells in spleen (Wang et al., 2013).  
The question of what drives the expansion of pre-leukemic cells led us to perform a 
detailed analysis of this compartment.  
Though N-RasG12D has recently been reported to increase proliferation of LT-HSCs 
(LSK+CD48-CD150+) but not of whole bone marrow (Li et al., 2013; Wang et al., 2013), 
we did not observe any alteration by N-RasG12D in cell cycle of stem and early progenitor 
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cells (LSK+) or myeloid progenitor cells (LSK-). Another study reported that K-RasG12D 
oncoprotein significantly increased cell cycle entry of HSCs (Flt3-LSK+) (Sabnis et al., 
2009). In consequence, a small population of cells expressing K-RasG12D dominated both 
primitive and differentiated hematopoietic compartments in Kras+/LSL-G12D/Mx1Cre mice 
in the absence of polyI:C treatment. This phenotype correlated with the an aggressive 
myeloproliferative neoplasm (MPN, medium latency as 84 days after polyI:C) observed 
in Kras+/LSL-G12D/Mx1Cre mice (Braun et al., 2004), in contrast to the indolent 
hematologic disorders (medium latency as 342 days after polyI:C) observed in Nras+/LSL-
G12D/Mx1Cre mice (Li et al., 2011). The cytokine sensitivity and downstream effector 
activation were also different between Kras+/LSL-G12D/Mx1Cre and Nras+/LSL-G12D/Mx1Cre 
myeloid progenitor cells (Li et al., 2011). Our data suggest that the primary role of Nras 
in the pre-leukemic cells is to provide survival capacity, while Kras may maintain a 
primary proliferative phenotype. The difference may be explained in that K-RasG12D is 
expressed at higher levels and has more GTP binding forms than N-RasG12D in bone 
marrow cells (Li et al., 2011). In this regard, it remains unclear how K-RasG12D alters the 
pre-leukemic cells in the presence of Cbf-SMMHC, compared to what we found in the 
Nras+/LSL-G12D/Cbfb+/56M/Mx1Cre mice.   
The allelic expression of Cbf-SMMHC showed a bimodal behavior since we have 
observed that it increased the proliferation of stem and early progenitor cells but reduced 
the proliferation of myeloid progenitor cells. The reduced S/G2/M phase in the myeloid 
progenitors correlated with previous studies, which have shown that ectopic expression of 
Cbf-SMMHC inhibited G1 to S transition in murine myeloid or lymphoid cell lines and 
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slowed cell cycle of primary murine and human myeloid progenitors (Cao et al., 1998; 
Cao et al., 1997; D'Costa et al., 2005). 
In this context, NRasG12D reduced apoptosis of pre-leukemic stem and progenitor 
cells expressing Cbf-SMMHC. Our results are consistent with studies revealing a 
critical role of oncogenic NRAS mutations in providing survival advantages to pre-
leukemic and leukemic cells (Chou et al., 2011; Kim et al., 2009). Furthermore, HSCs 
from Runx1-null mice also presented reduced apoptotic cells (Cai et al., 2011). These 
data suggest that the survival advantage mediated by Cbf-SMMHC is probably due to 
inhibition of Runx functions. We will discuss in details on regulation of pro-apoptotic 
protein Bim by these two oncogenes in the subchapter IV.C. Other potential targets could 
be discovered by expression profiling analysis of N-RasG12D / Cbfb+/MYH11 pre-leukemic 
cells compared to, NrasG12D, and CbfbMYH11 cells. It would provide additional valuable 
information to compare Cbf-SMMHC pre-leukemic progenitor cells treated with and 
without AI-10-49, the small molecule disrupting Cbf-SMMHC/Runx binding.  
We have previously shown that Cbf-SMMHC induced an abnormal myeloid 
progenitor population (Kuo et al., 2006). This pre-leukemic population was maintained in 
bone marrow of NrasG12D/CbfbMYH11 mice. Significant reduction of lineage positive cells 
and increase of lineage negative cells in pre-leukemic CbfbMYH11, and NrasG12D/CbfbMYH11 
cells led us to conduct a detailed morphology analysis of the whole bone marrow cells in 
addition to the immunophenotypic analysis focusing on the small percentage of stem and 
progenitor cells. This analysis revealed a similar accumulation of blasts/myeloblasts and 
promyelocytes and a reduction of neutrophils in pre-leukemic CbfbMYH11 and 
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NrasG12D/CbfbMYH11 cells. These data suggest that the block of differentiation ocurrs at the 
myeloblast / promyelocyte stage and the activity of N-RasG12D cannot by pass the 
differentiation block set by Cbf-SMMHC. Analysis of expression levels of master 
myeloid differentiation regulators, such as Cebpa, Pu.1 and Gfi1 in Cbf-SMMHC pre-
leukemic cells and the usage of RNA interference or retroviral overexpression coupled 
with differentiation assays to test the roles of those potential targets will help us to better 
understand the mechanisms of the differentiation block. 
In summary, we have shown that different oncogenes deregulate specific properties 
of the hematopoietic stem and progenitor cells before full blown transformation occurs. 
In addition, we have developed a valuable mouse model for studying functional and 
genetic changes that drive leukemia development. Studies on the molecular alteration of 
the pre-leukemic cells by oncogenic mutations will help in understanding the functions of 
those critical genes in normal hematopoiesis, the progression of leukemia from pre-
leukemia stage, possible mechanisms of relapse and development of targeted therapies to 
those pre-leukemic clones.  
 
IV.B Cooperation between CBF-SMMHC and N-RASG12D in leukemogenesis 
As a driver mutation in inv(16) AML, CBF-SMMHC dictates the leukemic 
phenotype in our NrasG12D/CbfbMYH11 mouse model. The acceleration and higher 
leukemia initiating-cell (L-IC) activity provided by N-RasG12D probably result from the 
enhanced survival capacity observed in the pre-leukemic cells. Accordingly, studies using 
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serial transplantation assays have noted an advantage of N-RasG12D in serial multi-lineage 
repopulation activities (Li et al., 2013).  
The related concept of whether these two mutations are sufficient to induce 
leukemia was addressed in our experiments. The median latency of leukemia in 
Nras+/G12D/Cbfb+/MYH11 mice was significantly shorter than in Cbfb+/MYH11 mice. However 
the extended time needed for leukemia development suggests that additional mutations 
may be required for leukemia development. To address this question, future studies may 
utilize a retroviral mutagenesis approach on transplantation assays of NrasG12D/CbfbMYH11 
pre-leukemic cells and assess whether the emerging leukemia is poly- or olig-oclonal . 
Does the activation of Cbf-SMMHC and N-RasG12D need to occur in hematopoietic 
progenitor cells before the stage of Cbf-SMMHC-mediated differentiation block? Our 
finding that one out of six Nras+/G12D/Cbfb+/MYH11 mice developed a mixed phenotype that 
included MPN and AML cells. Since the MPN population did express Cbf-SMMHC 
(data not shown), it is possible that the fusion protein-mediated differentiation block may 
not be effective in myeloid cells after the myeloblast/promyeloblast stage, and NrasG12D 
may direct enhanced myeloproliferative phenotype.  
The presence of homozygous oncogenic NRAS alleles has been reported in juvenile 
myelomonocytic leukemia patients, resulting from uniparental disomy (Dunbar et al., 
2008). This phenomenon was recaptured in the N-RasG12D chronic myelomonocytic 
leukemia and AML mouse models (Wang et al., 2010a; Xu et al., 2013). However, we 
found that the three AML clones analyzed maintained one wild type allele. Our results 
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correlate with studies of human AML cases that all the patients were found heterozygous 
for mutated NRAS or KRAS genes (Bacher et al., 2006; Bowen et al., 2005).  
Mutations in NRAS or KRAS are frequently found in inv(16) AMLs, with 26–38% 
and 7-17%, respectively (Bacher et al., 2006; Bowen et al., 2005; Valk et al., 2004a). 
However, no spontaneous mutations in codon 12, 13 or 61 of Nras or Kras transcripts 
were revealed in sequencing of 9 murine Cbf-SMMHC leukemic samples in our study. 
As we are aware, approximately only half of the cells are c-kit+ in each sample and we 
were not performing a deep sequencing analysis in those samples. Therefore it is possible 
that any small subclone but not the predominant one which contained the Ras mutations 
could be overlooked in this type of analysis due to sensitivity issues. Also, we could not 
exclude the existence of other types of Ras mutations or mutations in other factors related 
to the receptor tyrosine kinase signaling pathways. 
 
IV.C Bim is a potential downstream target of CBF-SMMHC and N-RASG12D 
The CBF-SMMHC directed a reduction in apoptosis of pre-leukemic progenitor 
cells. Analysis of apoptosis related proteins revealed that the pro-apoptotic Bcl-2-like 
protein 11 (Bcl2l11 or Bim) protein levels correlated with the reduced apoptosis in the 
pre-leukemic and leukemic cells expressing both CBF-SMMHC and N-RasG12D.  
The BIM protein is a BCL-2 homology 3 (BH3) - only protein (BOP), a pro-
apoptotic member of the BCL-2 protein family (Ewings et al., 2007b). Alternative 
splicings of BCL2L11 (BIM) mRNA give rise to the short, long and extra long protein 
variants (BIM-S, BIM-L and BIM-EL) (Bouillet et al., 2001). The BCL-2 family proteins 
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are evolutionarily conserved regulators of the cell intrinsic apoptosis pathway, which act 
to regulate the integrity of the outer mitochondrial membrane (Cory and Adams, 2002; 
Strasser, 2005).  
Upon stress induced signaling, BOPs, such as BIM, bind to the pro-survival BCL-2 
proteins, such as BCL-xL and MCL-1, neutralizing them and thereby relieving their 
inhibition of BAX and BAK (Chen et al., 2005; Ewings et al., 2007a; Puthalakath and 
Strasser, 2002; Willis et al., 2005). BAX and BAK are also BCL-2 family members. 
They are critical downstream effectors of apoptosis since cells lacking both proteins are 
resistant to a wide variety of apoptotic insults (Wei et al., 2001; Willis and Adams, 2005). 
In viable cells, BAX and BAK are restrained by their physical interaction with the pro-
survival BCL-2 proteins (Ewings et al., 2007b). After activation mediated by BOPs, BAX 
and BAK promote the release of cytochrome c through the outer mitochondrial 
membrane, leading to activation of caspase 9 (initiator caspase) and caspase 3 
(executioner caspases), and eventually cell death (McCubrey et al., 2008; McIlwain et al., 
2013).  
The levels of BIM are regulated at both transcriptional and post-translational levels. 
Transcription of the BCL2L11 gene is normally repressed by serum, growth factors and 
cytokines while increased expression of BCL2L11 is required for optimal cell death 
following cytokine withdrawal (Bouillet et al., 1999; Ewings et al., 2007a; Whitfield et 
al., 2001). This increase is promoted by the FOXO3 transcription factor (Gilley et al., 
2003; Yamamura et al., 2006). FOXO3 is inhibited by both ERK and AKT pathways. 
AKT phosphorylates and sequesters FOXO3 in the cytosol by binding to 14-3-3 proteins 
149 
 
 
 
to prevent it from activating BIM transcription (Fu and Tindall, 2008). ERK1⁄2-
dependent phosphorylation of FOXO3 targets it for proteasome-dependent degradation 
(Yang et al., 2008). BIM-EL is the most abundant isoform and undergoes the most 
dynamic changes in expression upon withdrawal of survival factors (Ewings et al., 
2007a). Many studies have shown that BIM-EL is phosphorylated at multiple sites in 
response to activation of the ERK1⁄2 pathway, and this has the effect of promoting its 
ubiquitination and proteasome dependent degradation (Hubner et al., 2008; Ley et al., 
2003; Ley et al., 2005; Luciano et al., 2003; Marani et al., 2004). Accordingly, our results 
showed that in leukemic cells expressing Cbf-SMMHC and N-RasG12D, Bim transcript 
and protein levels increased upon MEK inhibitor treatment and the leukemic cells are 
more sensitive to MEK inhibitor than wild type cells or leukemic cells only expressing 
Cbf-SMMHC. In the contrast, PI3K inhibitor did not significantly affect Bim levels and 
there is no difference in the sensitivity to the inhibitor between groups. The observation 
in the pre-leukemic cells is similar except the sensitivity to MEK inhibitor is lower and 
PI3K inhibitor did induce an increase in Bcl2l11 transcript levels but not necessarily 
protein levels. These results suggest a rewiring of pathway dependence during leukemic 
progression.  
As we should be aware, even though reduced Bim levels were observed in pre-
leukemic and leukemic cells expressing N-RasG12D and were increased upon MEK 
inhibitor treatment, whether this regulation is dependent on the activity of N-RasG12D 
needs further investigation. The usage of RNA interference selectively targeting N-
RasG12D but not wildtype N-Ras in pre-leukemic or leukemic cells expressing N-RasG12D 
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will provide useful information about whether the activation of MEK/ERK pathway, the 
reduction in Bim levels and the survival advantage are mediated by N-RasG12D activity.  
The RUNX3 and RUNX1 proteins are also potential regulators of BCL2L11 
transcripts. RUNX3 inhibits AKT transcription and cooperates with FOXO3 to induce 
BCL2L11 transcripts in gastric epithelial cells (Lin et al., 2012; Yamamura et al., 2006; 
Yano et al., 2006). RUNX3 is transcriptionally repressed by CBF-SMMHC (Cheng et al., 
2008) and can be induced by treating ME-1 with CBF-SMMHC/RUNX inhibitor AI-10-
49 (Illendula et al., manuscript submitted). Therefore, inhibition of the RUNX3/BIM axis 
could be a potential survival mechanism provided by CBF-SMMHC. However, we 
found that though AI-10-49 induced expression of BCL2L11 and specifically reduced the 
viability of murine and human leukemic cells expressing Cbf-SMMHC, decrease of 
RUNX3 expression by RNA interference did not affect the efficacy of AI-10-49 in ME-1 
cells. RUNX1 has also been shown to cooperate with FOXO3 in mediating transforming 
growth factor  (TGF)-induced BCL2L11 transcription in hepatic cells (Wildey and 
Howe, 2009). The RUNX1/FOXO3/BIM axis could be another potential mechanism to 
be investigated. We have shown that knock-down of Bcl2l11 in pre-leukemic cells 
expressing Cbf-SMMHC reduced apoptosis. Testing whether those cells or pre-
leukemic Cbf-SMMHC cells in a Bcl2l11-/- background are resistant to AI-10-49 
treatment will provide more information on the how critical Bim is for pre-leukemic cell 
survival downstream of Cbf-SMMHC.  
We have shown that loss of one copy of wildtype Bcl2l11 allele did not cooperate 
with Cbf-SMMHC in leukemogenesis. The first possibility is that the Bim levels in the 
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Bim+/- background are not low enough to cooperate with Cbf-SMMHC in leukemia 
development. To test that, a comparison of Bim levels between Bim-/+ and Nras+/G12D 
hematopoietic progenitor cells will provide very useful information. If the Bim levels are 
higher in Bim+/- cells, it will be necessary to analyze leukemogenesis in Bim-/-Cbfb+/MYH11 
mice, keeping in mind the possible autoimmune kidney diseases induced by loss of Bim 
(Bouillet et al., 1999).  Regarding that, monitoring leukemogenesis in mice transplanted 
with Cbfb+/MYH11 cells harboring shRNAs targeting Bim is an alternative option. The 
second possibility is that there are other potential targets downstream of N-RasG12D 
involved or not involved in apoptosis that are critical in cooperation with Cbf-SMMHC 
in leukemia development.  I am aware that we have not performed an exhaustive analysis 
of all cell death associated proteins/pathways that may be involved in N-RasG12D and 
Cbf-SMMHC-mediated pro-survival of pre-leukemic and leukemic cells. We have not 
explored other possible mechanisms besides survival signals in leukemia initiation and 
maintenance, either. Therefore, future efforts may be required to further explore other 
important factors driving the anti-apoptotic response and leukemogenesis. 
 
IV.D Target the MEK/ERK pathway in AMLs with NRAS mutations 
Oncogenic RAS mutations are dominant mutations that are found in many cancers, 
and represent compelling targets for the development of small molecule inhibitors. 
However, constitutive activation of RAS results from an inactivation of its intrinsic 
enzyme activity and restoration of this activity is a daunting proposition that has not been 
achieved to date (Braun and Shannon, 2008). Therefore, inhibition of downstream 
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components of RAS signaling pathway, such as MEK, becomes a recent trend in targeted 
therapies for cancer patients with RAS mutations. However, studies of knockout mice 
raised concerns about potential toxicity of inhibition the MEK/ERK pathway. Erk1-/- 
mice presented a twofold reduction in the number of mature thymocytes and T-cell 
proliferation was reduced in response to activating factors (Pages et al., 1999). Mek1-/- 
mice underwent embryonic lethality, resulting from impaired placental development 
(Giroux et al., 1999).  
Our results demonstrate that MEK inhibitor PD0325901 specifically affected 
viability of leukemic cells expressing both Cbf-SMMHC and N-RasG12D with minimal 
toxicity to wild type bone marrow progenitor cells and leukemic cells expressing only 
Cbf-SMMHC. In contrast, PI3K inhibitor GDC-0980 reduced the viability of all the 
three biological groups. This observation represents an example of signaling network 
remodeling by cancer cells. The dependence of Cbf-SMMHC/N-RasG12D leukemic cells 
on MEK/ERK pathway but not on PI3K/AKT pathway points out a clinical implication 
that targeting MEK/ERK pathway using MEK inhibitors may be an efficient 
complimentary therapy to inv(16) AMLs with NRAS mutations.  
A variety of MEK inhibitors have been developed and tested in preclinical models 
and clinical trials in patients with solid tumors and hematopoietic malignancies 
presenting activated RAS/RAF/MEK pathway. PD098059 was the first MEK inhibitor to 
be disclosed (Dudley et al., 1995). It has been mostly used in an in vitro to understand the 
role of MEK/ERK pathway in carcinogenesis (Dudley et al., 1995; Murphy et al., 2001; 
Xing and Imagawa, 1999). Two other potent MEK inhibitors, U0126 (Favata et al., 1998) 
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and Ro 09-2210 (Williams et al., 1998), were subsequently identified in cell-based assays. 
These inhibitors were highly selective in inhibiting activation of MEK (Davies et al., 
2000; Williams et al., 1998). However, none of these compounds was moved to clinical 
evaluation because of their pharmaceutical limitations (Fremin and Meloche, 2010). 
PD184352 (subsequently named CI-1040) was the first MEK inhibitor reported to 
inhibit tumor growth in vivo (Sebolt-Leopold et al., 1999). CI-1040 is a potent (IC50 of 17 
nM against purified MEK1) and highly selective inhibitor of MEK1/2 (Sebolt-Leopold et 
al., 1999). Though CI-1040 was ineffective in preclinical MPN model with inactivation 
of Nf1, it induced markedly extended survival in insertional mutagenesis models of 
AMLs initiated by Nf1 inactivation (Lauchle et al., 2009). However, insufficient 
antitumor activity, poor solubility and low bioavailability of CI-1040 precluded further 
clinical development of this compound from Phase II study (Rinehart et al., 2004).  
PD325901 was developed as a significantly more potent MEK inhibitor (IC50 of 
1nM against purified MEK1/2) with longer in vivo duration than CI-1040 (Barrett et al., 
2008; Lauchle et al., 2009; Sebolt-Leopold and Herrera, 2004; Solit et al., 2006). 
PD0325901 have been shown to prolong survival of KrasG12D or Nf-/- MPN mice (Chang 
et al., 2013; Lyubynska et al., 2011). However, PD0325901 has minimal activity in RAS-
mutant tumors, and was associated with more severe toxicity than CI-1040, including 
blurred vision as well as acute neurotoxicity (Haura et al., 2010; Solit et al., 2006; Wang 
et al., 2007). The clinical development of PD0325901 has been suspended. Prompted by 
the successful use of this inhibitor in MPN mouse models, we have tested the efficacy of 
PD0325901 in mice transplanted with N-RasG12D/Cbf-SMMHC leukemic cells. In line 
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with the toxicity found in clinical trials and contrary to the MPN studies in mice, we have 
also observed toxicity and no efficacy in our studies (data not shown). These results 
suggest a possibility that targeting hyperactive Ras signaling could be differentially 
effective in MPN, where RAS and NF1 mutations seem to initiate the diseases, versus 
AML, where RAS and FLT3 mutations are thought to serve as cooperating events.  
AZD6244 is another highly selective MEK1/2 inhibitor with an IC50 of 14nM 
against purified MEK1/2 (Yeh et al., 2007). AZD6244 has an potent antitumor activity 
against a panel of mouse xenograft models of colorectal, pancreatic, liver, skin and lung 
cancer (Davies et al., 2007; Haass et al., 2008; Huynh et al., 2007; Yeh et al., 2007). 
Some phase II studies of AZD6244 in subjects with solid tumors showed clinical 
improvements companied by a high rate of adverse events (Carvajal et al., 2014; Janne et 
al., 2013; Patel et al., 2013). However, a recent phase II study of AZD6244 in advanced 
AML showed only modest and transient antitumor activity [NCT00588809, (Ward et al., 
2012)].  
GDC-0973 is a potent, selective, orally active MEK inhibitor with a biochemical 
IC50 of 4.2nM against MEK1 (Hoeflich et al., 2012; Rice et al., 2012). GDC-0973 has 
antitumor efficacy in BRAF and KRAS mutant human xenograft tumor models (Hoeflich 
et al., 2012). A phase I dose-escalating of study of GDC-0973 was initiated in subjects 
with solid tumors and preliminary results indicated the drug was well tolerated 
[NCT00467779, (Fremin and Meloche, 2010)]. However, though GDC-0973 was as 
potent as PD0325901 in affecting viability of Cbf-SMMHC/N-RasG12D leukemic cells in 
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vitro, we did not observe a significant survival benefit by GDC-0973 in vivo (data not 
shown). 
GSK1120212 is an orally available, selective MEK inhibitor [nanomolar activity 
against purified MEK 1 and MEK 2 kinases, (Yamaguchi et al., 2011)] with antitumor 
activity in mouse xenograft models (Gilmartin et al., 2011). A recent study has revealed a 
high efficacy of GSK1120212 in combination with imatinib mesylate in a murine model 
of BCR-ABL–independent imatinib mesylate-resistant chronic myeloid leukemia with 
sustained MEK/ERK signaling (Ma et al., 2014). A Phase III study of GSK1120212 has 
shown that it improved rates of progression-free and overall survival among patients who 
had metastatic melanoma with a BRAF V600E or V600K mutation, compared to 
chemotherapy [NCT01245062, (Flaherty et al., 2012)]. Another recent Phase II clinical 
trial demonstrated utility of GSK1120212 in relapsed/refractory myeloid neoplasm 
[NCT00920140, (Bachegowda et al., 2013)]. This MEK inhibitor could be a good 
candidate to be tested in our preclinical CbfbMYH11/NrasG12D leukemic mouse model.  
MEK162 is a novel small molecule inhibitor of the kinases MEK1/2. A recent Phase 
II study disclosed that MEK162 was the first targeted therapy to show activity in patients 
with NRAS-mutated melanoma [NCT01320085, (Ascierto et al., 2013)]. There are several 
Phase I/II clinical trials just starting to recruit patients for applying MEK162 in advanced 
AMLs (NCT02089230 and NCT01885195). Taken together, it will provide valuable 
information for future clinical trials utilizing MEK inhibitors as a cooperating drug in 
AMLs to test efficacy of those inhibitors in our preclinical inv(16) AML mouse model 
harboring NrasG12D mutation. 
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Even though KRAS and NRAS only differ in the hypervariable region (HVR) 
(Karnoub and Weinberg, 2008), constitutively activated mutant K-Ras induced a more 
aggressive MPN than constitutively activated mutant N-Ras (Braun et al., 2004; Li et al., 
2011). A recent report has revealed the dependency of K-RasG12D mediated MPN on 
activities of PI3K p110α isoform in mice (Gritsman et al., 2014), suggesting that cells 
harboring mutant K-RAS may have different dependency on downstream signaling 
pathways compared to cells harboring mutant N-RAS. Another interesting result from 
this study is that THP1 cells [a human AML cell line harboring a NRASG12D mutation 
(Morgan et al., 2001)] were sensitive to low dose of MEK inhibitor MEK162 but not 
PI3K inhibitor BYL719, but those two inhibitors synergized in affecting proliferation of 
THP1 cells (Gritsman et al., 2014). Therefore, it will be interesting to test in our mouse 
model if a similar synergy between MEK inhibitor and PI3K inhibitor can be achieved, 
even though we did not observe a significant dependency on PI3K signaling for survival 
of Cbf-SMMHC/N-RasG12D leukemic cells. 
 
IV.E The novel small molecule AI-10-49 targeting CBF-SMMHC 
Acute myeloid leukemia is a polyclonal disease that different clones share a 
founding mutation(s) and differ in the presence of secondary mutations (Jan and Majeti, 
2013). As such, AML follows a clonal evolution, as recently revealed by studies 
performing whole-genome sequencing of patient samples (Ding et al., 2012; Welch et al., 
2012). Studies have shown that chemotherapy failed to eradicate the founding clone and 
the pre-leukemic cells harboring the driver mutations (Ding et al., 2012; Shlush et al., 
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2014). Accordingly, current chemotherapy treatment induce a high complete remission 
(CR) rate in the initial treatment but a low 5 year overall survival (OS) rate and high 
incidence of relapse even in the favorable karyotype inv(16) AML patients (Lowenberg 
et al., 2011; Marcucci et al., 2005; Pulsoni et al., 2008; Ravandi et al., 2007; Schlenk et 
al., 2004). 
The inv(16) is a driver mutation invariably present in de novo and relapse samples 
(Castilla et al., 1999; Kuo et al., 2006; Laczika et al., 1998; Shih et al., 2008). It induces 
AML upon acquisition of other cooperating mutations (Castilla et al., 1999; Castilla et al., 
2004; Kuo et al., 2006; Kuo et al., 2009; Paschka et al., 2013). The development of 
inhibitors that target CBF-SMMHC activity without affecting the normal CBF function 
would represent an ideal therapy in treating inv(16) AMLs and might reduce the relapse 
risk. In collaboration with four research laboratories we have recently developed the 
small molecule AI-10-49, a first generation CBF-SMMHC/RUNX inhibitor with great 
efficacy in reducing viability of human and murine inv(16) AML cells. This inhibitor 
shows significant efficacy in vivo, using our N-RasG12D/CBF-SMMHC mouse model 
with minimal toxicity to normal hematopoietic cells. However, we should point out that 
even though the medium latency was significantly delayed in mice treated with AI-10-49 
compared with mice treated with DMSO, mice treated with AI-10-49 eventually died of 
leukemia. It would be unlikely for those mice to develop drug resistance in just 10 days 
of treatment. The possible explanation is that the 10-day treatment with AI-10-49 only 
reduced the pool of leukemic-initiating cells but not eradicated them. AI-10-49 has poor 
water solubility and precipitation of the inhibitor was observed in the peritoneal of the 
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treated mice where the injection was performed (data not shown). Therefore, the future 
direction for modifying AI-10-49 will be to improve the solubility of it without affecting 
the efficacy. 
This work serves as a proof-of-principle that the transcriptional factors, which are 
often disrupted in AML, can become therapeutic targets. In the next subchapter, I will 
discuss some future directions on this exciting inhibitor in both basic research and 
therapeutic aspect.  
 
IV.F Future perspectives 
 
IV.F.1 Studying downstream targets in Cbf-SMMHC and N-RasG12D leukemias 
My thesis has identified the pro-apoptotic protein Bim as a potential downstream 
target of both Cbf-SMMHC and N-RasG12D. Conceivably, other potential targets could 
also participate in the anti-apoptotic phenotype observed.  
We have found that the expression level of Bcl2 significantly increased in 
Cbfb+/MYH11 pre-leukemic cells but not in Nras+/G12D/Cbfb+/MYH11 pre-leukemic cells 
compared to wildtype bone marrow progenitor cell. Notably, AML1-ETO activates 
transcription of the BCL-2 gene in U937 cells (Klampfer et al., 1996). These data suggest 
that Bcl-2 may be an important target downstream of Cbf-SMMHC in providing 
survival advantage to pre-leukemic and leukemic cells. To test this hypothesis, we could 
treat the bone marrow cells harboring Cbf-SMMHC with AI-10-49 or shRNA 
specifically targeting the fusion protein and then assay the levels of Bcl-2. In addition, 
159 
 
 
 
transplantation of Cbfb+/MYH11 or Nras+/G12D/Cbfb+/MYH11 leukemic cells with reduced Bcl-
2 levels into recipient mice will evaluate whether up-regulation of Bcl-2 is required for 
maintenance of leukemic cells. Other Bcl-2 family proteins could also serve as potential 
downstream targets of NrasG12D in providing survival benefits, such as Bad, Puma, and 
Noxa, which are regulated by either MEK/ERK or PI3K pathways (McCubrey et al., 
2008). In addition, a RNA sequencing analysis comparing pre-leukemic and leukemic 
cells harboring either Cbf-SMMHC and/or NrasG12D mutations to normal hematopoietic 
progenitor cells will systemically unravel potential downstream targets downstream not 
only involved in pro-survival but also involved in other potential mechanisms related to 
leukemogenesis.  
 
IV.F.2 Dissecting differential roles of Cbf-SMMHC between pre-leukemic and 
leukemic cells 
The concept of oncogene addiction postulates that despite the diverse array of 
genetic lesions typical of cancer, some tumors rely on a single dominant oncogene for 
growth and survival, so that inhibition of this specific oncogene is sufficient to halt the 
neoplastic phenotype. This concept was introduced by Bernard Weinstein in 1990s 
(Weinstein, 2000; Weinstein, 2002; Weinstein et al., 1997) and has been demonstrated in 
vivo for several oncogenes. For example, mouse models using an inducible MYC 
oncogene have shown that MYC-driven skin papillomas, lymphomas, and osteosarcomas 
can all be reversed upon inactivation of MYC (Felsher and Bishop, 1999; Jain et al., 2002; 
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Pelengaris et al., 1999). Other experimental examples of oncogene addiction include H-
RAS, K-RAS, ABL, HER2 and EGFR [reviewed in (Torti and Trusolino, 2011)].  
We have found that Cbf-SMMHC is necessary but not sufficient to induce acute 
myeloid leukemia (Castilla et al., 1999; Castilla et al., 2004; Kuo et al., 2006). 
Experiments presented in my thesis, performed by a collaborative effort, have shown that 
inhibition of binding between CBF-SMMHC and RUNX1 specifically reduced the 
viability of murine and human inv(16) leukemic cells with minimal toxicity in normal 
hematopoietic cells. In contrast, while retroviral overexpression of Cbf-SMMHC in wild 
type murine hematopoietic progenitor cells blocked differentiation, overexpression of 
Cbf-SMMHC with two point mutations (G61A and N104A) which abrogate binding to 
Runx proteins (Lukasik et al., 2002; Tang et al., 2000) did not block differentiation of the 
progenitor cells (unpublished data, Castilla laboratory). These observations lead to a 
hypothesis that inhibition of CBF-SMMHC in pre-leukemic cells restores the normal 
differentiation of hematopoietic progenitor cells while inhibition of CBF-SMMHC in 
inv(16) leukemic cells induces cell death because the leukemic cells are “addicted” to the 
presence of the fusion protein for survival.  
To test this hypothesis, differentiation and apoptosis of wild type and pre-leukemic 
cells expressing Cbf-SMMHC could be tested after treatment with the specific inhibitor. 
To study the mechanism in the differential responses to inhibition of the fusion protein, a 
RNA sequencing analysis in pre-leukemic and leukemic cells treated with either DMSO 
or CBF-SMMHC inhibitor AI-10-49 could be valuable to identify potential targets. 
CBF-SMMHC has been shown to suppress the granulocytic differentiation factor 
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C/EBP in inv(16) AML (Helbling et al., 2005). Thus, the transcriptional factor C/EBP 
could be a potential target in differentiation block induced by Cbf-SMMHC. In addition, 
based on my thesis, Bcl-2 family proteins such as Bim and Bcl-2 could be potential 
targets in survival advantage provided by Cbf-SMMHC. We can verify candidate 
targets revealed by the analysis and investigate into the functions of those candidates by 
means of retroviral overexpression and/or RNA interference.  
 
IV.F.3 Combination therapies and drug resistance 
We have established the efficacy of CBF-SMMHC inhibitor AI-10-49 in murine 
and human inv(16) leukemic cells and CbfbMYH11/NrasG12D mouse models. The next step 
is to combine AI-10-49 with conventional and/or other targeted therapies in our 
preclinical leukemic mouse models.  
The standard regimen for AML induction therapy involves cytotoxic reagents, 
cytarabine and anthracycline. It will be informative to test the combination of AI-10-49 
with either cytarabine or doxorubicin (one type of anthracycline) in vitro and in vivo. A 
recent report showed that the sequential application of targeted and cytotoxic anticancer 
drugs were critical for enhanced cell death (Lee et al., 2012). Therefore, the order of 
application between AI-10-49 and conventional drugs should be taken into account. 
Furthermore, combination of AI-10-49 with other targeted therapies is another future 
direction. We did not observe efficacy of PD0325901 and GDC-0973 in the conditions 
we tested in vivo. We should modify the dose and duration of these two inhibitors and 
also assess other MEK inhibitors which have been using in the clinical trials, such as 
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GSK1120212 and MEK162. Finally, drug resistance is a major concern during therapy. 
In the case of AI-10-49, it will be important to develop drug resistance studies in order to 
define the potential mutations that can drive drug resistance. Based on the suggested 
binding targets within the CBF-SMMHC protein, mutations blocking the binding of the 
compound to the protein or compensatory mutations elsewhere in the protein that 
compensate the allosteric modifications in the runt homology domain binding domain of 
CBF  region induced by AI-10-49 (Illendula et al., manuscript submitted) should be 
explored. 
 
IV.G Closing remarks 
My thesis establishes a very useful mouse model with allelic expression of two 
important oncogenes recurrently found in human inv(16) AMLs cases: CbfbMYH11 and 
NrasG12D and demonstrates that NrasG12D and Cbf-SMMHC provide survival advantage 
to murine pre-leukemic progenitors. The activity of NrasG12D cannot bypass the myeloid 
differentiation block by Cbf-SMMHC. These two oncogenes cooperate in 
leukemogenesis and repress the pro-apoptotic gene Bcl2l11. The leukemic cells depend 
on MEK/ERK pathway to survival.  
In collaboration with other research laboratories, we develop and test a novel 
bivalent compound AI-10-49 which selectively disrupts CBF-SMMHC/RUNX binding 
and restores normal CBF function. My thesis indicates the specificity of AI-10-49 in 
affecting viability of leukemic cells without affecting normal hematopoietic cells. This 
compound also significantly prolongs the survival of the NrasG12D/Cbf-SMMHC 
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leukemic mice. AI-10-49 will be a very promising first-generation drug in inhibiting 
transcriptional factors and also benefits the research on mechanisms of inv(16) AMLs. 
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Appendix A 
 
This appendix lists all the supplementary figures for Chapter II.  
 
  
 
Figure A.1 Cbf-SMMHC and N-RasG12D expand pre-leukemic stem and progenitor 
cells. Representative FACS plots of Figure II.1 and Figure II.2. (A) cells were first gated 
by FSC-A/SSC-A, then gated for single cells by FSC-A/FSC-H, then gated for 7-AAD- 
population and the following gating of LSK+ compartment from Control, Nras, CM and 
Nras/CM mice is shown. 
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Figure A.1 (Cont.) Cbf-SMMHC and N-RasG12D expand pre-leukemic stem and 
progenitor cells. (B) cells were first gated by FSC-A/SSC-A, then gated for single cells 
by FSC-A/FSC-H, then gated for 7-AAD- population and the following gating of LSK- 
compartment from Control, Nras, CM and Nras/CM mice is shown. 
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Figure A.2 Apoptosis analyses of bone marrow pre-leukemic cells expressing Cbf-
SMMHC and N-Ras
G12D
. Data from Figure II.4 were reanalyzed by a different gating 
strategy. (A) the gating of each compartment is shown; (B) quantification of the ratio of 
apoptosis levels for LSK- (left) and LSK+ (right) cells of each group normalized to 
control group (n=4-9, *, P<0.05; **, P<0.01). Note: since it is a reanalysis of the previous 
data and one of the data file was corrupted, the dataset shown here is incomplete 
compared to the dataset in Figure II.4. 
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Figure A.3 Percentage of c-kit positive cells in peripheral blood and spleen weight of 
mice transplanted with either CM or Nras/CM leukemic clones. At the end of 
limiting dilution experiments (36 weeks) shown in Figure II.6F and H, mice that shows 
no appearance of diseases were analyzed for c-kit positive cells in peripheral blood (PB) 
by flow cytometry (A, C) or spleen (SP) weight (B, D). (A-B) CM A287 leukemic clone 
(C-D) Nras/CM B81 leukemic clone. 
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Figure A.4 Genomic PCR of peripheral blood and bone marrow cells from mice 
transplanted with either CM or Nras/CM leukemic clones. At the end of limiting 
dilution experiments (36 weeks) shown in Figure II.6F and II6.H, mice that shows no 
appearance of diseases were analyzed for recombination of CbfbMYH11 alleles in white 
blood cells from peripheral blood (PB) and bone marrow (BM) by genomic PCR. (A) 
CM A287 leukemic clones. Lanes 1-4 are PCR products from control genomic DNA 
samples: Lane 1, Mx1-Cre; Lane 2, Nras+/LSL-G12D/Cbfb+/56M; Lane 3, bulk Nras/CM 
Leukemic cells; Lane 4, water. 
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Figure A.4 (Cont.) Genomic PCR of peripheral blood and bone marrow cells from 
mice transplanted with either CM or Nras/CM leukemic clones. (B) Nras/CM A287 
leukemic clones. Lanes 1-4 are PCR products from control genomic DNA samples: Lane 
1, Mx1-Cre; Lane 2, Nras+/LSL-G12D/Cbfb+/56M; Lane 3, bulk Nras/CM Leukemic cells; 
Lane 4, water. SP represent the PCR reaction of spleen cells from the mice that 
transplanted with 160 Nras/CM B81 leukemic cells and present splenomegaly (spleen 
weight is 0.3418g as shown in Figure A.2D). 
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Figure A.5 No mutations in codon 12, 13, 61 of Nras or Kras genes were identified in 
CM leukemic cells. Complete sequencing results of Figure II.9 for 9 CM leukemic cells. 
(A) Clone A287, B235 and B90. 
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Figure A.5 (Cont.) No mutations in codon 12, 13, 61 of Nras or Kras genes were 
identified in CM leukemic cells. (B) Clone B92, B169 and B274. 
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Figure A.5 (Cont.) No mutations in codon 12, 13, 61 of Nras or Kras genes were 
identified in CM leukemic cells. (C) Clone E148, E200 and E211. 
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Appendix B 
 
This appendix lists all the plasmid constructs that I made during my stay in the 
Castilla laboratory.  
B.1 Construct information 
Table B.1 List of the construct information 
Construct Size Insert Name 
Insert 
Species 
Insert 
Size 
Insert Origin 
pMSCV2.2- 
CBL WT 
9.4 kb 
CBL wildtype 
cDNA 
Human 2800 bp 
pCR2.1- 
CBL WT 
pMSCV2.2- 
CBL Major 
9.3 kb 
CBL Major 
mutant cDNA 
Human 2668 bp 
pCR2.1- 
CBL Major 
pMSCV2.2- 
CBL Minor 
9.4 kb 
CBL Minor 
mutant cDNA 
Human 2840 bp 
pCR2.1- 
CBL Minor 
pMSCV2.2- 
Bim-EL 
7.2 kb 
Bcl2l11 extra-
long isoform 
cDNA 
Mouse 618 bp 
pCMV-Tag2B 
Flag Bim-EL 
pMSCV2.2-mSt18 
10.9 
kb 
St18 full length 
cDNA 
Mouse 4340 bp 
pCR-BluntII-
TOPO mSt18 
LMP-shScrambled 8.0 kb 
Scrambled 
shRNA 
/ 100 bp 
97mer 
oligonucleotide 
LMP-shId2-1 8.0 kb Id2 shRNA-1 Mouse 104 bp 
97mer 
oligonucleotide 
LMP-shId2-2 8.0 kb Id2 shRNA-2 Mouse 104 bp 
97mer 
oligonucleotide 
LMP-shId2-3 8.0 kb Id2 shRNA-3 Mouse 104 bp 
97mer 
oligonucleotide 
LMP-shId2-4 8.0 kb Id2 shRNA-4 Mouse 104 bp 
97mer 
oligonucleotide 
LMP-shId2-5 8.0 kb Id2 shRNA-5 Mouse 104 bp 
97mer 
oligonucleotide 
LMP-shCM 8.0 kb 
CBFB-MYH11 
shRNA 
Human 
(Junction) 
104 bp 
97mer 
oligonucleotide 
LMP-shBim-1 8.0 kb Bcl2l11 shRNA-1 Mouse 104 bp 
97mer 
oligonucleotide 
LMP-shBim-3 8.0 kb Bcl2l11 shRNA-3 Mouse 104 bp 
97mer 
oligonucleotide 
LMP-shBim-4 8.0 kb Bcl2l11 shRNA-4 Mouse 104 bp 
97mer 
oligonucleotide 
 
Note: All the plasmids listed have Ampicillin antibiotic resistance markers. 
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Figure B.1 Construction of pMSCV2.2-CBL. All the CBL wild type or mutant forms 
(CBL WT, Major and Minor) were cloned from original pCR2.1-CBL constructs by 
digesting with NotI and SpeI restriction enzymes. SpeI site of the inserts were blunted 
and the inserts were ligated into the pMSCV2.2 plasmids between NotI and PmeI sites. 
The red crossing sign means the PmeI site was destroyed by this cloning method. 
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Figure B.2 Construction of pMSCV2.2-Bim-EL. The Bcl2l11 extra-long isoform 
cDNA was cloned from original pCMV-Tag2B Flag Bim-EL construct by digesting with 
BamHI and SalI restriction enzymes. The insert was ligated into the pMSCV2.2 plasmid 
between BglII and SalI sites. The red crossing sign means the BglII site was destroyed by 
this cloning method. 
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Figure B.3 Construction of pMSCV2.2-mSt18. Mouse St18 full length cDNA were 
cloned from the original pCR-BluntII-TOPO mSt18 construct by digesting with XhoI and 
BamHI restriction enzymes. BamHI site of the insert was blunted and the insert was 
ligated into the pMSCV2.2 plasmid between XhoI and PmeI sites. The red crossing sign 
means the PmeI site was destroyed by this cloning method. 
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Figure B.4 Construction of LMP-shRNA. All the LMP-shRNAs were constructed 
according to LMP technical manual (Thermo Scientific, Billerica, MA). Basically, 97mer 
(or 90mer as in the Scrambled shRNA case) oligonucleotides containing unique shRNA 
sequences were amplified using primers containing XhoI and EcoRI restriction sites. The 
amplification products and LMP plasmid were digested by XhoI and EcoRI restriction 
enzymes and ligated to create LMP-shRNAs constructs.  
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B.2 Sequence of Inserts 
 
B.2.1 cDNA inserts: 
Note: all the sequences of the cDNAs below are color-coded. Blue, restriction enzyme 
sites of the inserts; Red, start and stop codons of open reading frame.  
a. CBL wild type cDNA 
GC_GGCCGCCAGTGTGATGGATATCTGCAGAATTCGGCTTCAGGCCATGGCC
GGCAACGTGAAGAAGAGCTCTGGGGCCGGGGGCGGCAGCGGCTCCGGGGGC
TCGGGTTCGGGTGGCCTGATTGGGCTCATGAAGGACGCCTTCCAGCCGCACC
ACCACCACCACCACCACCTCAGCCCCCACCCGCCGGGGACGGTGGACAAGAA
GATGGTGGAGAAGTGCTGGAAGCTCATGGACAAGGTGGTGCGGTTGTGTCAG
AACCCAAAGCTGGCGCTAAAGAATAGCCCACCTTATATCTTAGACCTGCTAC
CAGATACCTACCAGCATCTCCGTACTATCTTGTCAAGATATGAGGGGAAGAT
GGAGACACTTGGAGAAAATGAGTATTTTAGGGTGTTTATGGAGAATTTGATG
AAGAAAACTAAGCAAACCATAAGCCTCTTCAAGGAGGGAAAAGAAAGAATG
TATGAGGAGAATTCTCAGCCTAGGCGAAACCTAACCAAACTGTCCCTCATCTT
CAGCCACATGCTGGCAGAACTAAAAGGAATCTTTCCAAGTGGACTCTTTCAG
GGAGACACATTTCGGATTACTAAAGCAGATGCTGCGGAATTTTGGAGAAAAG
CTTTTGGGGAAAAGACAATAGTCCCTTGGAAGAGCTTTCGACAGGCTCTACA
TGAAGTGCATCCCATCAGTTCTGGGCTGGAGGCCATGGCTCTGAAATCCACT
ATTGATCTGACCTGCAATGATTATATTTCGGTTTTTGAATTTGACATCTTTACC
CGACTCTTTCAGCCCTGGTCCTCTTTGCTCAGGAATTGGAACAGCCTTGCTGT
AACTCATCCTGGCTACATGGCTTTTTTGACGTATGACGAAGTGAAAGCTCGGC
TCCAGAAATTCATTCACAAACCTGGCAGTTATATCTTCCGGCTGAGCTGTACT
CGTCTGGGTCAGTGGGCTATTGGGTATGTTACTGCTGATGGGAACATTCTCCA
GACAATCCCTCACAATAAACCTCTCTTCCAAGCACTGATTGATGGCTTCAGGG
AAGGCTTCTATTTGTTTCCTGATGGACGAAATCAGAATCCTGATCTGACTGGC
TTATGTGAACCAACTCCCCAAGACCATATCAAAGTGACCCAGGAACAATATG
AATTATACTGTGAGATGGGCTCCACATTCCAACTATGTAAAATATGTGCTGAA
AATGATAAGGATGTAAAGATTGAGCCCTGTGGACACCTCATGTGCACATCCT
GTCTTACATCCTGGCAGGAATCAGAAGGTCAGGGCTGTCCTTTCTGCCGATGT
GAAATTAAAGGTACTGAACCCATCGTGGTAGATCCGTTTGATCCTAGAGGGA
GTGGCAGCCTGTTGAGGCAAGGAGCAGAGGGAGCTCCCTCCCCAAATTATGA
TGATGATGATGATGAACGAGCTGATGATACTCTCTTCATGATGAAGGAATTG
GCTGGTGCCAAGGTGGAACGGCCGCCTTCTCCATTCTCCATGGCCCCACAAG
CTTCCCTTCCCCCGGTGCCACCACGACTTGACCTTCTGCCGCAGCGAGTATGT
GTTCCCTCAAGTGCTTCTGCTCTTGGAACTGCTTCTAAGGCTGCTTCTGGCTCC
CTTCATAAAGACAAACCATTGCCAGTACCTCCCACACTTCGAGATCTTCCACC
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ACCACCGCCTCCAGACCGGCCATATTCTGTTGGAGCAGAATCCCGACCTCAA
AGACGCCCCTTGCCTTGTACACCAGGCGACTGTCCCTCCAGAGACAAACTGC
CCCCTGTCCCCTCTAGCCGCCTTGGAGACTCATGGCTGCCCCGGCCAATCCCC
AAAGTACCAGTATCTGCCCCAAGTTCCAGTGATCCCTGGACAGGAAGAGAAT
TAACCAACCGGCACTCACTTCCATTTTCATTGCCCTCACAAATGGAGCCCAGA
CCAGATGTGCCTAGGCTCGGAAGCACGTTCAGTCTGGATACCTCCATGAGTA
TGAATAGCAGCCCATTAGTAGGTCCAGAGTGTGACCACCCCAAAATCAAACC
TTCCTCATCTGCCAATGCCATTTATTCTCTGGCTGCCAGACCTCTTCCTGTGCC
AAAACTGCCACCTGGGGAGCAATGTGAGGGTGAAGAGGACACAGAGTACAT
GACTCCCTCTTCCAGGCCTCTACGGCCTTTGGATACATCCCAGAGTTCACGAG
CATGTGATTGCGACCAGCAGATTGATAGCTGTACGTATGAAGCAATGTATAA
TATTCAGTCCCAGGCGCCATCTATCACCGAGAGCAGCACCTTTGGTGAAGGG
AATTTGGCCGCAGCCCATGCCAACACTGGTCCCGAGGAGTCAGAAAATGAGG
ATGATGGGTATGATGTCCCAAAGCCACCTGTGCCGGCCGTGCTGGCCCGCCG
AACTCTCTCAGATATCTCTAATGCCAGCTCCTCCTTTGGCTGGTTGTCTCTGGA
TGGTGATCCTACAACAAATGTCACTGAAGGTTCCCAAGTTCCCGAGAGGCCT
CCAAAACCATTCCCGCGGAGAATCAACTCTGAACGGAAAGCTGGCAGCTGTC
AGCAAGGTAGTGGTCCTGCCGCCTCTGCTGCCACCGCCTCACCTCAGCTCTCC
AGTGAGATCGAGAACCTCATGAGTCAGGGGTACTCCTACCAGGACATCCAGA
AAGCTTTGGTCATTGCCCAGAACAACATCGAGATGGCCAAAAACATCCTCCG
GGAATTTGTTTCCATTTCTTCTCCTGCCCATGTAGCTACCTAGCACACCATCTC
CAAGCCGAATTCCAGCACACTGGCGGCCGTTACTAG_AAAC 
 
b. CBL Major mutant cDNA (missing exon8) 
GC_GGCCGCCAGTGTGATGGATATCTGCAGAATTCGGCTTCAGGCCATGGCC
GGCAACGTGAAGAAGAGCTCTGGGGCCGGGGGCGGCAGCGGCTCCGGGGGC
TCGGGTTCGGGTGGCCTGATTGGGCTCATGAAGGACGCCTTCCAGCCGCACC
ACCACCACCACCACCACCTCAGCCCCCACCCGCCGGGGACGGTGGACAAGAA
GATGGTGGAGAAGTGCTGGAAGCTCATGGACAAGGTGGTGCGGTTGTGTCAG
AACCCAAAGCTGGCGCTAAAGAATAGCCCACCTTATATCTTAGACCTGCTAC
CAGATACCTACCAGCATCTCCGTACTATCTTGTCAAGATATGAGGGGAAGAT
GGAGACACTTGGAGAAAATGAGTATTTTAGGGTGTTTATGGAGAATTTGATG
AAGAAAACTAAGCAAACCATAAGCCTCTTCAAGGAGGGAAAAGAAAGAATG
TATGAGGAGAATTCTCAGCCTAGGCGAAACCTAACCAAACTGTCCCTCATCTT
CAGCCACATGCTGGCAGAACTAAAAGGAATCTTTCCAAGTGGACTCTTTCAG
GGAGACACATTTCGGATTACTAAAGCAGATGCTGCGGAATTTTGGAGAAAAG
CTTTTGGGGAAAAGACAATAGTCCCTTGGAAGAGCTTTCGACAGGCTCTACA
TGAAGTGCATCCCATCAGTTCTGGGCTGGAGGCCATGGCTCTGAAATCCACT
ATTGATCTGACCTGCAATGATTATATTTCGGTTTTTGAATTTGACATCTTTACC
CGACTCTTTCAGCCCTGGTCCTCTTTGCTCAGGAATTGGAACAGCCTTGCTGT
AACTCATCCTGGCTACATGGCTTTTTTGACGTATGACGAAGTGAAAGCTCGGC
TCCAGAAATTCATTCACAAACCTGGCAGTTATATCTTCCGGCTGAGCTGTACT
CGTCTGGGTCAGTGGGCTATTGGGTATGTTACTGCTGATGGGAACATTCTCCA
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GACAATCCCTCACAATAAACCTCTCTTCCAAGCACTGATTGATGGCTTCAGGG
AAGGCTTCTATTTGTTTCCTGATGGACGAAATCAGAATCCTGATCTGACTGGC
TTATGTGAACCAACTCCCCAAGACCATATCAAAGTGACCCAGGAATCAGAAG
GTCAGGGCTGTCCTTTCTGCCGATGTGAAATTAAAGGTACTGAACCCATCGTG
GTAGATCCGTTTGATCCTAGAGGGAGTGGCAGCCTGTTGAGGCAAGGAGCAG
AGGGAGCTCCCTCCCCAAATTATGATGATGATGATGATGAACGAGCTGATGA
TACTCTCTTCATGATGAAGGAATTGGCTGGTGCCAAGGTGGAACGGCCGCCT
TCTCCATTCTCCATGGCCCCACAAGCTTCCCTTCCCCCGGTGCCACCACGACT
TGACCTTCTGCCGCAGCGAGTATGTGTTCCCTCAAGTGCTTCTGCTCTTGGAA
CTGCTTCTAAGGCTGCTTCTGGCTCCCTTCATAAAGACAAACCATTGCCAGTA
CCTCCCACACTTCGAGATCTTCCACCACCACCGCCTCCAGACCGGCCATATTC
TGTTGGAGCAGAATCCCGACCTCAAAGACGCCCCTTGCCTTGTACACCAGGC
GACTGTCCCTCCAGAGACAAACTGCCCCCTGTCCCCTCTAGCCGCCTTGGAGA
CTCATGGCTGCCCCGGCCAATCCCCAAAGTACCAGTATCTGCCCCAAGTTCCA
GTGATCCCTGGACAGGAAGAGAATTAACCAACCGGCACTCACTTCCATTTTC
ATTGCCCTCACAAATGGAGCCCAGACCAGATGTGCCTAGGCTCGGAAGCACG
TTCAGTCTGGATACCTCCATGAGTATGAATAGCAGCCCATTAGTAGGTCCAG
AGTGTGACCACCCCAAAATCAAACCTTCCTCATCTGCCAATGCCATTTATTCT
CTGGCTGCCAGACCTCTTCCTGTGCCAAAACTGCCACCTGGGGAGCAATGTG
AGGGTGAAGAGGACACAGAGTACATGACTCCCTCTTCCAGGCCTCTACGGCC
TTTGGATACATCCCAGAGTTCACGAGCATGTGATTGCGACCAGCAGATTGAT
AGCTGTACGTATGAAGCAATGTATAATATTCAGTCCCAGGCGCCATCTATCAC
CGAGAGCAGCACCTTTGGTGAAGGGAATTTGGCCGCAGCCCATGCCAACACT
GGTCCCGAGGAGTCAGAAAATGAGGATGATGGGTATGATGTCCCAAAGCCAC
CTGTGCCGGCCGTGCTGGCCCGCCGAACTCTCTCAGATATCTCTAATGCCAGC
TCCTCCTTTGGCTGGTTGTCTCTGGATGGTGATCCTACAACAAATGTCACTGA
AGGTTCCCAAGTTCCCGAGAGGCCTCCAAAACCATTCCCGCGGAGAATCAAC
TCTGAACGGAAAGCTGGCAGCTGTCAGCAAGGTAGTGGTCCTGCCGCCTCTG
CTGCCACCGCCTCACCTCAGCTCTCCAGTGAGATCGAGAACCTCATGAGTCA
GGGGTACTCCTACCAGGACATCCAGAAAGCTTTGGTCATTGCCCAGAACAAC
ATCGAGATGGCCAAAAACATCCTCCGGGAATTTGTTTCCATTTCTTCTCCTGC
CCATGTAGCTACCTAGCACACCATCTCCAAGCCGAATTCCAGCACACTGGCG
GCCGTTACTAG_AAAC 
 
c. CBL Minor mutant cDNA (with exon 8 + 40 bp from intron 8-9) 
GC_GGCCGCCAGTGTGATGGATATCTGCAGAATTCGGCTTCAGGCCATGGCC
GGCAACGTGAAGAAGAGCTCTGGGGCCGGGGGCGGCAGCGGCTCCGGGGGC
TCGGGTTCGGGTGGCCTGATTGGGCTCATGAAGGACGCCTTCCAGCCGCACC
ACCACCACCACCACCACCTCAGCCCCCACCCGCCGGGGACGGTGGACAAGAA
GATGGTGGAGAAGTGCTGGAAGCTCATGGACAAGGTGGTGCGGTTGTGTCAG
AACCCAAAGCTGGCGCTAAAGAATAGCCCACCTTATATCTTAGACCTGCTAC
CAGATACCTACCAGCATCTCCGTACTATCTTGTCAAGATATGAGGGGAAGAT
GGAGACACTTGGAGAAAATGAGTATTTTAGGGTGTTTATGGAGAATTTGATG
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AAGAAAACTAAGCAAACCATAAGCCTCTTCAAGGAGGGAAAAGAAAGAATG
TATGAGGAGAATTCTCAGCCTAGGCGAAACCTAACCAAACTGTCCCTCATCTT
CAGCCACATGCTGGCAGAACTAAAAGGAATCTTTCCAAGTGGACTCTTTCAG
GGAGACACATTTCGGATTACTAAAGCAGATGCTGCGGAATTTTGGAGAAAAG
CTTTTGGGGAAAAGACAATAGTCCCTTGGAAGAGCTTTCGACAGGCTCTACA
TGAAGTGCATCCCATCAGTTCTGGGCTGGAGGCCATGGCTCTGAAATCCACT
ATTGATCTGACCTGCAATGATTATATTTCGGTTTTTGAATTTGACATCTTTACC
CGACTCTTTCAGCCCTGGTCCTCTTTGCTCAGGAATTGGAACAGCCTTGCTGT
AACTCATCCTGGCTACATGGCTTTTTTGACGTATGACGAAGTGAAAGCTCGGC
TCCAGAAATTCATTCACAAACCTGGCAGTTATATCTTCCGGCTGAGCTGTACT
CGTCTGGGTCAGTGGGCTATTGGGTATGTTACTGCTGATGGGAACATTCTCCA
GACAATCCCTCACAATAAACCTCTCTTCCAAGCACTGATTGATGGCTTCAGGG
AAGGCTTCTATTTGTTTCCTGATGGACGAAATCAGAATCCTGATCTGACTGGC
TTATGTGAACCAACTCCCCAAGACCATATCAAAGTGACCCAGGAACAATATG
AATTATACTGTGAGATGGGCTCCACATTCCAACTATGTAAAATATGTGCTGAA
AATGATAAGGATGTAAAGATTGAGCCCTGTGGACACCTCATGTGCACATCCT
GTCTTACATCCTGGCAGCAGCGACTTTTTTCAGCTATGTAATAACCTTGGAAA
ATTCGAATCAGAAGGTCAGGGCTGTCCTTTCTGCCGATGTGAAATTAAAGGT
ACTGAACCCATCGTGGTAGATCCGTTTGATCCTAGAGGGAGTGGCAGCCTGT
TGAGGCAAGGAGCAGAGGGAGCTCCCTCCCCAAATTATGATGATGATGATGA
TGAACGAGCTGATGATACTCTCTTCATGATGAAGGAATTGGCTGGTGCCAAG
GTGGAACGGCCGCCTTCTCCATTCTCCATGGCCCCACAAGCTTCCCTTCCCCC
GGTGCCACCACGACTTGACCTTCTGCCGCAGCGAGTATGTGTTCCCTCAAGTG
CTTCTGCTCTTGGAACTGCTTCTAAGGCTGCTTCTGGCTCCCTTCATAAAGAC
AAACCATTGCCAGTACCTCCCACACTTCGAGATCTTCCACCACCACCGCCTCC
AGACCGGCCATATTCTGTTGGAGCAGAATCCCGACCTCAAAGACGCCCCTTG
CCTTGTACACCAGGCGACTGTCCCTCCAGAGACAAACTGCCCCCTGTCCCCTC
TAGCCGCCTTGGAGACTCATGGCTGCCCCGGCCAATCCCCAAAGTACCAGTA
TCTGCCCCAAGTTCCAGTGATCCCTGGACAGGAAGAGAATTAACCAACCGGC
ACTCACTTCCATTTTCATTGCCCTCACAAATGGAGCCCAGACCAGATGTGCCT
AGGCTCGGAAGCACGTTCAGTCTGGATACCTCCATGAGTATGAATAGCAGCC
CATTAGTAGGTCCAGAGTGTGACCACCCCAAAATCAAACCTTCCTCATCTGCC
AATGCCATTTATTCTCTGGCTGCCAGACCTCTTCCTGTGCCAAAACTGCCACC
TGGGGAGCAATGTGAGGGTGAAGAGGACACAGAGTACATGACTCCCTCTTCC
AGGCCTCTACGGCCTTTGGATACATCCCAGAGTTCACGAGCATGTGATTGCG
ACCAGCAGATTGATAGCTGTACGTATGAAGCAATGTATAATATTCAGTCCCA
GGCGCCATCTATCACCGAGAGCAGCACCTTTGGTGAAGGGAATTTGGCCGCA
GCCCATGCCAACACTGGTCCCGAGGAGTCAGAAAATGAGGATGATGGGTATG
ATGTCCCAAAGCCACCTGTGCCGGCCGTGCTGGCCCGCCGAACTCTCTCAGA
TATCTCTAATGCCAGCTCCTCCTTTGGCTGGTTGTCTCTGGATGGTGATCCTAC
AACAAATGTCACTGAAGGTTCCCAAGTTCCCGAGAGGCCTCCAAAACCATTC
CCGCGGAGAATCAACTCTGAACGGAAAGCTGGCAGCTGTCAGCAAGGTAGTG
GTCCTGCCGCCTCTGCTGCCACCGCCTCACCTCAGCTCTCCAGTGAGATCGAG
AACCTCATGAGTCAGGGGTACTCCTACCAGGACATCCAGAAAGCTTTGGTCA
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TTGCCCAGAACAACATCGAGATGGCCAAAAACATCCTCCGGGAATTTGTTTC
CATTTCTTCTCCTGCCCATGTAGCTACCTAGCACACCATCTCCAAGCCGAATT
CCAGCACACTGGCGGCCGTTACTAG_AAAC 
 
d. Bcl2l11 extra-long isoform cDNA 
A_GATCCATGGCCAAGCAACCTTCTGATGTAAGTTCTGAGTGTGACAGAGAA
GGTGGACAATTGCAGCCTGCTGAGAGGCCTCCCCAGCTCAGGCCTGGGGCCC
CTACCTCCCTACAGACAGAACCGCAAGGTAATCCCGACGGCGAAGGGGACC
GCTGCCCCCACGGCAGCCCTCAGGGCCCGCTGGCCCCACCGGCCAGCCCTGG
CCCTTTTGCTACCAGATCCCCACTTTTCATCTTTGTGAGAAGATCTTCTCTGCT
GTCCCGGTCCTCCAGTGGGTATTTCTCTTTTGACACAGACAGGAGCCCGGCAC
CCATGAGTTGTGACAAGTCAACACAAACCCCAAGTCCTCCTTGCCAGGCCTT
CAACCACTATCTCAGTGCAATGGCTTCCATAAGACAGTCTCAAGAGGAACCT
GAAGATCTGCGCCCGGAGATACGGATTGCACAGGAGCTACGGCGGATCGGA
GACGAGTTCAACGAAACTTACACAAGGAGGGTGTTTGCAAATGATTACCGCG
AGGCTGAAGACCACCCTCAAATGGTTATCTTACAACTGTTACGCTTTATCTTC
CGTCTGGTATGGAGAAGGCATTGAGAATTCGATATCAAGCTTATCGATACCG_
TCGAC 
 
Note: This sequence containing 229-819 (coding sequence) of mouse Bcl2l11 extra-long 
isoform cDNA with silence mutations. 
 
e. St18 full length cDNA 
C_TCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGCCCTTTACACGC
AGGTGCTTATCTCCGAGCAGTCAAAGGCACTGGATGTCATATCATGGAGACT
ACCTTTCAAGGCAACAGCTTTAGTGTCTCCTGTCAGCACACCAGAGAGAAGA
GAAATAGTTTTGGAAACAAACACAAAAAACTCCAGCTCCAGATGAACCAGG
GTAGTGTGTGGTGGCAGGAACAGCTGACTCATTAGTAGAGAGCAGTGAAAGC
AATGACATTTCTTCTGTTCAAGTTCAGTAGCTGCTAGAGAAGATGGATGCCGA
GGTTGAAGATAAAACGTTGCATACTCTTTCAAAAGGAACTGAAGTTCCAATG
GATTCTCTGATCCCAGAGCTCAGGGTTCCATATGATTGCTCTATGGCGAAGAA
GAGGAGAGCTGAAGAGCAGGCATCGGGAGTTCCAATTAACAAGAGGAAATC
TCTGCTAATGAAACCCCGGCACTACAGCCCAGACATGGGCTGCAAGGAAAGC
CCAGACAACAGGAACGAGGATGATGGCCTCCTAGAAACAAACGACCATGCC
ACTGCAGATGAAATCATGGTAAAATCCATGGATGAAACTCTTCATTTACCTGC
ACAAGACAGCTCACTCCAGAAGAAAGACCAATACACATGTTATCCAGAGCTC
ATGGTCAAATCTCTGGTGCACTTAGGCAAATTTGAGGAAAGTGAGTCTGTGC
AGACCACATGTGAGAACTTAAATGGCAGCAGTATCCAGTCTTTAAAAGCAGA
GAGTGATGAAGCACATGAAGGTTCTATGGTTCATTCCGACAATGGAAGAGAC
AAAGTCCACCATTCCCAGCCACCTTTCTGCTCTTCTGGTGACAGCGAAAGTGA
CTCTGACAGTGCAGAGAATGGGTGGGGCAATGGCTCCAACTCATCAGAAGAC
ACTGACACTCACAAAGGCCCCAAACACAAGCTGACATACAATAGAAAGGAC
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CTGTTGGAAGTTCCTGAGATAAAAGCTGAAGATGACAAGTTTATCCCTTGTG
AGAACAGGTGTGATTCTGACACAGATGGGAGAGACCCACAGAACTCTCATAT
GGAACCCTTGGTTGTGAAAGCCCAGCCTTCCTTCCCAGAGGTTGAAGAGGGT
GAGAGCCTGGCCACAGTAACAGAAGAGCCTGCTGAGGTGGAGAAAGCAAAG
GGGAACCTGAGTTTGCTGGAACAGGCTATTGCTCTACAGGCTGAACGAGGTT
CTGTCTTCCATCACACTTATAAGGAGCTGGACCGATTTTTCCTGGACCACCTG
GCAAGGGAACGGAGGCAACCTAGAGTTACTGATGCAAATGGAAGACAAATC
TTTACTAATAAACATTCACCAAGACCTGAAAGGAGGGAGGCCAAGTGCCCCA
TTCCTGGCTGTGATGGCACGGGGCACGTAACAGGGCTCTACCCTCACCACCG
CAGCCTTTCTGGGTGCCCCCACAAAGTGCGAGTTCCTCTGGAAATTCTCGCCA
TGCATGAGAACGTGCTCAAGTGTCCCACGCCAGGATGCACAGGAAGGGGAC
ATGTGAACAGCAATCGCAACACTCACAGAAGTCTTTCTGGTTGTCCGATTGCT
GCAGCTGAAAAGCTGGCAATGACCCAGGACAAAAGTCAACTTGATTCTTCTC
AGACGGGGCAGTGTCCTGAGCAGGCACACAGGGTGAATTTGGTGAAGCAAA
TTGAATTTAATTTCCGCTCACATGCCATCACTTCTCCAAGAGCCTCTGCATCA
AAAGAACAAGAGAAGTTTGGGAAAGTACCGTTTGATTATGCCAGTTTTGATG
CACAAGTATTTGGGAAACGTCCTCTCCTACAAACAGGGCAAGGACAAAAAGC
ACCACCATTTCCTGAATCAAAGCATTTTTCAAATCCAGTGAAATTTCCTAATG
GACTGCCTAGTGCTGGCGCCCACACACAGAGCACAGTCCGTGCCAGCTCTTA
TGGCCATGGTCAGTACAGTGAAGACACCCACATAGCAGCAGCTGCTGCCATC
CTGAACCTTTCCACCCGCTGCAGGGAAGCCACAGACATCCTCTCCAACAAAC
CACAAAGCCTGCGTGCCAAGGGAGCTGAGATAGAAGTAGATGAAAACGGCA
CATTGGACTTAAGCATGAAAAAAAATCGAATCCACGACAAGTCTATACCCCC
AACTTCCTCACCTACTACAATTACAACCCCATCCTCATCCCCATTCAACGCAA
GCAGCCTTCTGGTCAATGCTGCCTTCTATCAGGCCCTCTCTGATCAAGAAGGC
TGGAATGTGCCCATCAACTATAGCAAATCCCATGGGAAGACAGAGGAGGAG
AAAGAGAAAGATCCTGTGAACTTCCTAGAAAATTTAGAGGAAAAAAAGTTTG
CTGGAGAGGCCTCTATCCCAAGCCCAAAGCCCAAGCTGCATACAAGAGATCT
CAAGAAAGAATTAATCACCTGTCCAACACCAGGATGTGATGGAAGCGGCCAT
GTCACAGGCAACTATGCATCTCACCGCAGTGTCTCTGGATGTCCTCTAGCAGA
TAAGACTCTGAAGTCTCTCATGGCTGCCAACTCTCAAGAGCTTAAGTGTCCAA
CCCCAGGTTGTGATGGTTCTGGTCATGTGACTGGAAACTATGCCTCCCACCGA
AGCTTGTCTGGTTGCCCTCGTGCAAGGAAAGGTGGCATCAAAATGACCCCAA
CAAAAGAAGAAAAAGAAGACTCTGAACTTAGATGCCCTGTAATAGGGTGTG
ACGGCCAAGGCCACATATCAGGTAAATACACATCACACCGCACAGCTTCTGG
CTGTCCTCTGGCTGCCAAAAGACAGAAAGAGAATCCCCTCAATGGGGCACCT
CTCTCCTGGAAACTGAACAAGCAAGAGCTTCCTCACTGTCCTCTGCCAGGAT
GCAATGGTCTGGGTCATGTAAACAACGTTTTTGTCACCCACAGAAGCTTATCT
GGATGCCCTCTTAATGCACAAGCTATCAAAAAAGTCAAGGTCTCTGAGGAAC
TAATGACTATCAAGCTCAAAGCAACTGGGGGTATTGATGGTGATGAAGAAAT
TAGGCATCTGGATGAAGAAATCAAGGAACTGAATGAATCCAACCTTAAAATT
GAAGCAGATATGATGAAACTTCAGACCCAGATAACATCTATGGAGAGCAACT
TGAAGACCATAGAGGAGGAGAACAAGCTTATAGAACAGAGCAATGAGAGTC
TGCTGAAGGAGCTGGCAGGGCTTAGCCAGGCTCTCATCTCCAGCCTTGCTGA
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CATCCAACTTCCACAGATGGGGCCTATCAATGAGCAGAATTTTGAAGCATAT
GTAAATACTCTCACAGACATGTACAGCAATCTGGAACAGGACTATTCCCCAG
AATGCAAAGCTCTACTGGAAAGCATCAAGCAGGCGGTGAAGGGCATCCATGT
GTAGAACGACAGTATGCAGGAAACAGAGGTCACTACGGCCATGAACTCCCA
CAAATCTGCAGGGGCCTAATACCCCTGGAGCCCAGAGGCTGTCCCTGTGTTT
ATAATTGCAACATTGCACTAATTTTTCCCCAGCTGACATAAAAAGGAAAGAA
AAACTATGATAAACTCTTTGGATTAAAAGCAATGCAGTCAATTATTAAACTC
GTTTATTTTCATATCTTTTTCTTTTCTTTCTTCATTGCACTCTTTATTTTGTAAA
GTATATGTAAAAATAAATGTGACATTTTATATTTTATTTATTACTAATCAAAG
AGTTTTTTATCTTTTAACTGCATTTTGAAGTCTACTATATTTTTACAGGTGTGT
TTATTAATTTATCTTCTAATAGGATTTAAATAGAAATGCTGTTCTCAAATCAC
ATATCTTTCTGGATTTAAATGAGAAAAACAAAACAAAAGAAATGTATGAAGG
AAATCCTGATGTCAGGACTACACTGTGGTCAAGCTTGGTTTCTACTGTGCACT
TCCATTTCTCCTTTACTGGTTTTGTTTTTATAAATGGCTTTTGGTAATGTGAGC
TGTGAAGGATTATGAAGATAAATGGCGCCCACTAGTGGGAAATCCACACTCA
CAAAAGCACAGGATGTTAGCAAACAGCGCACTCAGAACTTGATAGCAATAAT
TAAATAAAATAGTCAGCATAGTATTCCACATGGCTGCAGAGATTTAATTAAT
ATGAATTATTTATTTAGACTGCTTAAAGCATACATTTTAAGTGAATCAGATTT
GTCTTCTTGTTTTTCAAGTCATATTGGCTAGTTGGCAACCCTTTCCCAAAATGA
GAAATAAGCTTTGATGGGACCAGCTTGGCTAAGGGCGAATTCCAGCACACTG
GCGGCCGTTACTAGTGGATC_AAAC 
 
B.2.2 shRNA inserts 
Note: all the sequences of the shRNAs below are color-coded. Black, mir30 context; Red, 
sense sequence of the shRNA; Green, mir30 loop; Blue, anti-sense sequence of shRNA. 
a. Scrambled shRNA (93mer, used in Chapter II) 
TGCTGTTGACAGTGAGCGCGAAAGTCTTAGAGATAGTATAGTGAAGCCACAG
ATGTATACTATCTCTAAGACTTTCTTGCCTACTGCCTCGGA 
 
b. Id2 shRNA-1 (97mer) 
TGCTGTTGACAGTGAGCGCGCAGCACGTCATCGATTACATTAGTGAAGCCAC
AGATGTAATGTAATCGATGACGTGCTGCATGCCTACTGCCTCGGA 
 
c. Id2 shRNA-2 (97mer) 
TGCTGTTGACAGTGAGCGCGCAAAGTACTCTGTGGCTAAATAGTGAAGCCAC
AGATGTATTTAGCCACAGAGTACTTTGCTTGCCTACTGCCTCGGA 
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d. Id2 shRNA-3 (97mer) 
TGCTGTTGACAGTGAGCGCCGACTGCTACTCCAAGCTCAATAGTGAAGCCAC
AGATGTATTGAGCTTGGAGTAGCAGTCGTTGCCTACTGCCTCGGA 
 
e. Id2 shRNA-4 (97mer) 
TGCTGTTGACAGTGAGCGCCTGAGCTTATGTCGAATGATATAGTGAAGCCAC
AGATGTATATCATTCGACATAAGCTCAGATGCCTACTGCCTCGGA 
 
f. Id2 shRNA-5 (97mer) 
TGCTGTTGACAGTGAGCGCATGTCGAATGATAGCAAAGTATAGTGAAGCCAC
AGATGTATACTTTGCTATCATTCGACATATGCCTACTGCCTCGGA 
 
g. CBFB-MYH11 shRNA (97mer) 
TGCTGTTGACAGTGAGCGCCGGGAGGAAATGGAGGTCCATTAGTGAAGCCAC
AGATGTAATGGACCTCCATTTCCTCCCGATGCCTACTGCCTCGGA 
 
h. Bcl2l11 shRNA-1 (97mer) 
TGCTGTTGACAGTGAGCGCGATGTAAGTTCTGAGTGTGACTAGTGAAGCCAC
AGATGTAGTCACACTCAGAACTTACATCATGCCTACTGCCTCGGA 
 
i. Bcl2l11 shRNA-3 (97mer) 
TGCTGTTGACAGTGAGCGACCTCAAATGGTTATCTTACAATAGTGAAGCCAC
AGATGTATTGTAAGATAACCATTTGAGGGTGCCTACTGCCTCGGA 
 
j. Bcl2l11 shRNA-4 (97mer, used in Chapter II) 
TGCTGTTGACAGTGAGCGCGGCCTTTGTACTTAAATATATTAGTGAAGCCACA
GATGTAATATATTTAAGTACAAAGGCCTTGCCTACTGCCTCGGA 
 
  
186 
 
 
 
Appendix C 
 
This appendix lists all the inhibitors that I used during my stay in the Castilla 
laboratory.  
Table C.1 List of inhibitors 
Inhibitor Target 
in vivo 
Comments 
Dose Delivery 
PD098059 MEK / / High efficacy, in vitro only 
PD325901 MEK 5 mg/kg O.G. Toxic in vivo 
GDC-0973 MEK 10 mg/kg O.G.  Minimal efficacy in vivo 
LY294002 PI3K / / High efficacy, in vitro only 
GDC-0941 PI3K 100 mg/kg O.G.  No efficacy in vivo 
GDC-0980 PI3K/mTOR / / High efficacy in vitro 
BEZ235 PI3K/mTOR 45 mg/kg O.G. Toxic in vivo 
Rapamycin mTOR 0.8mg/kg IP No efficacy in vivo 
 
Notes: O.G., oral gavage; IP, intraperitoneal injection. 
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